var title_f8_34_8736="Distal radius measurements lateral view";
var content_f8_34_8736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal radius measurements: Lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a true lateral projection, the radius and ulna should be superimposed, and the pisiform projected over the distal pole of the scaphoid (white arrow). Normally, the lunate is seated within the fossa of the distal radius, and the curvature of their articular surfaces should correspond. Palmar migration is a sign of radiocarpal instability. Palmar tilt is the angle formed by the intersection of one line perpendicular to the longitudinal axis of the radial shaft and a second line drawn through the apices of the palmar and the dorsal rims of the radius. AP distance can also be measured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8736=[""].join("\n");
var outline_f8_34_8736=null;
var title_f8_34_8737="Pedunculated fibroid";
var content_f8_34_8737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pedunculated fibroid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound image of the right adnexa showing a pedunculated fibroid. A solid appearing mass is noted in the right adnexa (long arrow). No cystic areas are identified. The mass is slightly heterogeneous and has no appreciable posterior enhancement, but has some areas of shadowing (short arrow). The mass is separate from the right ovary. The arrowhead demonstrates a thick stalk which connects the fibroid to the uterus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thomas D Shipp, MD. Copyright &copy; Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8737=[""].join("\n");
var outline_f8_34_8737=null;
var title_f8_34_8738="Patient information: Strep throat in children (The Basics)";
var content_f8_34_8738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16968\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/28/8641\">",
"         Strep throat",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/26/28066\">",
"         Patient information: Sore throat in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/22/3427\">",
"         Patient information: Sore throat in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Strep throat in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/strep-throat-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3295558\">",
"      <span class=\"h1\">",
"       What is strep throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Strep throat is an infection that is caused by bacteria and leads to a sore throat. However, most sore throats are caused by a virus, and are not strep throat. (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=see_link\">",
"       \"Patient information: Sore throat in children (The Basics)\"",
"      </a>",
"      .)",
"     </p>",
"     <p>",
"      About 3 out of every 10 children with a sore throat actually have strep throat. It is most common in school-age children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295565\">",
"      <span class=\"h1\">",
"       How can I tell if my child has strep throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is hard to tell the difference between strep throat and a sore throat caused by a virus. But there are some clues you can look for.",
"     </p>",
"     <p>",
"      People who have strep throat often have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Severe throat pain",
"       </li>",
"       <li>",
"        Fever (temperature higher than 100.4&deg;F or 38&deg;C)",
"       </li>",
"       <li>",
"        Swollen glands in the neck",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might also be able to see redness on the roof of your child&rsquo;s mouth, or white patches in the back of the throat (",
"      <a class=\"graphic graphic_figure graphicRef78761 \" href=\"UTD.htm?8/28/8641\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Children older than 5 who have strep throat DO NOT usually have a cough, runny nose, or itchy or red eyes. Strep throat is uncommon in very young children, but if they do get it, it can cause a runny or stuffy nose, plus a slight fever. Babies with strep throat might act fussy and not want to eat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295572\">",
"      <span class=\"h1\">",
"       Is there a test for strep throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you think your child might have strep throat, a doctor or nurse can check for it easily. He or she can run a swab (Q-Tip) along the back of your child&rsquo;s throat, and test it for the bacteria that cause strep throat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295579\">",
"      <span class=\"h1\">",
"       Does my child need antibiotics?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a test shows that your child has strep throat, then yes, he or she needs antibiotics. Most people with strep throat get better without antibiotics, but doctors and nurses often prescribe them anyway. That's because antibiotics can prevent problems that strep throat can sometimes cause. Plus, antibiotics can reduce the symptoms of strep throat and keep it from spreading to other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295586\">",
"      <span class=\"h1\">",
"       What can I do to help my child feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Make sure that your child takes his or her antibiotics as directed. There are also other ways to help relieve symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Soothing foods and drinks",
"        </strong>",
"        &ndash; Give your child things that are easy to swallow, like tea or soup, or popsicles to suck on. Your child might not feel like eating or drinking, but it&rsquo;s important that he or she gets enough liquids. Offer different warm and cold drinks for your child to try.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines",
"        </strong>",
"        &ndash;",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         Acetaminophen",
"        </a>",
"        &nbsp;(sample brand name: Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        &nbsp;(sample brand names: Advil&reg;, Motrin&reg;) can help with throat pain. The right dose depends on your child&rsquo;s weight, so ask your child&rsquo;s doctor how much to give.",
"        <br/>",
"        <br/>",
"        Do not give",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        or medicines that contain aspirin to children younger than 18 years. In children, aspirin can cause a serious problem called Reye syndrome. Do not give children throat sprays or cough drops, either. Throat sprays and cough drops are no better at relieving throat pain than hard candies. Plus, throat sprays can cause an allergic reaction. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Other treatments",
"        </strong>",
"        &ndash; For children who are older than 3 to 4 years, sucking on hard candies or a lollipop might help. For children older than 6 to 8 years, gargling with salt water might help.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295593\">",
"      <span class=\"h1\">",
"       When can my child go back to school?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child should be on antibiotics for at least 24 hours before going back to school. By then, he or she will be a lot less likely to spread the infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295600\">",
"      <span class=\"h1\">",
"       How can I keep my child from getting strep throat again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Wash your child&rsquo;s hands often with soap and water. It is one of the best ways to prevent the spread of infection. You can use an alcohol rub instead, but make sure the hand rub gets everywhere on your child&rsquo;s hands.",
"     </p>",
"     <p>",
"      Try to teach your child about other ways to avoid spreading germs, such as not touching his or her face after being around a sick person.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295550\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=see_link\">",
"       Patient information: Sore throat in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=see_link\">",
"       Patient information: Sore throat in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/34/8738?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16968 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8738=[""].join("\n");
var outline_f8_34_8738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295558\">",
"      What is strep throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295565\">",
"      How can I tell if my child has strep throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295572\">",
"      Is there a test for strep throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295579\">",
"      Does my child need antibiotics?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295586\">",
"      What can I do to help my child feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295593\">",
"      When can my child go back to school?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295600\">",
"      How can I keep my child from getting strep throat again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295550\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/28/8641\">",
"      Strep throat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=related_link\">",
"      Patient information: Sore throat in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_34_8739="Inosine pranobex: Drug information";
var content_f8_34_8739=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Inosine pranobex: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16144138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imunovir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16222941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Immunomodulator, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16222976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Subacute sclerosing panencephalitis (SSPE):",
"     </b>",
"     Oral: 50 mg/kg/day in 3-4 equally divided doses (maximum: 3 g daily)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F16222975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Subacute sclerosing panencephalitis (SSPE):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16222977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16222978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is no dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16222979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is no dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F16222986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Imunovir&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16222985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16222980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally in 3-4 equally divided doses while awake.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16144139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of slowly progressive subacute sclerosing panencephalitis (SSPE); may delay neurologic deterioration and prolong life expectancy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16222950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness, fatigue, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Itching, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Constipation, diarrhea, stomach upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Urine output increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Joint ache",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16222945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s product monograph.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16222946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Uric acid: Inosine undergoes rapid metabolism to uric acid. Use with caution in patients with a history of gout, urolithiasis, nephrolithiasis, or renal impairment. Uricosuric agents (eg, probenecid) or antihyperuricemic therapy (eg, allopurinol) may be necessary for extremely elevated serum uric acid levels.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16265510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16265508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16222944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects to the fetus were not observed in animal reproduction studies. Due to the altered immune status of pregnant women, SSPE may be exacerbated during pregnancy and may progress rapidly. Because this condition is rare, use of inosine pranobex in pregnant women is limited to case reports (Cole, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16222983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uric acid (serum and urine)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16222966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism has not been fully elucidated; may possess antiviral and immunomodulating effects by potentiating T-lymphocyte and macrophage cell function and by influencing cytokine production (Milano, 1991; Petrova 2010; Wybran, 1978).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16222968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Rapid to uric acid; also undergoes glucuronidation and oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~50 minutes (Campoli-Richards, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1 hour (Campoli-Richards, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (as uric acid, glucuronide and oxide metabolites, and unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Campoli-Richards, Sorkin EM, and Heel RC, &ldquo;Inosine Pranobex. A Preliminary Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1986, 32(5):383-424.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8739/abstract-text/2431857/pubmed\" id=\"2431857\" target=\"_blank\">",
"        2431857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang TW and Weinstein L, &ldquo;Antiviral activity of Isoprinosine",
"      <i>",
"       in vitro",
"      </i>",
"      and",
"      <i>",
"       in vivo",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 1973, 265(2):143-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8739/abstract-text/4350802/pubmed\" id=\"4350802\" target=\"_blank\">",
"        4350802",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cole AJ, Henson JW, Roehrl MH, et al, &ldquo;Case Records of the Massachusetts General Hospital. Case 24-2007. A 20-Year-Old Pregnant Woman With Altered Mental Status,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, Aug 9;357(6):589-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8739/abstract-text/17687135/pubmed\" id=\"17687135\" target=\"_blank\">",
"        17687135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milano S, Dieli M, Millott S, et al, &ldquo;Effect of Isoprinosine on IL-2, IFN-&upsih; and IL-4 Production",
"      <i>",
"       in vivo",
"      </i>",
"      and",
"      <i>",
"       in vitro",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Int J Immunopharmacol",
"      </i>",
"      , 1991, 13(7):1013-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8739/abstract-text/1722191/pubmed\" id=\"1722191\" target=\"_blank\">",
"        1722191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohnishi H, Kosuzume H, Inaba H, et al, &ldquo;The Immunomodulatory Action of Inosiplex in Relation to its Effects in Experimental Viral Infections,&rdquo;",
"      <i>",
"       Int J Immunopharmacol",
"      </i>",
"      , 1983, 5(3):181-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8739/abstract-text/6194125/pubmed\" id=\"6194125\" target=\"_blank\">",
"        6194125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petrova M, Jelev D, Ivanova A, et al, &ldquo;Isoprinosine Affects Serum Cytokine Levels in Healthy Adults,&rdquo;",
"      <i>",
"       J Interferon Cytokine Res",
"      </i>",
"      , 2010, 30(4):223-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8739/abstract-text/20038210/pubmed\" id=\"20038210\" target=\"_blank\">",
"        20038210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wybran J, Govaerts A, and Appelboom T, &ldquo;Inosiplex, a Stimulating Agent for Normal Human T Cells and Human Leukocytes,&rdquo;",
"      <i>",
"       J Immunol",
"      </i>",
"      , 1978, 121(3):1184-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8739/abstract-text/80429/pubmed\" id=\"80429\" target=\"_blank\">",
"        80429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88326 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8739=[""].join("\n");
var outline_f8_34_8739=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16144138\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222941\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222976\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222975\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222977\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222978\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222979\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222986\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222985\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222980\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16144139\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222950\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222945\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222946\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265510\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222944\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222983\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222966\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16222968\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88326|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_34_8740="Variability in presentation of rapid cycling bipolar disorder";
var content_f8_34_8740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F72619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F72619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Variability in presentation of rapid cycling bipolar disorder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 406px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGWAgMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACisXW/FnhzQbtLXXNf0jTbl0EixXl7HC5QkgMFZgcZBGfY1n/APCx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FV1VABRRRQAUUUUAFFFFAHK6b/yVPxD/wBgXTP/AEff11Vcrpv/ACVPxD/2BdM/9H39dVQAUUUUAFFFc3o3i211XxZrGgxW86XOmBWkkbG193pz71Si5JtdCZTUWk+p0lFFFSUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUGgAooooA5X4sf8AJLPGX/YFvf8A0Q9dVXK/Fj/klnjL/sC3v/oh66qgAooooAKKKKACiiigDldN/wCSp+If+wLpn/o+/rqq5XTf+Sp+If8AsC6Z/wCj7+uqoAKKKRiAMnoKAI7m4htYHnupo4YUGWkkYKqj1JPSvJPAus6Y/wAZPGEi6haFLtYFt2Eq4lIABCnuc+lHxW8feFtX8Caxp2n6vDcXkqqiRKj/ADEOCecY7V4D4PZYPFmiyOBtS8iJ/wC+xXq4XBuVKbldN6fkzxsbjlGrBQs0tfzR9vUUUV5R7IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwWofERLD4iXPhi501lgjtUlTUPO+Vp3WR0hK7flLLDIQcnJXGOa72uF8R/DyDXbzxRPcX7xtrFvZxwtHF89nLbGRklVs/Md0gOMD7pGTngAfYfEzQX0bRrzU5nsri/wBPt9RkhSGWdLRJlBUyyom2NckgM+0HBNaMfjvw9Jrn9krezfbPtRssm0mEXngE+V5pTy92ASBuyccZrlf+FXXcOif2RZeIVhsbvR7XR9TD2O9544YzHvibzB5TMjMDkOBkEcjJ24vAixRpGl/hF10a0B5PQD/ll97/AMe/SgDo9e1zTtAtYbjV7kW8MsywIxRm3O2cLhQeuDWbH400dtQtbOT+07aa6ZI4Wu9KureN3Zdyp5kkYQMR/CTnPGM8VXvPAujj7D/Ytjp+j+RqMOoTfZLNE+0GPdgNtxz8x5Ocelc/qPwua98aLr0mpWTldTi1FXm07zLtAgH7hbgyfLFxwAgxnkmgDbT4h+Hb0Tw2OpPHOI7gxTT2FwIWaEN5gViqiQptJKK2cA/Ws3xT8R7PSdEX+z7hb/Vwlo7GOwuGgUTOgDSFQRDuViVV3B6de+R4c+Hms3ehW1r4iv4LeC0m1GS0tIrbMkb3DToskkolKyAJMxCqqY3AEkirt18M777LdWVj4ghgsL77E94klgZJHktkiQFH80BAywpkENjsaAO717XNP0G1juNTmaNZZBDEkcTzSSyEEhUjQFnbAJwoJwCe1ZMPjzw5NYX14t+6w2UCXFwJLaVHRHZlU7GUMSWRlwATuBGM8VY8W+H59Zk0m70++Sx1PS7k3NtNLB58eWjeNldNykgrI3RgQcHNctrPgrUdX8XeFLjVJjdx2Ucsmp3kaJDFdlZEkghMOWOFkAcdcBCCSWoA0vFHxD0rTrDWo9OnabVbK2uWjDWkxtzPFA0piaUKE3ALkpvDDB6GiLx7pllDLLrepR7jLbW629rp87SRzS24lEfy7zIWGWG0DAIU5PJrXHgTVDaa7pdn4hhg0LVnvZXtm0/fMr3KPuHm+YAUEkhcAKG427sU6H4eeVq8N9/amfL1G01DZ9n6+RaG32Z3fxZ3Z7dMHrQBqnx94cNjZ3Ud5cTC7eWOKGCxnluC0R2yAwqhkXYeG3KMZGeorc0TVbPXNIs9U0ubz7G7iWaGXay70IyDhgCPxFea614R1vw7frrHhRri+1WWfUCwS1hdFiupUl2sJbiLBVkXDgt3ynau1+HWjXHh3wH4f0e9Km6srGKCXYcjeqgNg9xnNAFf4sf8ks8Zf9gW9/8ARD11Vcr8WP8AklnjL/sC3v8A6IeuqoAKKKKACiiigAooooA5XTf+Sp+If+wLpn/o+/rqq5XTf+Sp+If+wLpn/o+/q1418HaF430qLTfE9j9usophcJH50kWJArKDlGB6M3Gcc0AdBUdxgQSZ6bTn8q8u/wCGfPhh/wBCz/5P3X/xyj/hnz4Y/wDQs/8Ak/df/HKAPmOTHnS4/vn+daPhwgeINLPBxdRf+hivov8A4Z8+GP8A0LP/AJP3X/xyqOq/AD4a2unahcx+H33JAzoDfXBCEKTkfvOfxzXsf2rzacn4/wDAPC/sblfNz/h/wT2OivzsXw7phH/Hsf8Av43+NOHhzS8f8ex/7+N/jWP9l1u6/H/I6f7Wo9n+H+Z+iNFfAHh/wlot5cXiXFoWWOznmUCVxhlQkHr61kHw/po/5dv/ACI3+NL+zKt7XX4/5Ff2rR3s/wAP8z9E45Ek3eW6vtYqdpzgjqD70+vjj9n/AOG3hTxXr+q2+v6X9rggtlkjX7RLHhi+M5Rgele5f8M+fDHH/Is/+T91/wDHK469F0Z8kjtoVlWhzxPVaK8pP7Pnwx/6Fo/+B9z/APHKUfs+fDH/AKFrP/b/AHX/AMcrI1PVScdaZDKk0SywuskbjKspyCPUGvLG/Z7+GJBx4aI47X9zx/5EqOD9nn4Zxwoknh95WVcGR764BY+pxIB+QoEetUV5T/wz58Mf+haP/gfc/wDxyg/s9/DE/wDMtEf9v9z/APHKBnq1MlkSGNpJXVI1GWZjgAe5ryw/s+fDH/oWj/4H3P8A8cpsv7PXwzeNlXw68bEYDrf3OR78yEUCZ6wKK8p/4Z8+GP8A0LR/8D7n/wCOUf8ADPfwx/6Fo/8Agfc//HKBnq1FeUj9nz4Y8/8AFNn/AMD7n/45R/wz58Mcf8i0f/A+5/8AjlAHqcsqQxl5XVEHVmOAKfXk0/7PPwzkiKp4feJsj50vrgnr7uRz06U//hnz4Y/9C0f/AAPuf/jlAj1aivKj+z58Mf8AoWf/ACfuv/jlIv7PnwxAGfDRPub+5/8AjlAz1am718zZuXfjdtzzj1xXlf8Awz58Mf8AoWj/AOB9z/8AHKaf2evhkZQ//COuF242fb7nGfX/AFmc/jQB6xRXlP8Awz58Mf8AoWT/AOB9z/8AHKP+GfPhjn/kWj9Pt91/8coA9Woryn/hnz4Y/wDQtf8Ak/c//HKX/hnz4Y/9Cz/5P3X/AMcoA9SSWN5HjR1Z0xvUHJXPTI7U+vJl/Z5+GYkdj4edgxGFN/cYX6fvM/nmn/8ADPnwx/6Fo/8Agfc//HKBI9WJA6nFFeUH9nv4Yn/mWyPpf3P/AMcpf+GfPhj/ANC0f/A+5/8AjlAz1aivKf8Ahnz4Y8f8U0f/AAPuf/jlIP2e/hl/0LZP/b/c/wDxygD1eivKT+z58MT/AMy0R9L+5/8AjlIf2e/hlx/xTjDH/T/c8/8AkSgD1eivKf8Ahnv4Y/8AQtn/AMD7n/45R/wz38McH/imj9ft9z/8coA9Worylf2fPhiBg+Gi3ub+5/8AjlB/Z8+GP/QtH/wPuf8A45QB6tRXlP8Awz58MeP+KaP/AIH3P/xyj/hnz4Y/9C0f/A+5/wDjlAHqkjrGheRlVR1LHAFOryaX9nn4ZvEVXw88bH+Nb+4yPzkI/Sn/APDPfwxxj/hGz9ft9z/8coEerUd8V5R/wz38Msf8i23/AIH3P/xykH7Pfwy3E/8ACOMQRjH2+54/8iUDPWKRiFGWIA968pH7PfwyH/MuMf8At/uf/jlMm/Z4+GkiYTQJIjkHct9cE/q5oEetUV5R/wAM9fDL/oXW/wDA+5/+OU0/s8/DM4/4p5x/2/3H/wAcoGes0V5V/wAM+fDD/oWf/J+6/wDjld74T8NaT4S0SHSPD1p9k06FmZIvMeTBYljy5J6k96AM34sf8ks8Zf8AYFvf/RD11Vcr8WP+SWeMv+wLe/8Aoh66qgAooooAKKKKACiiigDldN/5Kn4h/wCwLpn/AKPv66quV03/AJKn4h/7Aumf+j7+uqoAKKKKACoL63W7sri2clVmjaMkdQCMf1qeigGr6HxNa+GUk+Iw8LfaiE/tA2X2gJzgOV3Y/DpWLqVv9i1K8tC277PM8W712sRn9K+tIvhR4bi8X/8ACSKL06h9qN5gz/u/MJz0x0z2zWde/BDwjeXtxdSjURJPI0jBbnAyxycce9e7HMqd9b7fifPyyyo1p3PN/g98ObfxD4Zvtcm1GWF3S4sxEkYIGUA3E59+lcJ8NfCKeNPFJ0iS8e0QRPJ5qxhz8uOMZHrX1r4P8K6b4T0Q6VpQm+ymRpD5z72Jbrz+FYvhD4Y+HvCetyappK3YuXRo8SzblAY5OBj2rD+0P4jvvsdH9m/w1bbcofC/4XweAtSvryHVJb1rqJYtrwhAuDnPBOa9HoorzKlSVWXNN3Z6lOnGlHlgrIKKKKg0CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKDQAUUUUAcr8WP+SWeMv+wLe/8Aoh66quV+LH/JLPGX/YFvf/RD11VABRRRQAUUUUAFFFFAHK6b/wAlT8Q/9gXTP/R9/XVVyum/8lT8Q/8AYF0z/wBH39dVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKDQAUUUUAcr8WP+SWeMv+wLe/+iHrqq5X4sf8ks8Zf9gW9/8ARD11VABRRRQAUUUUAFFFFAHK6b/yVPxD/wBgXTP/AEff11Vcrpv/ACVPxD/2BdM/9H39dVQAUUUUAFFFFABRXnOrfE1NP+Kdp4NbS2fz/LU3fnAbS65Hy45HQda9Gq505Qs5LfUiFSM21HoFFFeKaT8d4tQ8V2mjf8I/LGs94LTzjdAkZfaG27f0zVU6M6t3BXsTVrwpWU3a57XRRRWRqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFUtb1BdJ0a/wBQdGkS0gecopwWCqTgflXh0X7R1u23f4ZmGTzi8Bx/45W9LD1Kybgr2MKuJp0Xabse/UV558TviXD4Fh0qRtMlvjfhmAEoj2BQvXg5PzVP8K/iJF4/t9Rki06SwazZFZWlEgbcGwQcD+6aX1ep7P2tvdH9Ypup7K/vf0zvKKKKxNgooooAKKKKACiiigAooooAKKKKAOV+LH/JLPGX/YFvf/RD11Vcr8WP+SWeMv8AsC3v/oh66qgAooooAKKK434r6xqmg+FU1PSFumFveW73n2WFZpRa+YPN2qQc8deOBk9s0AdlRXkvwG1zxZqo1dPGM8k8vlW17GJIBEbZphIxgwAM7VWM88jfivWqAOV03/kqfiH/ALAumf8Ao+/rqq5XTf8AkqfiH/sC6Z/6Pv66qgAooooAKKKKAPl74p6xF4f/AGg49XuInmisxbyMiYDEeWOmfrXbD9oXQsf8gjUs/VP8a8x/aEUH4raj/wBcYP8A0WK89VK+ihhadalBzXRHzdTGVKFWag+rPpJf2gtCPXSNSH4p/jXgOi6pFp3jGy1h4neK3vluzGMZID7sfWs8JQUrelhadJNQW5y1sbUrNc72Po7/AIaD0If8wjU//HP8a6n4d/FDTPHOqXVjYWV5bSwQ+eTNtwy7gOx68ivkVlru/g54zsPBGvXt9qUFzNFPbeSogAJB3A85I44rkr5dTVNumtTtoZlUc0qj0Pr+ivGn/aC8NKMjTtWP/AE/+Kr2G3lWeCKZM7JFDrnrgjNeNUoVKVudWPbpV6dW/I7klFFFZGwUUUUAFFFFABRRRQAUUUUAFFFFABRXDePfiXpHgnUray1S3vZZZ4vOUwIpAXJHOSOeDXOf8L68MEZ+x6t/36T/AOLreOFqzXNGOhzTxdGD5ZSszf8AiL8TdL8C31paajaXlxLcRGUGALgKDjnJHNdnpd5HqOm2l9AGWK5hSZAwwQGUEZ9+a+TvjR4ysPG+s2F3pkNzFFb25iYTqASSxPGCa9r+FXxK0fX103w7aW95He29koLSIuw+Wqg4IOf0rprYNwoxmlr1OahjlUrSg3p0PUKKBRXnnpBRRRQAUUUUAFFFFABRRRQAUUUUAcp8VdSi0r4d6/czKzKbVoQF65k+Qfqwr4piUArntX2D8ev+SVa19Iv/AEalfIaDgV72VL9035nz+bS/epeX+Z6L8X/Hlh43t9FjsLS5tzYo4fzsclgvTB/2a6H9mXxFa6drd7oc0UpuNTKvFIuNq+WrkhvqDXjhUYrpvhn4gtfCvjSx1e/illt4A4ZYgC3zIV4zj1rpq4ePsHSiv63/ADOSjiZe3VWT66/l+R9p0VwngP4naL411SfT9LgvYp4ofOP2iNQCoIBwQx5yRXd183OnKm+Wasz6inUjUXNB3R574x+IF94f1LXkt9Ftbuw0Oyt768mk1AwyssrSALFH5TKzDyjwXXJIArpbnxXpVrrUOl3ZvoLqaRYo3lsLhYHdl3KgnKeUWI7Bs5yOoxXP+Jfhnp3iHxDqWtXkqrqE0FqljcJAvnWEsDSMJEck5DGRcrgAhMHOeMqT4WXNz4ottb1DV9OubqPUINQedtKzc5jCgwxymU+XCSCQgXIzyW7wWdCnxD8O3onhsdSeOcR3BimnsLgQs0IbzArFVEhTaSUVs4B+tZvin4j2ek6Iv9n3C3+rhLR2MdhcNAomdAGkKgiHcrEqruD0698jw58PNZu9CtrXxFfwW8FpNqMlpaRW2ZI3uGnRZJJRKVkASZiFVUxuAJJFXbr4Z332W6srHxBDBYX32J7xJLAySPJbJEgKP5oCBlhTIIbHY0Ad3r2uafoNrHcanM0ayyCGJI4nmklkIJCpGgLO2AThQTgE9qyofHvhyWwvrxb91hsYEubgSW0yOiOzKp2MoYksjLgAncCMZ4qfxb4fn1mTSbvT75LHU9LuTc200sHnx5aN42V03KSCsjdGBBwc1y2s+CtR1fxd4UuNUmN3HZRyyaneRokMV2VkSSCEw5Y4WQBx1wEIJJagDS8UfEPStOsNaj06dptVsra5aMNaTG3M8UDSmJpQoTcAuSm8MMHoaWHx7ptlDLLrepR7jLbW629rp87SRzS24lEfy7zIWGWG0DAIU5PJq3HgTVDaa7pdn4hhg0LVnvZXtm0/fMr3KPuHm+YAUEkhcAKG427sU6H4d+Vq8N9/amfL1G0v9n2fr5FobfZnd/Fndnt0wetAGqfH3hw2NndR3lxMLt5Y4oYLGeW4LRHbIDCqGRdh4bcoxkZ6itzRNVs9c0iz1TS5vPsbuJZoZdrLvQjIOGAI/EV5rrXhHXPDt+useFGuL7VZZ9QLBLWF0WK6lSXawluIsFWRcOC3fKV2vw60a48O+A/D+j3pU3VlYxQS7Dkb1UBsHuM5oAr/ABY/5JZ4y/7At7/6Ieuqrlfix/ySzxl/2Bb3/wBEPXVUAFFFFABXmf7REP2j4bvb/ZLq9M1/ZxfZIJfKFxunQeU75G1Wzt3diQa9MrhPjUNIk8Cy22u6NPrkN1cwQQadBMYXuJ2cCNd4I288k+3egDF+A3h3/hH7TWB/wgn/AAiHnPEdv9sf2h9pwG56nZtz+O72r1WvJPgJYaRo76/pdn4Qm8J6zCYJL2zk1A3odGD+U6yFiMcScDH4163QByum/wDJU/EP/YF0z/0ff11Vcrpv/JU/EP8A2BdM/wDR9/Vrxr4l/wCEV0qK+/sXW9Z8yYQ/Z9HtPtEy5VjvK5GF+XGfUj1oA6CivKv+Fyf9U4+JP/gj/wDs6zNW/aD0fR5Y49X8H+ObGSQFkS50xIiwHcBpBkU0m9EJtLVntFFeFf8ADTXhX/oXvFv/AIBRf/HaP+GmfC3/AEL3i7/wCi/+O1Xs59mT7SHdHmHxt1KHU/idrMsCuqwuts28Yy0Y2sR7ZBxXFKa0/EDa54o1/U9c0fwd4qn0/ULqW4gkXTHYFWc45XIz24Jqgmj+KSWC+CvFhKnDAaVLwcZ549xX0NLE0YQUebZHzVXCV6k3Ll3AMKNwp39i+K/+hI8W/wDgpl/wo/sXxX/0JHi3/wAFMv8AhWn1yh/MjL+z6/8AKyNiKibFWf7F8Vn/AJkjxb/4KZf8KjOjeKPMCf8ACF+K95G4L/ZUuceuMe4o+uUP5kNYGuvssqtX01YfHrwrb2FtDJaaxvjjVDtgjIyABx89fN50HxWf+ZI8W/8Agpl/wpv9geK/+hI8W/8Agpl/wrnrzwte3PLY66FLFUL8kdz7K+H3j/SvHS3zaPBexCzKCQ3MarndnGMMfQ119fI/wl+JEHwv/ta08V+GPFMFxemKWKMWAVgq7hkh2U454xnoa9Cb9pnwtg7fD3i0nsDZRD/2rXj16SVR+yV4nsUKrdNe1dpHu1FeEJ+014XKLv8ADvixXx8wFnEQD7Hzead/w0z4V/6F7xb/AOAUX/x2svZz7M29rDuj3WivCv8Ahprwr/0L3i3/AMAov/jtH/DTPhX/AKF7xb/4BRf/AB2j2c+zD2kO6PdaK8IX9prwxvcN4c8VhBjaRaREn1yPN4/Wnf8ADTXhX/oXvFv/AIBRf/HaPZz7MPaQ7o91orwr/hprwr/0L3i3/wAAov8A47Qf2mvCv/Qv+Lf/AACi/wDjtHs59mHtId0ex+I9YtvD+h3mq34kNtap5jiNcsR7DPvXnA+PPhMj/Uat/wB+E/8Ai65Xxj8YIPGfgHVbTw/4L8b3H2pfIS4/ssNCG3LkFkdufb1Irw0aJ4s/6Ejxb/4KZf8ACuzC0qDi/bOzucWKq4hSXsFdWO9+M3jDTvGniCxvNJjuUhgtvJbz0CkncTwATxzXBqRTho3isf8AMkeLf/BTL/hSjR/FX/Qj+Lf/AAUy/wCFetTxGHpxUIy0R4tXCYmrJzlHVkRx2rvvgLqMGm/EuwNwHxco9shUZw7Yxn24rhjo/ir/AKEfxb/4KZf8K1vBCeItH8WaTq1x4H8YS21nciSQQ6TIzEKcEDOBnr3FTWxVCdOUebdFYfCYinUjLl2Z9t0V5V/wuT/qnHxJ/wDBH/8AZ0f8Lk/6px8Sf/BH/wDZ184fUHqtFeVf8Lk/6px8Sf8AwR//AGdZ+s/Hqy0eKGbUvAvjuzt3k2GS70tYR0JwpL4J46ccZPamk27ITaSuz2WivCv+GmvCv/Qv+Lf/AACi/wDjtH/DTPhX/oXvFv8A4BRf/Har2c+zJ9pDuj3WivC/+GmfC3/QveLv/AKL/wCO0f8ADTPhb/oXvF3/AIBRf/HaPZz7MPaw7o90orwhP2mfDBU+Z4c8WKcnhbOI8Z4/5ajtj/6/Wn/8NM+Fv+he8Xf+AUX/AMdo9nPsw9rDuj3SivC/+GmfC3/QveLv/AKL/wCO0f8ADTPhb/oXvF3/AIBRf/HaPZz7MPaw7o7D4/SCP4W6sCrNvaJeB0/eKcn8q+R1OBXsPxE+OGl+NPC914f0Twz4oe8vTGsW+zQksJFO0KrknIB6d68m/sTxX/0JHi3/AMFMv+FexgK0KNJxqOzv/keLmFCderzU1dW/zIiaYxqx/Yniv/oSPFv/AIKZf8KQ6H4rP/MkeLf/AAUy/wCFdv1yh/MjhWBr/wArOz+DfjLTfBXiS71DVormWGa1MC/Z1DMCWU5wSOPlr2n/AIXz4S4zDq3Iz/x7r/8AF18vvoXipVLN4K8VqoGSTpUoAH5VING8VOqsvgnxYVIyCNKlII/KuSssJWlzylqdlH65QjyQjofUNl8c/Cd3ewW0cWqK80ixqzQLgEnAzhuleqV8JaZpPii11SzuJPA/i4pDMkjBdJlyQGBOOK+idV+PmmaOkb6t4K8eWCSEqjXWlLEGI7DdIM152Kp0U0qDuelhalZpuurHslFeFf8ADTPhX/oXvFv/AIBRf/Haav7TPhne+/w54rCAjYRaREkY7jzOOfrXN7OfZnV7WHdHu9FeF/8ADTPhb/oXvF3/AIBRf/HaT/hpnwr/ANC94u/8Aov/AI7R7OfZh7WHdHutFeFf8NM+Fe/h7xb/AOAUX/x2hf2lvDc0scNp4a8WzTyOqLGLKPLEnGABIST6DvR7OfYPaQ7nutFeVf8AC5P+qcfEn/wR/wD2dd74T1z/AISPRIdS/svVdK8xmX7Lqlv5E64JGWTJwDjI56VBZm/Fj/klnjL/ALAt7/6Ieuqrlfix/wAks8Zf9gW9/wDRD11VABRRRQAV5T+0Lrtrp3hyx0vUPDWp65aalcxrKbO3ZxAqyx5IdWBSU7v3fqwweM16tXAfHLRNQ8QeAJrHStOl1Sb7VbySWKXQthcRLIpdGckYBUEdc9+1AHP/ALPsdqv9vyaR4a1nSNKkMDR3WtK4u7uQBw+4szAquFAxj7x716/XhHwV03xV4Z8W31snw/fQfC+psjMg1uK6jsXSN8sq5LMZDsB6Y4r3egDldN/5Kn4h/wCwLpn/AKPv66quV03/AJKn4h/7Aumf+j7+uqoAK+bf2qRnxJoP/XpJ/wChivpKvm79qj/kY9B/69ZP/QxXdl38dfM4cx/gM8TRafjApFNKx4r6M+XZ9hfBE5+Fugf9cn/9GPXcVw3wQ/5JZoH/AFyf/wBGPXc18piP4svV/mfYYb+DD0X5BRRRWJsFFFFABRRRQB8v/tOoP+E/sj66dGf/ACJJXkirxXrf7TRz8QbMemnR/wDoySvKUr6jB/wI+h8ljnavL1G7KNntU4WlxXScXOV/L9qTy+asGmmgakyEpTSntUrMBUllZ3eo3S22n2011cMDtihQux9cAc0XsVG7Kqr1prD0roF8HeKCSB4c1g46/wChyf4Ug8GeKTIgHhvWOWH/AC5yf4VHtIdzVU532PpX9n7SNQ0X4fi31a0ltJ3upJVjkGCUIXBx+FelVFaBltYVcbWCKCPQ4qWvlas3Um5vqfXUYKnBQXQKKKKzNAooooAKKKKACvKP2lrOe7+HKvBE0gtr2OaUj+BNrLk+2WH516vXEfGw4+FviA/9MV/9GLW+Gly1ovzRz4qPNRkvI+OkSplQYpkdTCvqj4+TECCjy8VIMUuaDPmZFs9qNlSUuRQHMyLZ7U0rUxNRuaBps6L4ZcfEXw5/1/Rf+hV9pV8VfDM5+I3hvn/l/i/9CFfateHmvxx9D6PJ/wCHL1CiiivKPYCiiigArw79qbnRNBH/AE8yf+givca8N/alb/iU6APWeU/+OrXXgf8AeI/10OLMP93l/XU+eVTPaniP2pyCp1H519MfIykQeX7U0x1bxxTGFAuZlR0rW8CoT468P7Rz9vhx/wB9iqKxPNIscSM8jHCqoySa2Ph0B/wsTw2G4/4mEOc/74qKj9x+h0UXeSPtiiiivkT7Q5X4sf8AJLPGX/YFvf8A0Q9dVXK/Fj/klnjL/sC3v/oh66qgAooooAK8z/aIh+0fDd7f7JdXpmv7OL7JBL5QuN06DynfI2q2du7sSDXplcJ8bdOg1P4e30N5b6VcWyPHLJHql49pCyqwJzKhBU+nbPWgDF+A3h3/AIR+01gf8IJ/wiHnPEdv9sf2h9pwG56nZtz+O72r1WvAf2evFvw+hvp9G8MaHeaDqeoSbWR55LuC4eJWbEc+5lOF3n+HPvxXv1AHK6b/AMlT8Q/9gXTP/R9/XVVyum/8lT8Q/wDYF0z/ANH39dVQAV87ftO6bqN94h0N7Gwu7pFtZAzQws4B3jg4FfRNFbYet7CamlcxxFFVocjdj4SXQNc7aNqf/gJJ/hQ2g65j/kC6n/4CSf4V920V6P8Aa0v5fxPO/siP834HE/BaC4tvhjoUN3BLBOsT7o5UKsP3jYyDz0rtqKK8upLnk5dz1KcOSCh2CiiioLCiiigAooooA+W/2mW/4uJbe2nx/wDocleVo1en/tO7x8Rbb5WIOnx4wP8AbevKEZv7jfka+owf8CPofKY2N60vUuB6UtVYMw/gb8jQXb+635Guk4uQsxiSaRY4UeSRjhVQZJPsKtNour/9ArUP/AZ/8K2/g+zH4m+Hhsc/6Tz8p/umvs6vPxeNeHkopXPSweXrERcm7WPhI6Nq5JxpWoHH/Ts/+Feg/AHTdSt/ibYyXGn3kUKwzbnkhZVX5CBkkeuBX1ZRXFUzN1IOHLv5no0srjTmp823kFFFFeWeqFFFFABRRRQAUUUUAFFFFABXFfGeCe5+GOvRWsMk0zRLtjjUsx/eKTgD2rtaKunLkkpdiKkOeDj3PhCPRdZ/6BOo/wDgM/8AhU66LrP/AECNR/8AAV/8K+6KK9T+1pfy/ieS8ni/tfgfDR0TWh10fUh9bV/8KQaLrJ6aRqP/AIDP/hX3NRR/a0v5fxF/Y0P5vwPho6LrQ66RqI/7dX/wpBous/8AQI1H/wABn/wr7moo/taX8v4h/Y0P5vwPhhtF1nHOkaj/AOAr/wCFMbRdZ/6BGo/+Az/4V91UUf2tL+X8RrJor7X4Hxr8M9G1ZPiJ4dkk0u/SNL2N3ZrdwFAOSSccCvsqiiuLFYl4iSk1ax34XCrDRaTvcKKKK5TqCiiigArw39qcgaRoH/XxL/6CK9yrwj9qvf8A2Z4e2o7L582Sqk4O1f8A69deA/3iP9dDjzD/AHeXy/NHgMbD1qcNxVFC/wDzzk/75NSh37xv/wB8mvpj5KUC2XqNmqHzGH8D/kaYZD/db8qCVA6TwGWbxpowQFmNwuABkk1P4H0vVF+IuiMdOvFK6jGzFoGAXDjJPHGKh+FjM3xI8ODY5/02P+E+tfalebjcV7CXKle6PYwGDVaN27WYUUUV4B9Gcr8WP+SWeMv+wLe/+iHrqq5X4sf8ks8Zf9gW9/8ARD11VABRRRQAVwHxuvbLT/BsM+r2NleaZ/aNqt39thaWGKIygNIyqRnHbPGSM56V39eZ/FD4paT4F1m10zxNp0jaZfQowuirOjEy7JEKBCDsT5zzkjgDJoApfATxfqfiiyvYNW03TrGK3it72xisYjGkUE/m7EIzgMAmeOocV6zXH/D3xp4S8ZrqE/g25iuPs5jS5ZLV4COCEB3KueFIHXGK7CgDldN/5Kn4h/7Aumf+j7+uqrldN/5Kn4h/7Aumf+j7+uqoAKKKKACiiigAooooAKKKKACiiigAooooAY8aOQXRWPqRmjyox0jQfhT6KAsN8tP7i/lR5af3F/KnUUBYYsaK2VRQfUCn0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjAHqAaWigBNq/wB0flRtX+6PypaKAG7E/ur+VIYoz/Av5U+igBgjRTlUUH1Ap9FFABRRRQByvxY/5JZ4y/7At7/6Ieuqrlfix/ySzxl/2Bb3/wBEPXVUAFFFFABXB/GvVbjRfAz3lobWFxd26te3Vt9ojsVMi5uCmDkp1HocGu8rF8X63a+H9Cmv9Qs7y8tFIjljtLczttY4JKDkqM8+1AHC/A7xPqGuya/ZXev2/iazsGg8jWILIWqys6sXjKjgldq8j+9Xqlc34K8S+F9fsMeEdQ0+eCPkw2uEaP8A3o8Ar17gV0lAHK6b/wAlT8Q/9gXTP/R9/XVVyum/8lT8Q/8AYF0z/wBH39dVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFeOJ8WdRPxYbwodNtPsYvfsgm3tvx/e9Pwr2OtalGVK3N11MqVaNW/L0CiiisjUKKKKACiiigDz3xj8QL7w/qWvJb6La3dhodlb315NJqBhlZZWkAWKPymVmHlHguuSQBXS3PivSrXWodLuzfQXU0ixRvLYXCwO7LuVBOU8osR2DZzkdRiuf8S/DPTvEPiHUtavJVXUJoLVLG4SBfOsJYGkYSI5JyGMi5XABCYOc8ZUnwsubnxRba3qGr6dc3UeoQag87aVm5zGFBhjlMp8uEkEhAuRnkt3AOhT4h+Hb0Tw2OpPHOI7gxTT2FwIWaEN5gViqiQptJKK2cA/Ws3xT8R7PSdEX+z7hb/Vwlo7GOwuGgUTOgDSFQRDuViVV3B6de+R4c+Hms3ehW1r4iv4LeC0m1GS0tIrbMkb3DToskkolKyAJMxCqqY3AEkirt18M777LdWVj4ghgsL77E94klgZJHktkiQFH80BAywpkENjsaAO717XNP0G1juNTmaNZZBDEkcTzSSyEEhUjQFnbAJwoJwCe1ZUPj3w5LYX14t+6w2MCXNwJLaZHRHZlU7GUMSWRlwATuBGM8VP4t8Pz6zJpN3p98ljqel3JubaaWDz48tG8bK6blJBWRujAg4Oa5bWfBWo6v4u8KXGqTG7jso5ZNTvI0SGK7KyJJBCYcscLIA464CEEktQBpeKPiHpWnWGtR6dO02q2VtctGGtJjbmeKBpTE0oUJuAXJTeGGD0NLD4902yhll1vUo9xltrdbe10+dpI5pbcSiP5d5kLDLDaBgEKcnk1bjwJqhtNd0uz8QwwaFqz3sr2zafvmV7lH3DzfMAKCSQuAFDcbd2KdD8O/K1eG+/tTPl6jaX+z7P18i0Nvszu/izuz26YPWgDVPj7w4bGzuo7y4mF28scUMFjPLcFojtkBhVDIuw8NuUYyM9RW5omq2euaRZ6ppc3n2N3Es0Mu1l3oRkHDAEfiK811rwjrnh2/XWPCjXF9qss+oFglrC6LFdSpLtYS3EWCrIuHBbvlK7X4daNceHfAfh/R70qbqysYoJdhyN6qA2D3Gc0AV/ix/ySzxl/2Bb3/wBEPXVVyvxY/wCSWeMv+wLe/wDoh66qgAooooAK8r/aA8YaT4d8PWOm6nreoaPLqtyiCew3LMsCyIJmVwrY2q4OOp6DmvVK82+MOhade29tc6rq3iS2W6mtdPgg0q5WMJMbhXSZQwwrgjl8/dHHOKAOV+COk/DnVvEN3qPgvT7u5l0co667cTTeZdSTJIsisHC5IHXjHzA8Gvc68g/Z51TS9QttcGl6x4u1LbJGwPiK5ExMRLhJIcdFYq4PuntXr9AHK6b/AMlT8Q/9gXTP/R9/XVVyum/8lT8Q/wDYF0z/ANH39dVQAVyvifxaND8T+HtINmZv7WmMXm+Zt8rA64xz+ldVXlfxNH/Fzvh+2BgXL/XpW1CCnO0uz/IwxM5QhePdfmeqUVwHwy+JVr48u9SgttOnszZBSTJIG3gkjt06V39RUpypy5ZqzNKdSNSPNB3QUVi2viCG48W32grDIJrW2juWlJG0hyRgd88frW1UuLjuVGSlsV9QuPsdhc3JXf5MbSbc4zgZx+leafCj4rv481u6099IFj5NubgSC48zOGVcY2j+91rovix4ni8KeDbm8mtpLkXB+yKiMFwXVuST2GK+ZvhL4yg8Ca5dahcWUt4s1sYAkbhSCWVs8/7td+GwvtaM5Wu+h52Kxfsq0Y3sup9lUVj+Edcj8SeG7DWIIXgju494jcgleSMZH0rYNcEk4uzPRjJSSa2Z5r8Vvic3gPUNPtU0oXxuomlLGfy9uDjH3TmuG/4aIl/6FpP/AAM/+wrD/aX1JLzxxa2KxsrWNsAzk8Nv+bj6V5GRXu4XBUp0oynHV+p8/isdWhWlGEtF6H2N8KvHB8d6NdXzWH2JoJ/J2CXzA3yg5zgetdVq14NP0q9vTGZBbQvNsBxu2qTjP4V4D+zX4ogtbqXw01tIZryR7lZww2jag+Ujr2NeyfEnUl0jwHrl5JG0qrasm1TjJf5B/wChV5mIoclfkS0ex6mGxHtMP7RvVXueQD9ombGR4aT/AMDD/wDEV2vwq+KT+OtYvLCTSRZGCDzw4n8zd8wXGNo9a+VFX5QK7b4U+NIvAmtXd/cWUl4txb+QEjcKV+YNnn6V6tfAUvZv2cdfU8mhmNX2i9pLT0/4B9iUVzPw98WQ+NPDo1a3tZLVTK0RjkYMcrjnI+tdJIwRGY5woycV4MouEnGW59DCanFSjszw3xD8eJdJ17UtOTw8sotLh4PMN3jftYjONnGcVUtf2hJZruCJvDihZJFQkXnTJx/crxTxBfrq2v6nqKRmNbu5knCE5KhmJx+tUrWQQ3UExG4RyK+PXBzivoVgKHLrHX1Z808xr82ktPRH3uKK8g8L/G+x1/xHp+krot1A95KIlkMysFJ9RivXxXg1aM6TtNWPoqVeFZXg7hRRRWRqFeC6x8fZrDVr2zj8PI6287wh2uiC21iM42+1ek/ErxxB4F0y1u57KW8NxKYlRHCY4zkk18g6rcDUNVvLzbsFxM823Odu5icfrXqZfhI1U5VI3XQ8nMcY6TUacrPqe76J8e59R1mwsZPD8aLdXEcG9bokruYDONvPWveK+EtFvF03WLC+aPzBa3Ec5QHG7awOM/hX174D8cW/i7RoNQis5rUS3b2gR2DYZYy+cjtgUY/CKlaVOOnUMuxjq3jVlr0Owoooryz1gooooAK8s+KfxVk8D6/babHpC3oltxOZGn8vGWYYA2n+7+tel6hcizsbm6dSywRtKVHUhQTj9K+P/il4zi8c6/b6lDZSWaRWwg2O4cnDMc8f71d2Aw6rT95XSPPzDEujD3XaTPQj+0Pc4/5FyL/wLP8A8RXtXgnXf+Em8K6drBt/sxu495i379uCR1wM9K+ICAa+p/2efEkWreD/AOyktnifSFWJpGYESbyzAj06V1Y/CU6dPmpx6nJl+MqVavJUl0PVKKK5D4leN4PA2l2t7PZS3n2ibyQkbhccE5yfpXkwhKclGO7PYnONOLlJ6I+bvFWrNoHxs1TVkgE7WmpNKIy23djtntXvPwn+JL+PLnUYZNLFibRUcMJvM3biRj7ox0r5j8V6qmveJtT1ZITAt5O0wjLbiue2e9dP8J/H0PgO61KafT5L0XaIoEcgTbtJ9R717+JwvtKK095JHzuGxns62/utn15RWJ4N8Qw+KNAt9Vt4JII5sjy5CCRj3FbdfPyi4txe59HGSmlKOzCiignA5pFBTJn8qF5MZ2qWx64FeI3H7QlhFcSxroF2wRioP2hRnB69Kr3P7QlnJbyRr4eugXUqCble4+ldawNf+X8jieYYf+b8y94N+N8viLxXYaO+grbpdSmPzRdbivB5xtGele118OeDNaTw74q0/WJLdp1tZfMMSttLcEdfxr7G8E+Io/FXhmy1mC3ktkuQxETkErhivUfStswwyotSgrL9THLsU6ycajvL9Ddooorzj0wqtqV0LLTrq6KFxBE0u3ON20E4/SrNeU/Fn4oW3ha8uNBk0ue5luLMnzVkCqu8Mo4xk1rRpSqy5Yq5lWqxpQ5pOx1nw08W/wDCa+F49X+x/Yy0rxGLzN+Np65wP5V1VfLnwy+Ltt4K8LJpE2jz3TLM8vmJMFHzdsEV2ulftAWF/qlnZnQbuL7RKsW/z1O3cQM4xXVWwNVTfJHQ5KGPpOC55ant1FFFcB6ByvxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9dVQAUUUUAFef/HRrMfDy5iv9Fn1kT3NvBDbQT+Q3nNIojYS/wAGGI+b3weCa9Arzr49mwb4ey22p6bBqUd3d29vHDc3LW0KyM4CvJIpBVQeTg89KAKvwS0i906PUpNQ8IP4ZPk2tpCjapHeiSKJXAAKAbcFiTnOS5Nen14X+zE+iiDV00HSrOwWWzsLuc2s80o8yRJMxsZHfBUgnAxw4znGa90oA5XTf+Sp+If+wLpn/o+/q1411TXtI0qKfwx4c/4SG9aYI9r9ujtNke1iX3uCDghRjr82e1VdN/5Kn4h/7Aumf+j7+uqoA8q/4Tb4n/8ARI//AC5bX/4muW8UXXxP1zxJoGrD4YCD+ypGk8r+37V/NyMYzxj8jXv1FVGbg7xJnCM1aR8o+DJ/HvwettX1nWfAPn2VwI0d/wC2IF8s7jjhd5OS3pWwv7TOpsG2+AM4GT/xOV6f9+q9f+Muhah4k8AX2m6PAJ7yR42SMuFyFcE8k46V8cwo0RvEkGHRCrD0IYA16mHoRxidSrJ83y/yPKxOIlg2qdKKt8/8z3bwh408ea5r174w0T4a/a7O+t0tAn9uwR4MbHJyygnrj7o6da6DWPih8QNF0m61LVfhS0FlbH95IdfgO3kAcBCTyRyBiuj+AVjcWHww0tLtNjSl50GQcozEqfxHNbXxS0i917wDrGmaXEJb24jURIXChiHU9TwOAa4Zxj7bkb0Tt8juhKSo88Vq1e3meAeJviF4q+L+my+G9C8BGO7t5Fu5G/tiI4VSV/iVB1Yd65T/AIVX8T8f8iZ/5VLX/wCLr1/4GeAvEnhfxrql/rlgltaS2zRI4nR9zGRSMBST0B617rXRUryw0vZ0J+78n+hz0qEcVH2leHvfNfqfNFr8V/FXwv0XSvDevfD3FzBb7kf+2ov3ilm+bCowHIPGe1OX9pjVHOF+H+TjP/IZXp/36qt+1OceNtL/AOwcv/oySua0r4S+NrqOK5h0hfImiLozXMQyGXI43Z5zW8MJRnBVasrN+aRhPF1oTdKlG6Xk2T+JtL+IPxM1IeKtJ8C+VZXsSiMf2tbtkL8ufmKnqPQVkH4WfFA/8yX/AOVS1/8Ai6+qfhbpF7oPgDRtN1SIQ3tvEVljDBtpLscZHB611Vcrxlam3CEtFottvuOqOCo1Upzj7z1e+/3nyj8PPCnxP8H+KINY/wCFfi88qN08n+2bWPO4Yzu3H+VaHjz4u+JfEMN/4Ik8AfZNWu5Es8f2zHJsk3qQPuBTnjndjnrX09Xyp4nsrix/aPtVuUC/aNWtp4+QdyM64P6GroN4mo51HqldbdCK6jhaahTjo3rv1+Zysfwx+Jz7tvgthtO07tTth+WX5HuKcfhZ8Tz/AMyZ/wCVW1/+Lr7TorP+0MR/N+C/yNP7Ow38v4v/ADPmDQvHXjH4O+GbXSvEPw+3C5nlkhm/tmEbvu5GEV8YyOp71aT9pHVrx1tofh+TLMfLQf2yvJPA/wCWXvXR/tT6bdXOj6DeQRbre3nkjkbcBtLhdvHvtNeR/D3wL4j8RXFlqelWAl0+K7VZJjMihSrAtwTk4HoK6qWGpVqft6stXvt/kctXE1KNT2FKOi23/wAyu3wx+JqyKh8FNufJBGpWxHHqd+B+NP8A+FWfE/H/ACJf/lVtf/i6+06K5f7QxH834L/I6f7Ow/8AL+L/AMz5A8KeAvifoHiXTdW/4QUXH2OZZvK/te1Tfjtnccfka7LUv2i9b0zUbmxvvh2Yrq2kaKVP7aQ7WBwRkRYP4V9G18YfF3T7jT/iTr6XSBWmuWuEwQco/wAyn8q2w8frs2q0tl5f5GWIksDBOjHd+f8Amd1/w0zqeM/8K/8A/Kyv/wAaoP7S+qoqF/AH3hkEayvP/kKvIdMsbjUr2CxsYzLdXEixxICBuY9BzXcz/Bzxy8cAXR4yQhBH2uLjk/7VdM8BhoaSnb5r/I5YZjianwwv6J/5jvF3j7xN8YWsdG0TwR5N3bu9xj+1om3DGD95UAx9axP+FW/FD/oTP/Kra/8Axdep/BL4ceJ/DPjQajrdhHb2ggdNwuEclj04UmvoAVy1a8sM/Z0J3j8n+h1UsPHEp1K8LS+a/U+Lf+FW/E//AKEv/wAqtr/8XXV6H4j8d/Cfw9bRa94A3WaXxuFmGrQjLvEybPlD+hP4V9T1558c/Dmp+J/BaWWi263F1HdpMULhPlCsDgk47jis44mpXkqdWXuv0/yNJ4Wnh4upRj7y9X+p5b/w0zqn/RP/APysr/8AGqX/AIaY1T/on/8A5WV/+NV4xtIYgjkHBp4XmvR/sqj3f4f5HmPN63Zfj/mex/8ADTGqf9E//wDKyv8A8aoP7TGqEHHgDB9TrK//ABqvGmApje1P+yqPd/h/kNZtWfRfj/mfRmm/Evx74w8Nzz6L8LvOs7lJIFm/4SCBcHBU/KyA8V44PhX8Txj/AIoz/wAqlr/8XX0z8FND1Dw94BtLHV4RBdeZJJsDhsKxyORx0ru68r208POUaMtPket7CGJhGVaOvzR8V/8ACrPif/0Jf/lVtf8A4uut8Iat47+Dekalea54A860vJYl8z+2YF2MA2BhQ5Oc+3SvqevPvjloGpeI/Aklno8AnuUnSYoXC/Kuc8njvVrFVK7VOrL3XvsRLC0sOnVpR95bb/5nlX/DTGqZ/wCRA4/7DK//ABqsnxN4z8X/ABmsE0/w/wCBPLbT5RPK39rwnhgVA+dU9+ma8qJ55r6A/ZW0+6Ua7qTIBZyeXAj5HLrkkY9gw/Ouytg4YWDqwbuttv8AI4qOMnipqjUirPff/M8u/wCFW/E/H/Il/wDlVtf/AIukPwt+J5H/ACJf/lVtf/i6+06K4v7QxH834L/I7v7Ow38v4v8AzPljw98Y/EHw+sV8M6j4E8y7s3KP/wATeMfMT04Rh+tb2rftDa9pN19n1D4dGGbG7b/bcbcZx2iPpXG/HHR73S/iNc3N5Eqw38pnt2Dg7lyB+H41mfFRg3ibP/TLn/vpq7o4GnV5Ztv3ten+R57x9SjemopKOi32+872f9pLV4Cgl+HxUuocf8TpDkHof9VUb/tLaoEBb4fkBhx/xOV/+NV5z4h0PUU0Sy11rfGmMsdsJt4/1mzOMdelaemfC/xfrmi2GoaXpiTWs8ZZHNzGpIyezMDQ8Bh4q8pW+a/yCOY4mbtGCfyf+ZmWvw++I2rWcepWXg7zLW6Xz42GpW4yrcjgtn9M1Mvwt+JzKGHgvgjIzqlsD+W+vrzwZYT6X4T0iwvFC3NvaxxSKDuAYKARnvWzXHLH102lL8F/kd0MvoOKco6+r/zPiwfCz4ngf8iX/wCVW1/+Lru9O+Jvi34VeH9L8Pa/8Pf3yRu8cn9tRfvFLk5wqNjrjrX0xXzx+1LYXH9oaJqGwfZTE9vuzzvzuxj6VVKrPFzVKtLT5f5EVqUMHB1aMdfn/mUf+GmNU/6J/wD+Vlf/AI1R/wANL6rn/kn/AB/2GV/+NV40q0u2u/8Asqj3f4f5Hn/2vW7L8f8AM9k/4aY1T/on/wD5WV/+NVy/ieLx58W7+PxJongfyrTyxbAf2tA2WUnP3tp7+lcA4wDX1p+z7Y3Fj8NLL7Umzz5ZJ4+c5Rjwf0rCvh1go+0pSd9un+R0YfEyx0vZ1Yq2/X/M+cj8Kvief+ZM/wDKpa//ABdS2Hw1+J2m6haXx8EmT7PMkuwanbHdhgccOa+0KK4/r+Ie8vwX+R3fUMOto/i/8zyr/hNvif8A9Ej/APLltf8A4mu98J3+ranokN14g0X+xNRZmD2X2pLnYASAfMQAHIwfbNbFFcZ2HK/Fj/klnjL/ALAt7/6Ieuqrlfix/wAks8Zf9gW9/wDRD11VABRRRQAV5r8b7zxKmj2Fh4c8Jr4is72dVv0eWMKIhIn7tlcHhwWG8fcxu7V6VXnvx00e+8Q+A5dL0qxk1O6kuIJW0+O7W2NzCkimRC5I+Urx7ZBoAp/BTTdZ05NYW/8AClj4T0lzEbPTra4iuG8wBvNkaRBk5/dgBskbfSvTq8o+A2gL4fg1uH/hBl8IySPCWj/tj+0DPgNgnk7MZ/Hd7V6vQByum/8AJU/EP/YF0z/0ff11Vcrpv/JU/EP/AGBdM/8AR9/XVUAFFFFABXxjd/Djxm9/qbJ4dvypaQg7R8w39uefwr7Oorqw2Klh78qvc5cThY4i3M9jnvh7ZXOneB9Cs7+Iw3UNnGkkZ6qwXkGuhoornlLmbk+p0RjyxUV0CiiipKPmz9pvR9S1HxtoI0+ymuDdWn2eERjO+RXZio9wGB/GvoPw9BLbaBpkE6FJorWJHU9mCAEfnXIfEDT7y78d+Abi1tZpoLa8naeRFysQMXBY9hxXf111qvNSpw7f5nJRpctWcv67hRRRXIdYV4L8QfCuvX/x50LVbLS7mbTIpLRnuVHyKEfLZPbAr3qitqNZ0W5LtYxrUVWiosBRRRWJsee/HLRtS13wVHaaNaSXV0L2GTy0IztBOTz9ar/s/wCi6loXgJrTWbOWzujeSyeXKMNtOMH9DXpVFb+3fsvZW0vcw+rr2vtr6hRRRWBuFfKX7SFlc2/xGe6mhZLe5t4/JkPR9ow2Poa+ra+df2poprjXPDFvbRSTTyRzKkaKWZiWTAAHU135dK1dedzgzKHNQ9Ged/CGwutQ+IeiCzheX7Pcx3Eu3+CNWGWPt/jX2dXzV+zn4e1vTvHNxdanpF/Z24s3TzLiBo1LFlwMkdeDX0rVZnPmqpLoiMsp8lNt9WFFFFecekFNlBMbAdSDinUUAfDPiDQtV8P33ka1Yy2c0uXRZMfMuSMjHaqdnbXF9eQ2lnE09zMwSONBksx6AV7X+0poWtap4n0mbStKvr2BbMoz28LSBW3k4OBxxiuI+GXhXxJB8QdAnutB1OG3iu0eSWW2dVRQckkkcV9PTxKlR9o7XsfK1cI41uRbXM7/AIVv4zbp4dvv++R/jTT8NPGpYD/hHb3r6L/jX2jRXmf2rU/lR6qymmurIbNGjs4EkGHWNQw9DipqKK8s9VKwVDeo0lnOiDLtGyj6kVNRQD1Pipvhn423sP8AhHL7qey/419Dfs96Dqvh7wXdWut2UlncvevIscmMldqDPB9Qa9Porur46deHI0jhoYGFGfOmFFFFcJ3Hhf7Q3hLX/EWu6FNoWmTXkUUbJI0ZX5DuB5yRXFfEj4eeLbvxAJrPRZ7iIx/fiZWGdx96+qaK7qWOnSjGKS0OCrgIVZOTb1PnrxF4J8SS/BWw0qLSpn1JL9J3t1ZSwTy9uevr261698MtPu9K8A6HY6jC0F3DbhZI2IJU5JwcV09FY1cTKrHla63NqOFjSlzJ9LBRRRXOdIV4/wDtKaPqOqeGNPm060e4is5nmuGQj92mz7xHpXsFYXju3nu/Beu29nE81xLZTJHGgyzsUIAHvW2Hn7OrGRhiaftKUonxErVZsbW41C8htLKFprmZgkcadWY9AK0I/BfiwgY8Nax/4CP/AIV03w18KeJrbx/oM914f1OGCK7R5JJbZlVFB5JJGK+mnVjGLaaPlo0JSklYzJPhn41IOPDt5/47/jX1V8ONPutL8C6JY38RhuoLZVkjJBKn04rpKK+fxGMniIqMlsfR4bBQw8nKLCiiiuM7QooooA5X4sf8ks8Zf9gW9/8ARD11Vcr8WP8AklnjL/sC3v8A6IeuqoAKKKKACvPPiH8N38ZeKNJ1QeIdV0aOxtZoCdLm8idy7IR8/Py/KcjHPFeh0UAcF8M/h9J4I1XxDctrmoawmpm3Ky6jL5twvlqwIZ+N33uOBgDFd7RRQByum/8AJU/EP/YF0z/0ff11Vcrpv/JU/EP/AGBdM/8AR9/XVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXjnxatbqb4tfDmWC3mkiS5O90QlV+dCcntxXsdFa0qnspc3qZVqftY8twooorI1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfix/ySzxl/wBgW9/9EPXVVyvxY/5JZ4y/7At7/wCiHrqqACiiigAooooAKKKKAOV03/kqfiH/ALAumf8Ao+/rqq5XTf8AkqfiH/sC6Z/6Pv66qgAooooAKKKKACiiigAooooAKKK5D4aavfazp2sS6jN5zw6tdW8R2gbY0fCrx6VSi3Fy7EOaUlHudfRRRUlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXPeOtbudA0W3vLNIXkk1CztCJQSNk1xHEx4I5CuSPfHXpXJ+OvGWr6d4lu9KsGhghgOjyCUR7nYXN8YZVO7K4KLgYAIyTnpgA9NorzfRviTcGC+l1rQdRjRNam0q2ktkicSkSMqLtEpbcAvzHAXJ44q9N8StOs/E9hoOq6feaff3rxxRpNdWbsHdcqGjjnaQc/Lu2bc98YNAHdUVyl94/8AD0Nqk2n30Ws7ruOyMelyx3LpK+7aGCtxnaaoTfErTrPxPYaDqun3mn3968cUaTXVm7B3XKho452kHPy7tm3PfGDQB3VFeer8TNPu7VmbTtc0+1uBdxW1+0cG2SWBZC6xje3zYicrvUKdv4VneKPiHNH4dlTw7b6tcXNsth9o1J47cJbmdomCyAsMu0bgkRowG8dOwB6nRWN4l8QQaClkr211e3l9P9ntbS1VTLM+1nIG5lUAKjMSzAADrWHN8RdPtbe/bUNM1axurS3huPsdxFGs03mytEqR4cqW8xdvUDLKQSCDQB2tFee+JvHz/wBieIzomm6tmxt72JNWEMTW0VzBC7MpBct8rIV3FNhYbcmo4PH8Gn71uI9a1W+kubOyFtDFbgCaW0EwEZynykAkl24YnGF6AHo1FcRbfEWzvFtItP0fWLvVJ3uUbTY0hE8H2eQRymQtIIwAzKMhzncMZro/C2t23iTw5p2tWKTR2t/AlxEkwAcKwyAwBIz9CaAMn4sf8ks8Zf8AYFvf/RD11Vcr8WP+SWeMv+wLe/8Aoh66qgAooooAKKKKACiiigDldN/5Kn4h/wCwLpn/AKPv66quV03/AJKn4h/7Aumf+j7+uqoAKKK5zxFrF1p1+6weWY00+a52sucuroBz6fMaqMXJ2RM5qCuzo6K57QNauNR8R+IrCZI1h0+SJIioOTuQk5/GuholFxdmEJqauv6sFFcvqeu3dt8QdF0SNYjZ3lpcTysQdwZCm3B9OTXUUSi42b6hGSle3QKKK4vxn4pvdF8Y+EdKtY4Ht9WmljuC4JYBQuCuDx94+tOEHN2QqlRU1zMra14m1K1+Lvh/w/C8Y0y8tZZZlKAszBZCOe33RWR8Er2Zvhzq2oOQbhr+8nJxxuznp9a5zxfrc8XxesdRVIxLY2V6sYIO07BMBmtr4IH/AIs9fs3eW7Y/rXfOko0U7b8v5s82nWc6zV9ub8kdV8PNf1DW9H0OfUGR5brTRcysqbcvvA6duO1dnXiP7Omv3msQfZLpIli0yzW2hKAgld+fm969urlxVP2dRxOzCVPaUlIKKoWd68+p6hbMqhLby9rDqdy5Oaow6zNJdQxGKPD38toSM8KiMwP1ytY8jNvaI3aK5n4g69c+HdCivbKOKSZ7y3t8SAkbXkVT074Jq/Y6pLcaxLZtGoRDLhhnJ2GPH/oZ/Kn7N8vML2kVLl6mvRVLR7t77ToriRQrOWGF6cMR/SuZ8JeK7vW/FmtaZNDClvZRRPGyZ3Eszg5z/uihU5NN9gdWKcV32OkS6kbXJrQ48lLdJRxzuLMD/IVfrmdHvpLrx34ht3VQlnDbRIR1IZWc5/FjWzcXjxatZWgVSk8crs3cbduP/QqJRs7eX6XFCaav52/Gxdoqg96y65FY7Bse2ecv3BDKMf8Ajxp2r3jWNi06IHYPGmD/ALTqv9anlei7l8ys32Lp6VR0O5lvdHs7mfb5ssQdtowMmudk8UXY8QeFLFYYfJ1YXZmJzuTylyu36nrmtLwfdmfS44SoAgiiUEd8xq39a0dNxjd/1ujONWMpWX9aJ/kzeoqnf3bWstkqqG8+cRHPYbWOf/HaXSbpr3TLW6kUK00auQOgyM1nZ2uacyvYt0VW1K4Nrp91cKAzQxPIAehIBNS27mWCOQjBdQxH1FFtLjvrYkoorO1q/fT4YpI0Vy7spBPYIzf+yihK7sgbUVdmjRUFjMbiygnIAMkauQO2Rmp6Q076hRWfqN+1pcwRBAwkjlkJJ6bAD/WrFhObmxt52UK0sauQO2RmnZ2uSpJuxYqjrl3JY6PeXUIUyQxM6humQKvVwN14luNRtPHlrLBEsekfuomXOXBi3Hd+PpV04OT9P8yKs1Bet/yOusbuWbVNQt3CiOARbMDn5lJOa0K57wpdNfSXN5Iqo88NtIyr0BMQP9aZrniGXTtFub2OCN3iuvs4VmOCN2M0ODcuVeQo1Eocz8zpKKBVS6umhvbOBUBWcuGbP3cLmoSuat2LdFFYfh/WpNU1PW7aSJI1sLkQIynJcbQcmhRbTfYTkk0n1J/E+hWniTRZ9MvzMkMjI4kgfZJG6OHR1bsysqkfSsH/AIV9ZTfa5dS1TVdRvrq4s55by4eISYtZRLFGAkaoqbs5AUE7jznmuzqrpl0b2whuCoUuM4HPelbqO+tjmY/AVkl+8w1LUjbHUxq6WZMXlR3G4sxB8vfhixJBY+2Khn+HVhLrr6iup6rFE+pR6s9lG0XkvcIAAxJjMhHH3d+PQCr/AIV8Sya3KyvbpEA0wyrE8IygfnurYW+JvL+Hyxi2jRwc/e3Bj/SrlCUXZkRqRkk0R65otvrP9n/anmT7FeR3sflkDLpnAOQeOe2D71zk/wAOrCXXX1FdT1WKJ9Sj1Z7KNovJe4QABiTGZCOPu78egFdFpupteTQRtGq+ZZx3JIPQsTx+lQ6PrLahrWsWLRKi2LoisDy+4E8/lS5Hr5D9pHTzOQ8NfDMwaXHB4h1W7u2ie+aC2iaPyLX7Q0oLofLDl/LlI+csAWbAxirl38MdNnWSKHVtYtbScWv2m2hki2XDW6osbvujLA7Y0B2lQdo4ruLqTybaWUDJRC2PXAzTbGY3NlbzldpljVyPTIzilbqVfWxmeJvD0GvJZM91d2N5Yz/abW7tColhfayHG9WUgq7KQykEGuevPAhu/E/hO9u7p7230NJ5GubuUtc3EzlSgYKqpsUgv7FUAAANdhqt0bHT5rkLvMYztJ681botpcL62OKuvh7aTtqkSazrVvpmpNcyT6dDLGIPMuEZJHGYy/JdnCliobnbU0XgDS49RjvVuL3zUvbe+ALpt3w2/wBnUfd+6UOT3z3A4rr6pXN4YdTsrUKCLgSEtnptAP8AWhK4NpbnBeIvAN7bypeeDriWDVGnvJZLmS/W3IW5dZJI/wDj2lDLvVSBhWG0Ybk11/gjQz4a8H6LojSiZrC0it2kAwHKqASB6E5rbopDOV+LH/JLPGX/AGBb3/0Q9dVXK/Fj/klnjL/sC3v/AKIeuqoAKKKKACiiigAooooA5XTf+Sp+If8AsC6Z/wCj7+uqrldN/wCSp+If+wLpn/o+/q1411TXtI0qKfwx4c/4SG9aYI9r9ujtNke1iX3uCDghRjr82e1AHQV5l8TtUnsPEtjBEkbR3enXMT7s5ABVsj/vmq//AAm3xP8A+iR/+XLa/wDxNec/EnxN48vfEmlve/D4afcJazCOE61BN5inGW3AADHp3row1vaa+Zy4y/svd8vzO6+H3iq4ufF3iF2tIwbprd2AJ4O9YsD8Hz+FdJ4E8a3niLxl4s0i5tbeK30ifyoZI925xuZfmyf9ntivm7RPHnifw3rbu3hOKSa5aNRG1+nVJEfqPXaB+NdFb+K/HXw21nV/Ems+BYlh8Qz+YinVYiFOWfA2bj0buBXVWpwd7LVpW0fkceGqVEld6Ju+q638z0zTPEE2t/HdbaaGOJdLiu7WMqSS4/dnJ96db/FTUZ9R8G2/9nWiprdxNDOdzExhJjGNvvgZ5zXlVhr3jrRtam+I7eB4zpt6zsoOqw4/fFVHT5uqj+Hv2p0ujfE/SpNB1W68CRrbeHDLdn/ibW53gyNK2cNnjOOAelD9jpzdrbPezv8Ai0OPt7O3dvdbaWe/ZM+p9NujeWzSsmzEskeM5+47Ln8cZr5y+Jvj69/4WhAfsdvjw5PKYBk/vSVGd35dqp6d+0Zrlna+W/geGTMskm4aoF+85bGNh6bq5TxjoXxA1DULzxVd+DRbWepyK6AapA+PNwFHBz3HYfhRhYRo1G6yaT20YYucq1JKi02tXqv8zpm1e41zWbHU7mONJrrS76ZlTO0FhKTj869L+C3HwXvT73f9a8Gmm8Y+H7a2uLzwkscVrDJpZb+0Yjl5PMHQZPZvbjrzXpPgm5+KGj/D59GsvhwlzHdRyPFdtrdsuBKMg7M9s+orTE1YOmlHuuj8zHCUaiqNy7PqvLzOd+C/iqbwzqNnBBbRzjVLqO0fexGxSw5GO/NfTEWrtJ4kl0vyAFSMv5u72Q4xj/a/Svj3StJ8c6D4mtLWTwiHv9Lcai8B1KAAomHPzA46ehJ9q7SL46+IY79/EH/CCxm1mLW4H9qr97CZ/gz2HbvU4tRrS5qab07P5F4NzoR5KjS17r59T6O0sf8AE+1s/wC3CP8AyGP8a4w65Jba0IBCh8vxCIAxbqJUcE/UZrym2/aL1iC6u5z4ERvtDKwA1ZRtwoHXy+entWFqvxN8T2+qS3dx4Oji26nHqRT+0o2xtzhCQOevX9Kxp0ZJvmi9uzNqtaNlySW76r/M9d/aL8Ry6Ro2lWkMCSGa5S5LMx4MTqwGPc1F8PPHVxrWrXt3PZRoVjEgRHP/AC1liUjJ9MZrynx/4i8cfEzX7HS7fwWltcwxkpbjU4WLEjcWLnaPugcVheG/HniDwhLdRyeFo5XdUiIa/QbTHIrHoD/dxXRCEPYKFnzej6v0OapUqfWOdSXL6rovXufVHgzWnn8H3t20ABspblAob7+wk59s14D4d+KV9oOsazqcWm280t0sce13YBQrMR9fvGtDwH8R/GV34Z12w0jwCl6kfm3E839sRR+SsoY/dYfNjB6elecQ+FPHd19gWHwqGOrhpLT/AImMA8wKNzfxccHviih7GEpqqt/J+oV/bTjTdJ6rzXp/wD6O+CXiOfxZqXiTV7qCOCWdoAUjJKjCleM/Sofhj8Qrvxz4uljurGC1Wxhl2mNy24MyDnP0ry7wPrvj/wCFt++nX/geO4fUdgjiOqQqdw3YO5dw6BuD6VleDtc8Y/C7VbnUtR8GLOlzaCUodUiXEbuNrZXd3GMYzUTjTk5uK3S5dH6GkHVgoKbtZvm1Xe66n0tPqpXxXqcnlZGnWEgA3ff/ANW/4elVvFniQxatY6N9lyLqOK6MgflcToNuMc/WvBz8ZfEU1zfX6+CI/L1aOS1iH9qJ8rbVB/h5xgdcda2fEXiX4gT+MdMef4dpBeR2kapb/wBtQNvXzgQ24cDLDGPxrFU1GS5k9uz/AK3N3UlKMuRrfuv62KWp/Ey9t/GFjImn2zDQBdRwgs373eNpLf8A1q0dN+Ml/ojwwLpFtMkwTcTIwI2oq8flmvM9d8O+PLecareeEhDFq05ig/4mMDbnkywXg57HkgVTtNM8Za2lxfWXhcSQ6bH5lwf7QhXaoHXkgn7p6Zr0b4WUdVp6P+tzy7YuM9Hr6x7evY+rPCPiqTxfY2F7JaLamPUWi2h9wIELnPQetdb4dBGgabng/Zo//QRXzp8NfE3j200O2XTPh8l/CNQkkEn9swRbn8lgUwRkYGTn2xTLD9o3WbKyt7VvAiO0EaxFv7WUbsDGceX7V5lWk5ScaUXZeT8z1qFXljGVWSu/NeR794+1FtK8HateRxiRkhKhScfeIX+tcl4T+I0+q65PpcmmRxpBbW0gdZSSTIUUjGO279K8i8TfHjXPEui3Wjw+B1ge6AXf/aqtjBB6bB6etZfgjxN4xtr291y08FpeQskUDD+1IownkvH68nPyjp39q0p0VGk/aRd+mj8v+CZVa8pVk6UlbrqvP/gH1DPrzRGb/RsiM3A+/wBfKUH075/Cq2s3ZvYHTy9nkysvXOc2rP8A+zYrwS9+LvioaH/a8ngRF067luoopf7XjPzOACNu3Py+uBn2qrcfHTxCUcnwTGomPnA/2op48nyf7n4/5zURoS3UX9zNJYiO0pL70fRPhTV2v5b2wMAjGnrDGHD58zdGDnGOKp6/4xOk+KrTR/sPmrPEZTN5mNuAxxjH+zXz94e+OutaNd39zL4JWf7cY2AGqqm3Yu3+4c5/CodQ+J3irxf4ps9S0jwXHHJAhi8ltTjbcNrE/MVXHBP5U1Q99uUXa3Z72/zJeJ/dpQmua/dbX/yPYfiF46k0m4s5I7ASFoSuDJj/AFsYPp2x+Nb+heKmbTPCiG0GdT3wkiT/AFflgjPTnOK+dfiP4j8Y3T2q6j4MWwKpFt/4mkUu7EQAPA4yOf0rf0nxV49hs/BbL4BSWG3kne2YavCpueu4f7GOevWrlCn7KOmuvR9mZwqVfbS1VtOq7r9D6L1jVxpt5p8Bh8z7XJ5e7djbyoz05+9Xld9qB0+1+KEoj8zzb+O3xnGN0arn8M1i6t8QfHurajpMkPw2WJoZlKIdcgbzGJjYDO0Y6r+ftXDeLvGfi2xGu2OpeC1tJteuxeJ/xNIpPLEZ2FflHPK9ePpU4eKWjW/k+/8AkaYmTd2mrK9tV2/zPozwndi2t7dNhbzltYc56f6MGz/47Xl+ofEVtYhm0n+zljD3rS+Z5meAxOMYrFj+I3jrw9odtqGqeAYjb28sGZhq0QDfuNqDYASMqQc15laa74ja9WWHw0rMzlwv26MZzk9a2oQhdykn5aM5sTOooxhBpb31W33n17beLlm09Ln7GQTuG0Seig+nvUY137b4s0azFuUDx3Eu4tnG35cdO/WvAZPiD4w0rSbJbnwMgjnmaGKT+1YiXcqoxgDjtyfWpb/4meLPDOu6Xqmr+BFjVI5444/7XiPmbnOTlVOMHjpzWHsl9lPr0Z0+2lpzSXS+q7o9gb4mbfHTeHTpZwLn7P5/n9ffbj+tR/DrXPPh8V6qYMbtRH7oN06L1r5zk+IGvf8ACZf8JQfCq+Wbg3IgN+h6k8bsf0rsfh/4p8cL4X1g6Z4BF9a3F2kjznWIY/LYsp27SMnPHPbNa1KUIQ0i1e3R99TGlWqTqe9JO17artpsfSQ1dfl/dH5rw2n3u4z836dKy9G1gQaBdHyi32C1E55+/kM2Pb7v615avi74kBY/+LZJn+1XkU/29b8yfNmPp9fm6cVj2Xjrx5HYazYD4exvI+miSRhrUI8qLDLvxjnqeAc8VyqMWmv8zslOSad+/bsTeHPiTLoWo2UK6Yky3E+w5lKkCVlJPTtivYNI1E3+q+Kx5ewWrLbj5s7tqE59utfI+knxhrmtWNrpPhhJb6N1njjN/EA2wbuSxA7eteveGvFnxFhn8VMvw3juZpZybnZrcEYt32YI5zuHfg114tUt4rX0fddziwTq7Tel+67Psd54g8V/8IlDp92bM3Xmafbx7A+zHLc5wa5fwh8RnHimZn0zjWbiMHEv+q52+nPX2riviP4m8b3Gm2Cal4BFjGtvCqv/AGxDLvA3YbCjjPPHbFch4f1jxUuuaS9r4SWaZZkMUf8AaMS+Y24YGT0/GqpRpOm3JO78mRWnWjVSjJWXmj7C+2C+8Pz3KpsDRSYUnOMZH9K4+28fLaTalp7acznSrBJzIJR+84TjGOPve/SvL9E+NniW8jl8O2fw+E9+EmQ/8TqNQMbix5THAz35xxXF6x438Uabr2tLqPg9YbjUbVLTyhqMZ8v5UIO4AhuAOOOtc9KiruM4vy0Z1Vq7SjKEl56rsfQ//CZrrelwQrYvC15ZC6yZNwX94F29OfrWr4k8Xf2N4w8O6H9jMw1YyAzeZjytuO2OevtXzBp3xV1vTorb/iklb7Na/Yif7RUZIbfn7v6V3esa98QvEniHwj4rtvhwI7W2ObeM65bn7R5gyOSAV4HcU50oQl7yaWvR720FSq1Jx0knLTqtup7L8RvF3/CG6TZXxs/tYuL2O0KeZs2hgx3Zwf7vSsLwJ41Hja/s7r7CbPyJrqDb5m/cAqYOcD1ryvx/4y8beOvA8d/D8PhaaVp139rluv7ahk/1W5WXZhW6k84PTiud8AeMPGPhFNJW38GR3X9o3rC23alGvnNKsfyD+6cbeTxz7UQpw9k9Hz69GOpUqe2VmuTTqv8Ahz6+oryr/hNvif8A9Ej/APLltf8A4mu98J3+ranokN14g0X+xNRZmD2X2pLnYASAfMQAHIwfbNcJ6Jm/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9dVQAUUUUAFFFFABRRRQByum/8lT8Q/8AYF0z/wBH39dVXK6b/wAlT8Q/9gXTP/R9/XVUAFeXfE7T5bzxVazxsgSz0uaVw3VsuqgD869RrifHen3G+/1EBfsw0xrc/NzvMqt09MA1vh5cs7nNi481No+cLixfUPF+n26EKxdpMn0VNx/lXpn7Th2+EvDSDp5x/SMVzvh7wpqt54httaiMP2KG3uZWy+GAEZTp35Irqv2mdOuJ/A+i3se3ybOYCXLYPzqAMDvyK9ac069NX2PHoU2sPUdt7fmbem+G5/FPwP0PS7OeKCV44Jd8oO3CyBiOPYGu58esF8D+ISRx/Z9x/wCi2rP+E2R8N/D2ev2Rf61reL7CfVfCur2Fnt+03VpLDHuOBuZSBk15c5/vbPZN/metTp/ueZbuK/I+GW/1afWvsPXNObUvAfh+wjcIZHshuPYDaT+gr5F1mwuNJ1K4069Crc2szQyBTkBgcHB719q2dnJdaFoHllR5AglbJ7BO3516eYztySR5WWw5lOLPG/iFYvf2H2KBlEs+uxxgt0H+vr3Lw2MeHdLA6C1i/wDQBXn3iHwXqssttcxSW7RwaoL5/mIIjCy57cn5hXoXh7/kAaZ/16xf+gCuDETUoRSZ6GFpuFSTatc88l0eXVfiz4laGVEMeliDD5+9LGAPw4NeCy6RLF8MpLp3TFprL2rqOpYxjke3ymvpjQP+SoeKj/072o/8cryTxf4J1vQ/hBq636QB11v+0GCSBv3JUoD9csOK68NW5ZKLf8v5HHiaHNFyS6yv955WNBun8JyeIA8P2KO7FmVyd+8ruzjGMY966PxRZyXEmoBCB5UJlYnuFxmtKw0e9uv2e9QuoFRo4tXF0+WwfLVNhP5sOK6KfwXrGqazrWn2n2c3DacJFDPgESY2jPr1rtddJtt7N/ocH1dtJJb2/U6f4aeHpbnx7da2skawWSrC0ZyWZmhAyPzrz3x18N9Tg8Z6Xo8V3aSXGrNM8LEsqpjk7uM9PSvffA2gXmhy6s168TC6ljePyznAWMLz+IrP8UeGdS1H4m+E9btViNhpyTC4LPhgWUgYHfOa82GLcaraelvyWn4nqvBRlRSa1v8Am9fwOX+DngHUtF0LXZL25tW/te2WOERljswrgluPVh0zWjo0Jt9Q+GsBwWit7pSR6iMCvQtAs5LDRrS1nKmWJNrFTkZrlH0i7s9f8FPMYylqtzBJtP8AE0eRj/vk1i67qTk5Pe/5NG31dUoQUVtb/wBKTM/x/wCGbrXPFNtfW8sMcOlok8wkzl12zcLgdfriuI+N9i8Xh+1vyymKfS4IFXuCjqT/AOhCvbLqwmkn1Z1K4urVIY8nowD9f++hXBfF7wdrPiDwjZ2mkJDNcW0AR0Zwu4gp0J4/hNVhq1pwUnov6/MjE4e8JuK1f+f+R4J4esn1NPCdjFIEe5vpIlLdASVGa+n9a8K3GoeLbLVo7mNIbe3SEoQdxKyh8/kMV4f8I/COraunhTWLNITZ6dqchuS0gDKAVPA719P1rj61ppRe1/zM8vw6cJOS3t+B5/rPhm68R+G/CiWk0MIsrqK7l80nlQrDAwOuWFcb4O0WbSvA/jySZ0baJbQhO7Rqdx+nzCvZtGtns9KtLeXBkijVWx0yBXG6Xod7c+DPFNonlCbUru7eDLcYY7Rn05U1hTrvlcW9Lr8zarh05KaWtn+Vjm/hKxTwla4BGdTuDx7WzV80tzMf97+tfVvw90C807wlELoRq0N5dTMFOePLeP8A9C/SvlAt+9P+9XqYOSlUqNf1ueTjIuNKmn2f6G/4I0WfxD4ustMtZEimnZsPJnAwpY9PYV794Y+G+paF4XvLW8vLR5i0rgx7iMFkYdQOyH8xXBfALwfrMvinTfE3kRjR4zMplMg3E7WXhevU19J3sbTWdxHHje8bKufUjiuXH4pqooRen6nXl2DjKm6k1r09LHzNq+izj4AaJeeZHsF5JIVyc4kk2j/0H9a4TUrGW2tNKZ2Ui7shIgB6DzCvP4qa9/1LwNrlx8FdL8NxxQf2rBIjSIZRtAEjMfm+hFeRfEfR7zQJvDemaiI1u7fSk8xUbcATPIeveurDV1NuKfV/cceMw7hFSa+yvvOQv7KSGLTgxUmeHzFwegLMOfyr074FeD7vWY5tUjngjtoJnhKtnczGPHGB0+YVxWv2Fz5fhZkUf6TZJ5XPU+a6/hzX0R8DPC2reFPC13aa7CkNzLeNMqJIH+XaozkcdjRjK/JR0erHgMPz1kmtEcj8R/D0+s+LNP0a2ljSdykYds7RthGT9OK6W10ie20Pwi7Mh/s+W5ik56kiQZH/AHya3b/w5fzeP7DWE8r7HC7M+W+YfutowPrVy6sJYdN020kKmVryUjB4+YSkfzrzZV7xjFPp/mepHDWnObW7/VNHJWQDajpLYwftMXf/AGYK8z+M5H/CU6OFwR5NwfzuJK9ksdDu5NQgePyttndqJct6LETj8jXkPxosLiPx7odkdhnkt32gHj553I/nXRhZJ1Vr0OXFwkqL0Nz4qIyfC2Ynqbqz/wDSZaoaV8L9Wj0a01lru0MDQJOIwzbwrAEDpjPI71q/GiGS0+G93bzEeZFf20bAHPIt1HFeqaNbPd/D/S4Isb3sIAMnA+4tS68qVJOPV/5FrDQrVWpLZHl3iLwNqepT6LpFtNb+daX7TSSMxC7QiEkcZJrmvjzp0sGkaFeM6GNpbiHb33CQnP0r6Cj02Ua59sYoY97sOecFEUf+gmvF/wBpa3e08NaBFIVLfa7huP8AaO4fzowtdzqwj/XUrFYaMKU5f1urHlNxp8q+DYdR+XyXl8gc87utfQ/wx8LXmleFtQ0q6lh+0G4hl3ISVxtRsflXjeoaReR/BLT9RZU+zNf7h83OD8oOPqDX09olrJC1zK+Nk/lMmOuBGqnP4g1pjqz5LJ9X+DRjl2HXPdrovxTIhpEmIf3ifJfvdnr0O7A+vzCuTi8LXEWt6nbiWEvd6J9mRsnAYHBJ46ZIr0aslv8Aka1/68j/AOjBXmQqyVz1qlGLseV/C/4e6ppHi9dWup7YwWhkt2VWJZm27cjjGMmu58N6XPBqXjCGV0LXdz5kZGcAPHxmui0i1ltVu/O25luZJVwf4SeKSwtJYdU1O4kx5dw0ZTB5wqAHP41pVxEqjbl2/Uzo4WNKMVFdX+KPLvjZpkkGiaZKWQovk2pwTncN3P05rj9C8O3dj4k0ppmjZbbUYbWTac/MTkY9uK9A+P7Y8OaWPW+T+RqHUdHvNN1eynuhGI7zXreSLDZJXaetddGq1RS73OCvRTrt22scj4f+Gmu+GvHU2r6g1m9lILzYYpSWO6KQjggVxXxVQr42ZWP8afh+7SvqXXrGe9SIW+zKiUHccfejZR+pFfOPxY8N6m3jOG5SNGhurloYyHHLRxqW/QVpg8Q6tS83rYjH4b2VO0E7X/Q5fQvBGseJdDv9R0sQNBbXflOrybWJIA449xX05p+mTaR4X8J6bdFWntZLeKQocjcqEHHtmuV+EfhHWNH8EanZ6lAkFxd3y3ES+YDmP5Dnjp0PFel6payXL2JjxiG4WVsnsFYf1Fc+MxPtJ8t9E/0OnBYX2cOazu0vzOC0/wAFarbfCHVvDbvbnUroXOwhzsy7krk49K4TxB4du/Dmq/DKyvnieU6pFkRkkAqsKkZI9Qa+hq88+JfhzU9a8W+BbzToBLbabqBmum3hfLTKHOD1+6elZ0MRJzfM9Hd/gbYjCxVNcq1Vl+J6HRRRXEd5yvxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9dVQAUUUUAFFFFABRRRQByum/wDJU/EP/YF0z/0ff11Vcrpv/JU/EP8A2BdM/wDR9/XVUAFZPiuzn1HQL20tVDTSphQTgdR3rWozzinF8ruiZRUk4vqec6FoGoaH4YvPt6IrR6fcqdrBsFjuHT2FHxn0HU/Efw2Nhotsbm8MkLiPcFJA69SBXb69BJc6HqEEC7pZbeREXOMkqQBVu3UpBGrdQoB/Kt/bvmVTrcwWHioun0sYfgDTrnSPBejaffRiO6t7ZElQMG2sOoyK6CiisZScm5PqbwioRUV0PiL4kbp/iLr6oNzPqcyqPU+YQK+0tIhe20qyglGJIoURhnOCFANfKnifwB4suPiPe3cOg3r2suqvKsqrlChlyGz2GOa+tq9LMJxlCmov+tDzcupuMptr+tSC+jaWyuI4xl3jZQPUkVHpED22k2UEoCyRQojAHOCFANW6K8y+lj07a3OR0C0nX4geKb1kxbOttCjZ6ssYJGP+BD86b8XNNvdY+HWtWGlW7XF7NGojiUgFsOpOM+wNb2lW0sN7q0kq4We5Dxn1Xyo1z+YNaVauo1NTXS34GMaSdOUH1v8Ai2eKeHPCOvQfADVNDm0901efzDHbMy7iC4I74HANd7oOjX1p41v7+eILaSafbwI4YHLrncMV11FOeIlO9+t/xt/kKOGjHld9rfhf/MBRRRWB0BWNrZ/4m2gj/p6f/wBEvWzWVqttNPqejyRJmOCZ3kOfugxsB+pFVDf7yKiuvu/M1abKCY2C9SDinUVJZ578DNC1Lw94Iaz1m1a1umvJpfLYgnaSMHj6V6FRRV1JupJzfUzpU1TgoLoFZ+hW8trpyxTrtk82VsA54aRiP0IrQoqb6WLtrcyrC0mh0Sa3dQJmM5Azx8zsR/MV8V33h3WbDxHFo15YSxanK6rHbnGXLH5cdua+6a8F8c+GtdvPj/omqWul3UumRyWrPdIhMahT82W6DFejgK/JKSfVX+483MMOpxjbpoegfBbR9Q0LwDaWOr2zW12ssrNGxBIBckdK7qig9OOtcFSbqSc31PQpwVOCgugV88/tGaJqdx4s03ULe0Z7J7aKzEoIwZjK5CfXkV9DVw/xZ0y+1XSNGh022kuJI9XtZpAg+6iscsfYcVtg6ns6qZz46l7Wi4nhnizTrvStW8A6bqcJhuYbSFZIyQSpNyxxxX1XXhvxh8M63rHxO0C807Tbi4sokgV5o1yqETEnPpgHNe5Vri6inCD66mOBpunOoul1+CCqOowSTXGntGuVin3uc9BscfzIq9RXEnY9Bq5Q0uCWGW/My7RLcl056rtUZ/Q15D8U/Dmsa18XdAuNMsZJ7a1tommlBAVB5rHkmvbazIIJl8Q3c7IRC1tEit6kM5I/UVtRrOnJzXY569BVIqD2uedfGrw1rGt+FdRg0qye6ml1GKdURhkoIlUn8xXo/hu3ls/D2l21wu2aG1ijdc5wwQAj8xWjRUyrOUFB9C4UVCbqLqFeI/tTafeXXhzSbu2t3ltrWdzO69I9wUKT9TxXt1cT8ZtOvdW+HepWemW0tzdSNFtijGWIEqk8fQZq8LPkrRfmRi481GS8vyPMfGOn3mkfs46TZ6jA1vdLcx7426rmRiM/hivf7MYtIB6Iv8q86+Oukajq/wAPY7PS7Oa8uRdQMYoV3NtBOTj0r0a3UpBGrcEKAR+FVWnz00+rb/QihT9nUceiUV+ZJWQf+RtH/Xif/Rla9Zn2eT/hJPtOw+V9k8vf23b84/KuePU6Z9DToooqSzzP45QTXel6La2sfmzzX6KieprpfGGm3V/L4d+yw+YttqMU0uCBsRQcmovHOn3d9qPhl7SB5Ut9RSWYr/AgHU11ldDqcsIW6XORUuapO/W34BXk/jbRdS1nVdIbTbV547bU7xpmBGEBiwpP1PFesVm6JDLCt95yFC93K657qTwailUdN8yNa1NVUovYuWaNHaQRtwyIqn6gVNRRWRstAooooAKKKKAOV+LH/JLPGX/YFvf/AEQ9dVXK/Fj/AJJZ4y/7At7/AOiHrqqACiiigAooooAKKKKAOV03/kqfiH/sC6Z/6Pv66quFvdVj0H4k6tdX9nq7211pNhHFLZ6Xc3aM8c14XUmGNgCBIhwcfeFaH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1VFcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xQB1WBnPeiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoA6qiuV/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYoAPix/ySzxl/2Bb3/wBEPXVV5r8QvFllq/gHxLpun6d4kmvbzTLm3gj/AOEev13yPEyqMmEAZJHJOK9KoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiioL5bl7OZbCaGG6KkRSTRGVFbsWQMpYewYfWgCeivGtD8f+KJbHx5f6veaKln4WuLm2cWukytJOY0JEgDXQA5x8meem4ZyNCT40aRZWQa607V7uWDR7bWLqa2t4kRYZgvzbWmJBBYZUFiOxbGaAPVaK81n+M3hi0j1Z9RS/sRp9rBeYnjTNxFNjy2jCueu4cNtIzyBg41/h78RtF8dz6pb6QJY7nTWjE8ckkMgw4JVleGR0YcEcMcEYOKAOzooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4qL4caRHpXjCwW5v8AyfFE0094xdN0bSLtYR/LwMdM7vxrLm+Dvh+a2vYGvNVCXejQaHIRLHkQQ7drD5PvnaMnp14Fek0UAebaj8GvDGpSXrX76hOLrTrfTWUyqNiQFTHIpCgh8qOc468YOK67w3oU+jGY3Ou6vq7yIiBtQeI+Wq5xtEcaDJzyxBY4GTxW3RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    12-month prospective follow-up of three bipolar patients with rapid cycling bipolar disorder at increasing frequencies compared to a non-rapid cycling patient with a single biphasic episode.",
"    <br>",
"     Excursion above each horizontal line represents hypomania or mania; excursion below the line represents depression. Amplitude indicates severity of symptoms.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from: the Stanley Foundation Bipolar Network: Kupka RW, Luckenbaugh DA, Post RM, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162:1273.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8740=[""].join("\n");
var outline_f8_34_8740=null;
var title_f8_34_8741="Agalsidase beta: Drug information";
var content_f8_34_8741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Agalsidase beta: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/56/13188?source=see_link\">",
"    see \"Agalsidase beta: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/37/34388?source=see_link\">",
"    see \"Agalsidase beta: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fabrazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fabrazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F130789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fabry disease: I.V.: 1 mg/kg every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4806347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/37/34388?source=see_link\">",
"      see \"Agalsidase beta: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Fabry disease: Children &ge;8 years: I.V.: 1 mg/kg every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F130771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F130772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F4806348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient with IgE antibodies to agalsidase beta (rechallenge): 0.5 mg/kg every 2 weeks at an initial maximum infusion rate of 0.01 mg/minute; may gradually escalate dose (to maximum of 1 mg/kg every 2 weeks) and/or infusion rate (doubling the infusion rate every 30 minutes to a maximum rate of 0.25 mg/minute) as tolerated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fabrazyme&reg;: 5 mg [contains mannitol; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fabrazyme&reg;: 35 mg [contains mannitol; derived from or manufactured using Chinese hamster ovary  cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F130755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antipyretics should be administered prior to infusion. Initial infusion rate should not exceed 0.25 mg/minute (15 mg/hour). Interrupt or decrease rate in the event of an infusion reaction; may be restarted after resolution of symptoms and/or after administration of antipyretics, antihistamines, and/or steroids. After patient tolerance to the infusion is established, rate may be increased in increments of 0.05-0.08 mg/minute (3-5 mg/hour) with each subsequent infusion. Maximum infusion rate: Patients &lt;30 kg: 0.25 mg/minute; patients &ge;30 kg: Infuse over at least 1.5 hours. An initial maximum infusion rate of 0.01 mg/minute should be used for rechallenge in patients with IgE antibodies; may increase infusion rate (doubling the infusion rate every 30 minutes) to a maximum rate of 0.25 mg/minute as tolerated. A 0.2 micron low protein-binding filter may be used during administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F130794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility when admixed:",
"     </b>",
"     Do not mix with other products.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy for Fabry disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2933645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Agalsidase beta may be confused with agalsidase alfa, alglucerase, alglucosidase alfa",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F130787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The most common and serious adverse reactions are infusion reactions (symptoms may include fever, tachycardia, hyper-/hypotension, throat tightness, dyspnea, chills, abdominal pain, paresthesia, pruritus, urticaria, vomiting).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (43%), fever (39%), headache (39%), fatigue (24%), dizziness (21%), pain (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Infusion site reactions (50% to 55%; severe: &ge;5%), procedural pain (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (31%), pain in extremity (19%), back pain (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (44%), cough (33%), nasal congestion (19%), lower respiratory infection (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: IgG antibody formation (69% to 79%), feeling cold (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (14%), tachycardia (9%), bradycardia (&ge;5%), chest pain/discomfort (&ge;5%), facial edema (&ge;5%), flushing (&ge;5%), hypotension (&ge;5%), pallor (&ge;5%), ventricular wall thickening (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hypoesthesia (9%), anxiety (6%), depression (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (20%), pruritus (10%), excoriation (9%), urticaria  (&ge;5%), bruising (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Toothache (6%), abdominal pain (&ge;5%), diarrhea (&ge;5%), nausea (&ge;5%), vomiting (&ge;5%), xerostomia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Postprocedural complication (10%), thermal burn (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (14%), burning sensation (6%), fall (6%), muscle spasms (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (8%), hearing impairment (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (9%), congestion (8%), dyspnea (8%), pharyngitis (6%), wheezing (6%), throat tightness (&ge;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (5%), fungal infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other reported severe reactions (frequency not established): Anaphylaxis, allergic reactions, arrhythmia, ataxia, cardiac arrest, cardiac output decreased, nephrotic syndrome, stroke, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic shock, angioedema (including dysphagia, edema of ears, edema of eye, edema of lips, edema of tongue, pharyngeal edema), arthralgia, bronchospasm, cerebrovascular accident, erythema, heart failure, hypoxia, hyperhidrosis, lacrimation increased, leukocytoclastic vasculitis, lymphadenopathy, MI, oxygen saturation decreased, palpitation, pneumonia, renal failure, respiratory failure, rhinorrhea, sepsis, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/allergic reactions: Life-threatening anaphylactic and severe allergic reactions have been reported. Reactions may include angioedema, bronchospasm, chest discomfort, dysphagia, dyspnea, flushing, hypotension, nasal congestion, pruritus, rash, and urticaria. Stop infusion if severe reactions occur; immediate medical support should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody formation: Development of IgG antibodies is common and has been observed within 3 months from the onset of therapy. Some patients may also develop IgE antibodies; consider IgE testing in patients with allergic reaction. Rechallenge of patients with IgE-mediated reaction may be done with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Infusion-related reactions are common, and may be severe (chills, vomiting, hypotension, paresthesia); pretreatment with antipyretics and antihistamines is advised. Decrease infusion rate, temporarily discontinue infusion, and/or administer additional antipyretics, antihistamines, and/or steroids to manage infusion reactions. Immediate discontinuation of infusion should be considered for severe reactions. Appropriate medical support for the management of infusion reactions should be readily available. Infusion reactions have occurred despite premedication. Use with caution when readministering to patients with history of infusion reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; may have increased risk of complications from infusion reactions; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Registry: A registry has been created to monitor therapeutic responses and adverse effects during long-term treatment, as well as effects on pregnant and breast-feeding women and their offspring; should be encouraged to register (www.fabryregistry.com or 1-800-745-4447).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gentamicin (Systemic): May diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not demonstrated adverse effects. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential are encouraged to enroll in Fabry registry (www.fabryregistry.com or 1-800-745-4447).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F130761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nursing mothers are encouraged to enroll in Fabry registry.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Fabrazyme Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $828.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (1): $5796.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Development of IgG or IgE antibodies in patients with suspected allergic reactions (test available from manufacturer). Monitor for infusion-related reactions.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fabrazyme (AT, AU, BE, BG, CH, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F130743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agalsidase beta is a recombinant form of the enzyme alpha-galactosidase-A, which is required for the hydrolysis of GL-3 and other glycosphingolipids. The compounds may accumulate (over many years) within the tissues of patients with Fabry disease, leading to renal and cardiovascular complications. In clinical trials of limited duration, agalsidase been noted to reduce tissue inclusions of a key sphingolipid (GL-3). It is believed that long-term enzyme replacement may reduce clinical manifestations of renal failure, cardiomyopathy, and stroke. However, the relationship to a reduction in clinical manifestations has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Children: 247-1097 mL/kg; Adults: 81-570 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Children: 86-151 minutes; Adults: 45-119 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Banikazemi M, Bultas J, Waldek S, et al, &ldquo;Agalsidase-Beta Therapy for Advanced Fabry Disease: a Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(2):77-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8741/abstract-text/17179052/pubmed\" id=\"17179052\" target=\"_blank\">",
"        17179052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eng C, Guffton N, Wilcox WR, et al, &ldquo;Safety and Efficacy of Recombinant Human Alpha-Galactosidase A Replacement Therapy in Fabry's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(1):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8741/abstract-text/11439963/pubmed\" id=\"11439963\" target=\"_blank\">",
"        11439963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lidove O, Joly D, Barbey, F, et al, &ldquo;Clinical Results of Enzyme Replacement Therapy in Fabry Disease: A Comprehensive Review of Literature,&rdquo;",
"      <i>",
"       Int J Clin Pract,",
"      </i>",
"      2007, 61(2):293-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/34/8741/abstract-text/17263716/pubmed\" id=\"17263716\" target=\"_blank\">",
"        17263716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8801 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8741=[""].join("\n");
var outline_f8_34_8741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130769\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130789\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130770\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4806347\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130771\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130772\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671329\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4806348\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130753\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130740\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130755\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130794\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130754\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2933645\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130787\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130758\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130744\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298692\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130747\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130749\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130760\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130776\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130761\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322966\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130751\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038318\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130743\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130757\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8801|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/56/13188?source=related_link\">",
"      Agalsidase beta: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/37/34388?source=related_link\">",
"      Agalsidase beta: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_34_8742="Shift cells";
var content_f8_34_8742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shift cell due to early release of reticulocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood smear in an anemic patient showing large, polychromatophilic \"shift\" cell (arrow) that is indicative of the action of erythropoietin on the bone marrow, leading to the early release of reticulocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8742=[""].join("\n");
var outline_f8_34_8742=null;
var title_f8_34_8743="Puerperal uterine inversion";
var content_f8_34_8743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Puerperal uterine inversion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8743/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8743/contributors\">",
"     John T Repke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8743/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8743/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8743/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8743/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/34/8743/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine inversion occurs when the uterine fundus collapses into the endometrial cavity, turning the uterus partially or completely inside out. It is a rare complication of vaginal or cesarean delivery, but when it occurs, it is a life-threatening obstetrical emergency. If not promptly recognized and treated, uterine inversion can lead to severe hemorrhage and shock, resulting in maternal death.",
"   </p>",
"   <p>",
"    Spontaneous inversion of the non-puerperal uterus accounts for approximately 5 percent of all uterine inversions, and will not be addressed by this topic review [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/1\">",
"     1",
"    </a>",
"    ]. It is almost always associated with presence of a polypoid uterine tumor, usually a leiomyoma, but other tumors (eg, teratoma, sarcoma) have also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine inversions are classified by the extent of inversion and time of occurrence: &nbsp;",
"   </p>",
"   <p>",
"    <strong>",
"     Extent of inversion",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1st degree (incomplete) inversion: the fundus is within the endometrial cavity",
"     </li>",
"     <li>",
"      2nd degree (complete) inversion: the fundus protrudes through the cervical os",
"     </li>",
"     <li>",
"      3rd degree inversion (uterine prolapse): the fundus protrudes to or beyond the introitus",
"     </li>",
"     <li>",
"      4th degree (total uterine and vaginal) inversion: both the uterus and vagina are inverted",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Time of occurrence",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute: within 24 hours of delivery",
"     </li>",
"     <li>",
"      Subacute: more than 24 hours but less than 4 weeks postpartum",
"     </li>",
"     <li>",
"      Chronic: one month or more postpartum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a review of 229 cases of puerperal uterine inversion, 83.4 percent were acute, 13.9 percent were chronic, and 2.6 percent were subacute [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/1\">",
"     1",
"    </a>",
"    ]. Another review including 358 cases suggested 90 percent were complete or prolapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of puerperal uterine inversion ranges from 1 in 1200 to 57,000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. This wide range may be related to differences in definition of inversion, postpartum assessment of the uterus, patient populations, case ascertainment, and routine obstetrical procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of uterine inversion is incompletely understood. It has been attributed to use of excessive cord traction and fundal pressure (Cred&eacute; maneuver) during the third stage of labor, especially in the setting of an atonic uterus with fundal implantation of the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a causal relationship between management of the third stage of labor and puerperal uterine inversion is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/12\">",
"     12",
"    </a>",
"    ]. It is likely that other factors play a role since spontaneous inversions occur and inversion is rare even though cord traction and the Cred&eacute; maneuver are common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7109044\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for inversion, which are present in fewer than 50 percent of cases, include fetal macrosomia, rapid labor and delivery, short umbilical cord, use of uterine relaxants, nulliparity, uterine anomalies or tumors (leiomyoma), retained placenta, and placenta accreta [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7109293\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Puerperal uterine inversion can follow vaginal or cesarean delivery, including inversion through the hysterotomy incision [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. The clinical presentation depends on the extent and time of occurrence of the inversion. Signs and symptoms may include mild to severe vaginal bleeding, mild to severe lower abdominal pain, the presence of a smooth round mass protruding from the cervix or vagina, and possibly urinary retention.",
"   </p>",
"   <p>",
"    The most common presentation is complete uterine inversion with severe postpartum hemorrhage, often leading to hypovolemic shock. Shock out of proportion to blood loss has been described and attributed to increased vagal tone from stretching of the pelvic parasympathetic nerves (neurogenic shock), but this is controversial and may just reflect underestimation of blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/15\">",
"     15",
"    </a>",
"    ]. On vaginal examination, the inverted fundus fills the vagina; on transabdominal palpation, the uterine fundus is absent at its expected periumbilical position. With severe prolapse, the inverted uterus is readily appreciated protruding at the perineum.",
"   </p>",
"   <p>",
"    Incomplete uterine inversion occurs in about 10 percent of cases and is associated with more subtle findings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast to complete inversion, blood loss may be minimal. Examination through the dilated cervix reveals a mass (ie, fundus) in the uterine cavity; on abdominal examination, a cup-like defect (fundal notch) may be palpated in the area of the normally globular fundus. In the absence of heavy bleeding or careful examination of the fundus, these patients may not be identified for days or weeks. Because of increasing cervical constriction over time, delayed recognition of inversion is more likely to require surgical intervention to replace the uterus, and the uterus may become edematous and infected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7109096\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination of uterine inversion shows an abnormal uterine fundal contour with a homogeneous globular mass (ie, inverted fundus) within the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7109086\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute uterine inversion is based upon clinical findings, typically including vaginal bleeding potentially resulting in shock, lower abdominal pain, and the presence of a smooth round mass protruding from the cervix or vagina. On abdominal examination, lack of palpation of a normally positioned fundus is the key finding. (See",
"    <a class=\"local\" href=\"#H7109293\">",
"     'Patient presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Radiographic imaging (eg, ultrasound, magnetic resonance) is rarely necessary, but has been used to confirm inversion when the diagnosis was uncertain and the patient was hemodynamically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/16\">",
"     16",
"    </a>",
"    ]. Importantly, in women with significant vaginal bleeding, treatment should not be delayed for radiologic confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common disorder in differential diagnosis is a prolapsed fibroid. Physical and ultrasonographic examination of the fundus help to distinguish the two disorders: the fundus is usually normal with a prolapsed fibroid, whereas with uterine inversion the fundus is absent from its normal position or markedly abnormal (eg, cupped and smaller than expected). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of puerperal uterine inversion is based on clinical experience described in case reports and small retrospective case series, as well as good clinical judgment. No randomized trials have been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7110949\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Replace the uterus to its correct position",
"     </li>",
"     <li>",
"      Manage postpartum hemorrhage and shock, if present",
"     </li>",
"     <li>",
"      Prevent recurrent inversion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions for the management of acute uterine inversion should begin promptly and simultaneously. A delay in diagnosis or in prompt initiation of treatment increases the risk of maternal morbidity and mortality. We suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Discontinue uterotonic drugs",
"      </strong>",
"      since uterine relaxation is needed for replacement of uterus.",
"     </li>",
"     <li>",
"      <strong>",
"       Call for immediate assistance",
"      </strong>",
"      , including anesthesiology staff, additional obstetrical staff (and where appropriate, more senior obstetrical staff), and operating room personnel. The patient may have to be taken to the operating room if manual replacement of the uterus is unsuccessful.",
"     </li>",
"     <li>",
"      <strong>",
"       Establish adequate intravenous access and aggressive fluid resuscitation",
"      </strong>",
"      . We suggest placement of two large bore intravenous lines (eg, at least one intravenous catheter should be 16-gauge) and begin infusion of crystalloid to support blood pressure. Draw blood for baseline laboratory tests, including a complete blood count and coagulation studies (fibrinogen concentration, prothrombin time, activated partial thromboplastin time). Blood should be administered, as needed, to treat hypovolemia and prevent cardiovascular collapse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"       \"Overview of postpartum hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Immediately attempt to manually replace the inverted uterus",
"      </strong>",
"      to its normal position. This is best accomplished by placing a hand inside the vagina and pushing the fundus along the long axis of the vagina toward the umbilicus (Johnson maneuver). Prompt intervention is critical since the lower uterine segment and cervix will contract over time and create a constriction ring, thus making manual replacement progressively more difficult.",
"      <br/>",
"      <br/>",
"      If a constriction ring is palpable, pressure should be applied to the part of the fundus nearest the ring to ease it through from bottom to top. This avoids attempting to push a wider diameter of the fundal mass through the ring, which is likely to fail.",
"     </li>",
"     <li>",
"      <strong>",
"       Give uterine relaxants",
"      </strong>",
"      when immediate uterine replacement is unsuccessful, which occurred in one-third of cases in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/18\">",
"       18",
"      </a>",
"      ]. Manual replacement is then reattempted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       Nitroglycerin",
"      </a>",
"      is an excellent uterine relaxant [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/19\">",
"       19",
"      </a>",
"      ]; we suggest 50 micrograms administered intravenously, followed by up to four additional doses of 50 micrograms, as needed to achieve adequate uterine relaxation for replacement. Nitroglycerin has an extremely short half-life [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/20\">",
"       20",
"      </a>",
"      ], which could be advantageous in women with severe hemorrhage and hemodynamic instability.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       Terbutaline",
"      </a>",
"      (0.25 milligrams intravenously or subcutaneously) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (4 to 6 grams intravenously over 15 to 20 minutes) are other options for uterine relaxation. Magnesium sulfate has a slow onset of action, both drugs have relatively mild effects on the myometrium, but both are acceptable if other agents are not available or if the practitioner is unfamiliar with their use.",
"     </li>",
"     <li>",
"      Inhalational anesthetic agents, such as halothane and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=see_link\">",
"       enflurane",
"      </a>",
"      , are also excellent uterine relaxants and may allow replacement without surgical intervention. Although these drugs have less hypotensive effect compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , they require controlling the maternal airway (intubation). Therefore, inhalational anesthetic agents are best administered in the operating room as an initial step before proceeding to laparotomy for correction of an otherwise refractory uterine inversion (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Secondary (surgical) interventions'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6943083\">",
"    <span class=\"h3\">",
"     Other options",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7111168\">",
"    <span class=\"h4\">",
"     Hydrostatic reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrostatic reduction of acute uterine inversion is an option if all other interventions have failed and surgical intervention is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. A bag of warmed fluid is hung above the patient and allowed to flow through tubing into the vagina using the physician's hand or a silastic ventouse cup to retain the water in the vagina and generate intravaginal hydrostatic pressure. This may force the inverted fundus back to its normal position. The author has no experience with this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Secondary (surgical) interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the above measures to replace the uterus fail, then the patient should be taken promptly to the operating room to attempt surgical correction of the inversion. Administration of general anesthesia and surgical release of the constriction ring should allow manual reduction of the uterine inversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1462899\">",
"    <span class=\"h3\">",
"     Vaginal approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvaginally, the cervical constriction ring is incised anteriorly (Spinelli procedure) or posteriorly (Cascarides procedure), which should allow the uterus to be repositioned manually [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/22\">",
"     22",
"    </a>",
"    ]. The incision is then repaired. Accidental cystotomy is a hazard of the anterior approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1462892\">",
"    <span class=\"h3\">",
"     Abdominal approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;At laparotomy, in place of the uterus, a constriction ring containing a dimple or cup is often observed and the adnexa (ovaries, fallopian tubes, round ligaments) are typically pulled into this depression. We prefer to start with the Huntington procedure because it is less invasive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Huntington procedure",
"      </strong>",
"      &mdash; The cup formed by the inversion is located. A clamp, such as an Allis or Babcock clamp, is placed on each round ligament entering the cup, about 2 cm deep in the cup. Gently pulling on the clamps exerts upward traction on the inverted fundus. Clamping and traction are repeated until the inversion is corrected. This procedure is similar to the hand-over-hand movements used when pulling up an anchor line. If available, a second operator with a hand in the vagina can apply upward pressure on the fundus to facilitate the procedure.",
"     </li>",
"     <li>",
"      <strong>",
"       Haultain procedure",
"      </strong>",
"      &mdash; The Haultain procedure involves making an incision in the posterior surface of the uterus to bisect the constriction ring, and thus increase its size. The inversion can then be corrected using the Huntington procedure described above, followed by repair of the incision. We prefer a posterior incision to an anterior incision (Ocejo incision) to reduce the risk of accidental cystotomy.",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &mdash; Other techniques require further investigation of safety and efficacy before they can be recommended. Successful laparoscopic-assisted reduction of acute and chronic uterine inversion has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. Another method used an obstetric vacuum device (ventouse) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of the placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author does not remove the placenta until the uterus has been replaced. Removing the placenta before replacing the uterus increases blood loss, which may be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. Leaving the placenta in situ rarely interferes with the operator's ability to restore the uterus to its normal position, provided that the patient has appropriate anesthesia. After the uterus has been replaced, the most conservative approach is to await spontaneous separation of the placenta, and performing manual extraction for usual obstetric indications (eg, hemorrhage, prolonged third stage).",
"   </p>",
"   <p>",
"    Alternatively, one may attempt manual removal, provided that the patient has appropriate anesthesia and is hemodynamically stable. Manual removal should be performed in an operating room so that surgical intervention can be undertaken if complications occur. A hand is placed into the vagina, through the cervix, and into the uterine cavity. The operator then attempts to develop a cleavage plane between the placenta and uterine wall. If this cannot be accomplished easily, or if bleeding increases, a repeat attempt can be supplemented with sponge-stick curettage or suction curettage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35208?source=see_link\">",
"     \"Diagnosis and management of retained placenta after vaginal birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the placenta remains attached, the possibility of placenta accreta should be considered. Risk factors, diagnosis, and treatment of placenta accreta are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management after correction of inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atony is common after restoration of the normal uterine position. Once placental removal has been successfully accomplished, uterotonic agents are administered to induce myometrial contraction and maintain uterine involution, thereby impeding reinversion and reducing the risk of hemorrhage. The fundus should be held in place and then monitored until the surgeon is sure that the uterus is firm and its position is stable. The fundus can be held in place with the clinician&rsquo;s hand(s) placed internally, externally, or both.",
"   </p>",
"   <p>",
"    An",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion (20 to 40 units in 1 liter of crystalloid infused at 150 to 200 mL per hour) is usually sufficient to keep the uterus contracted. Other options, which can be given with or without concomitant oxytocin, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/29/20948?source=see_link\">",
"       Carboprost tromethamine",
"      </a>",
"      (15-methyl prostaglandin F2 alpha) 250 mcg intramuscularly, may be repeated every 15 to 90 minutes for a maximum of eight doses",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      800 micrograms intravaginally. Rectal administration is acceptable, especially if there is heavy vaginal bleeding",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13927?source=see_link\">",
"       Dinoprostone",
"      </a>",
"      20 mg rectally",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"       Methylergonovine",
"      </a>",
"      200 mcg intramuscularly up to every six hours for a maximum of four doses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reactive airway disease is a contraindication to the use of prostaglandin F analogues and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"     ergonovine",
"    </a>",
"    . Poorly controlled hypertension is also a contraindication to use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Infection, which may be severe, has been described in nonacute uterine inversion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/13,28,29\">",
"     13,28,29",
"    </a>",
"    ]. We administer a single dose of a first generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ) for endometritis prophylaxis, provided that the patient does not have a penicillin allergy. In patients with true penicillin allergy, we would use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    in a prophylactic dose (900 mg clindamycin and 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    gentamicin in a single dose) to cover gram positive, gram negative, and anaerobic bacteria. Studies have reported inconsistent data on the efficacy of antibiotic prophylaxis in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/12,22,30\">",
"     12,22,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96351563\">",
"    <span class=\"h2\">",
"     Reinversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of reinversion is similar to that for the initial inversion. In a single case report, abdominal cerclage was used to prevent reinversion in a patient with chronic recurrent inversion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/31\">",
"     31",
"    </a>",
"    ]. In other cases reports, an intrauterine balloon [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/32\">",
"     32",
"    </a>",
"    ] or uterine compression sutures were used to treat postpartum hemorrhage and prevent recurrent uterine inversion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22711?source=see_link\">",
"     \"Intrauterine balloon tamponade for control of postpartum hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27336?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of postpartum hemorrhage at cesarean delivery\", section on 'Uterine compression sutures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECURRENCE IN FUTURE PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrence of uterine inversion in a future pregnancy is not well-defined. In one series of 40 cases of acute postpartum uterine inversion, there were no recurrences in 26 subsequent deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8743/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterine inversion is a rare complication of vaginal delivery, and an obstetrical emergency. If not promptly recognized and treated, it can lead to severe hemorrhage and shock, resulting in maternal death. (See",
"      <a class=\"local\" href=\"#H7109293\">",
"       'Patient presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine inversions are classified in terms of the extent and timing of the inversion. Most inversions are acute and complete. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine inversion has been attributed to excessive cord traction and fundal pressure (Cred&eacute; maneuver) during the third stage of labor, especially in the setting of a uterine atony and fundal implantation of the placenta. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute uterine inversion is based upon clinical findings, typically including vaginal bleeding potentially resulting in shock, lower abdominal pain, and the presence of a smooth round mass protruding from the cervix or vagina. On abdominal examination, lack of palpation of a normally positioned fundus is the key finding. (See",
"      <a class=\"local\" href=\"#H7109086\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial interventions for management of uterine inversion should be applied rapidly: summon help, discontinue uterotonic drugs, administer crystalloid aggressively and blood products (as needed), and attempt to manually reposition the uterus by pushing the fundus cephalad along the long axis of the vagina. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the placenta is attached to an inverted uterus, we suggest leaving it in place rather than extracting it before replacing the uterus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Placental extraction may increase hemorrhage. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of the placenta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the initial attempt at manual uterine replacement is unsuccessful, we recommend administering a uterine relaxant and reattempting reduction of the inversion rather than surgical intervention (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We recommend nitroglycerine over other uterine relaxants (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). It is highly effective and has a short duration of action. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical intervention is required if manual replacement remains unsuccessful after administering a uterine relaxant. We recommend the Huntington rather than the Haultain procedure, given the former does not require incising the uterus (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Secondary (surgical) interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A uterotonic agent is administered after uterine replacement to induce myometrial contraction, maintain uterine involution, and prevent reinversion. We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      because of its rapid action, short half-life, familiarity to personnel on labor and delivery units, and relative lack of side effects in virtually all patients. However, any standard uterotonic drug is acceptable, provided there are no medical contraindications to its use, such as hypertension (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"       methylergonovine",
"      </a>",
"      ) or reactive airway disease (carboprost). In the absence of any medical contraindications, we suggest, in order of preference, oxytocin, carboprost (Hemabate) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (Cytotec), and employ methylergonovine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13927?source=see_link\">",
"       dinoprostone",
"      </a>",
"      as second line agents. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management after correction of inversion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/1\">",
"      Dali SM, Rajbhandari S, Shrestha S. Puerperal inversion of the uterus in Nepal: case reports and review of literature. J Obstet Gynaecol Res 1997; 23:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/2\">",
"      Lupovitch A, England ER, Chen R. Non-puerperal uterine inversion in association with uterine sarcoma: case report in a 26-year-old and review of the literature. Gynecol Oncol 2005; 97:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/3\">",
"      Gomez-Lobo V, Burch W, Khanna PC. Nonpuerperal uterine inversion associated with an immature teratoma of the uterus in an adolescent. Obstet Gynecol 2007; 110:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/4\">",
"      Occhionero M, Restaino G, Ciuffreda M, et al. Uterine inversion in association with uterine sarcoma: a case report with MRI findings and review of the literature. Gynecol Obstet Invest 2012; 73:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/5\">",
"      Hu CF, Lin H. Ultrasound diagnosis of complete uterine inversion in a nulliparous woman. Acta Obstet Gynecol Scand 2012; 91:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/6\">",
"      Pauleta JR, Rodrigues R, Melo MA, Gra&ccedil;a LM. Ultrasonographic diagnosis of incomplete uterine inversion. Ultrasound Obstet Gynecol 2010; 36:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/7\">",
"      Livingston SL, Booker C, Kramer P, Dodson WC. Chronic uterine inversion at 14 weeks postpartum. Obstet Gynecol 2007; 109:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/8\">",
"      Morini A, Angelini R, Giardini G. [Acute puerperal uterine inversion: a report of 3 cases and an analysis of 358 cases in the literature]. Minerva Ginecol 1994; 46:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/9\">",
"      Baskett TF. Acute uterine inversion: a review of 40 cases. J Obstet Gynaecol Can 2002; 24:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/10\">",
"      Witteveen T, van Stralen G, Zwart J, van Roosmalen J. Puerperal uterine inversion in the Netherlands: a nationwide cohort study. Acta Obstet Gynecol Scand 2013; 92:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/11\">",
"      Lipitz S, Frenkel Y. Puerperal inversion of the uterus. Eur J Obstet Gynecol Reprod Biol 1988; 27:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/12\">",
"      Watson P, Besch N, Bowes WA Jr. Management of acute and subacute puerperal inversion of the uterus. Obstet Gynecol 1980; 55:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/13\">",
"      Adesiyun AG. Septic postpartum uterine inversion. Singapore Med J 2007; 48:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/14\">",
"      Rudloff U, Joels LA, Marshall N. Inversion of the uterus at caesarean section. Arch Gynecol Obstet 2004; 269:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/15\">",
"      Beringer RM, Patteril M. Puerperal uterine inversion and shock. Br J Anaesth 2004; 92:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/16\">",
"      Hsieh TT, Lee JD. Sonographic findings in acute puerperal uterine inversion. J Clin Ultrasound 1991; 19:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/17\">",
"      Momin AA, Saifi SG, Pethani NR, Mitha SH. Sonography of postpartum uterine inversion from acute to chronic stage. J Clin Ultrasound 2009; 37:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/18\">",
"      Brar HS, Greenspoon JS, Platt LD, Paul RH. Acute puerperal uterine inversion. New approaches to management. J Reprod Med 1989; 34:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/19\">",
"      Momani AW, Hassan A. Treatment of puerperal uterine inversion by the hydrostatic method; reports of five cases. Eur J Obstet Gynecol Reprod Biol 1989; 32:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/20\">",
"      Ogueh O, Ayida G. Acute uterine inversion: a new technique of hydrostatic replacement. Br J Obstet Gynaecol 1997; 104:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/21\">",
"      Tan KH, Luddin NS. Hydrostatic reduction of acute uterine inversion. Int J Gynaecol Obstet 2005; 91:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/22\">",
"      Kitchin JD 3rd, Thiagarajah S, May HV Jr, Thornton WN Jr. Puerperal inversion of the uterus. Am J Obstet Gynecol 1975; 123:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/23\">",
"      Vijayaraghavan R, Sujatha Y. Acute postpartum uterine inversion with haemorrhagic shock: laparoscopic reduction: a new method of management? BJOG 2006; 113:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/24\">",
"      Sardeshpande NS, Sawant RM, Sardeshpande SN, Sabnis SD. Laparoscopic correction of chronic uterine inversion. J Minim Invasive Gynecol 2009; 16:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/25\">",
"      Shepherd LJ, Shenassa H, Singh SS. Laparoscopic management of uterine inversion. J Minim Invasive Gynecol 2010; 17:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/26\">",
"      Antonelli E, Irion O, Tolck P, Morales M. Subacute uterine inversion: description of a novel replacement technique using the obstetric ventouse. BJOG 2006; 113:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/27\">",
"      You WB, Zahn CM. Postpartum hemorrhage: abnormally adherent placenta, uterine inversion, and puerperal hematomas. Clin Obstet Gynecol 2006; 49:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/28\">",
"      O'Connor M. Uterine inversion. J Am Board Fam Pract 2000; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/29\">",
"      Mahatme S, Badhwar VR, Gandi S. Subacute uterine inversion--an interesting encounter. J Indian Med Assoc 2010; 108:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/30\">",
"      Platt LD, Druzin ML. Acute puerperal inversion of the uterus. Am J Obstet Gynecol 1981; 141:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/31\">",
"      Garrett-Albaugh S, Stitely ML, Millan L, Hochberg C. Chronic postpartum uterine inversion treated by abdominal replacement and cerclage. W V Med J 2011; 107:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/32\">",
"      Soleymani Majd H, Pilsniak A, Reginald PW. Recurrent uterine inversion: a novel treatment approach using SOS Bakri balloon. BJOG 2009; 116:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/33\">",
"      Mondal PC, Ghosh D, Santra D, et al. Role of Hayman technique and its modification in recurrent puerperal uterine inversion. J Obstet Gynaecol Res 2012; 38:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8743/abstract/34\">",
"      Matsubara S, Yano H, Taneichi A, Suzuki M. Uterine compression suture against impending recurrence of uterine inversion immediately after laparotomy repositioning. J Obstet Gynaecol Res 2009; 35:819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4458 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-2A680BD67D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8743=[""].join("\n");
var outline_f8_34_8743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7109044\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7109293\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7109096\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7109086\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7110949\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6943083\">",
"      - Other options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7111168\">",
"      Hydrostatic reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Secondary (surgical) interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1462899\">",
"      - Vaginal approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1462892\">",
"      - Abdominal approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of the placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management after correction of inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96351563\">",
"      Reinversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECURRENCE IN FUTURE PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35208?source=related_link\">",
"      Diagnosis and management of retained placenta after vaginal birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22711?source=related_link\">",
"      Intrauterine balloon tamponade for control of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27336?source=related_link\">",
"      Management of postpartum hemorrhage at cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=related_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_34_8744="Lymphatic drainage of the breast";
var content_f8_34_8744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Lymphatic drainage of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 509px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH9Ag4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK861T4o28HjK/wDDml6Rc6leacYxdBLmCF/nAYCKORw0pAOTtHoBnIoA9ForDPizQhuzqdv8uojSTyeLs4xD/vcj86z7H4jeEb+4aG0120kkEEtxwWAKR58wgkYJXBJA5A5xigDrKK45viZ4O/s0X8WvW09oX8vzLZXmw2wOQQgJGFYE+meam1L4ieE9NgsZrvXLRYr2D7TAU3Sbof8AnodoO1O244FAHV0VwemfE/RJNGuNS1gtpsUeoXNgqlXmLmBirPhFJA4z049a138d+F0tpLhtbsxBHZpqDSb+Bbu21ZM+hbj68UAdLRXH/wDCwNFto9Vm1a7tbK3sr4WCsJTI8shQMF2Bdwcg/cAJwM1ct/HXhm4tbi5h1i2MNva/bpmOR5cO5l3sCMgZVh65BoA6SiuGsfiTpEtz4g+25tbPSbmG2W4G6X7QZYhIpVVXPQ9OematT/Erwbb6XZajceIrCGyvBL5EsrlA5jIDjBGQwLAYPPI4oA6+iuA8aeO5vD/xI8GeG4oIZIdbaYTsQxkQKo2FccdTyT2Fd/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVCtxA2xlmjO8lVw4+Y+g9TT45ElXdE6uoOMqc80APHFFFFABRRRQAUUUwyosixs6iRslVJ5OOuBQA+iiigAooooAKKKKACiiigAryvx/wDCU+NtZkuNT1azWzaWORSmlIL2FUIOyO6DAgEg9VYjJr1SigDyi6+Et3J4iku4PExj0l/EUPiQ6e1grN56Fdy+bvBwQoA4496wPAnwj1mXwzpcfirUVs5NPt9Ugs7CO3RjbvdtKpkeVZCJPkfIUbcZwTkV7tRQB5lr/wAL59T8LeEdFg18wRaFaraypJamSC9AiWPc8QkX5ht3LksASeDVTRPhPqHhyLTZPDvihbS/t9KXSbiabTVnSaNXZ1dULjY4LHqWU9wa9YrwfSPHfi+TXNIvJ9Qs7jTbzxFeaIdOWzCHZH5mx/N3Z3fIB0A9aANu/wDg9cT6bDZweJCkS6ne6hLDLZl4JxcHO14xIMsn8LE4yT8tRy/BG1m0/wAG2susvt0OEWt5ttsDUrcTJMInG/5QHQHq3U1y2i/FTxhLY31zCYNXvk0e7vrvTksjEdIuI3wkTfxNkZ+VvmO3IOKxbHxvrVjeeM9c0TWI/EV3/Z+lh76O2AjgV3cSOI14+QE/THzZwaAPVbz4VSPq15q9jrv2bVG1o6zaSNaCSOEmERNG6FxvBA6gqR2qn4l+FGsa5Pe3L+MBDdalpTaXqLDS0Kzrvd1ZF3jy8b8YySQOuea4e++Knim38IQ3I13RJv8AiZTRG8geHzZYFiVlVS37jzAWwRnJGMDOa938DajPq/g/RtRu/P8AtFzapK5ngEDkkdTGCQv0BNAHA3XwhuH0/VLe18SvbvfXtpdti1JjZYIREYpVEgLo2NxG5ecdccz+DfhKPDeqeHLz+2EuP7HuNRn8tLPyhJ9rCjaPnOwJt9857V6nRQB4h4tX7Z+1b4MgcApZ6PNcjHXJ85efyFe314vYBdR/at1KUgsdM0BIg3OAWdWx+Uh/OvaKACvOPG3jHU9B+JPh/SYPKOnX9jcSMHTJMqMmOev3SR/wL2r0evF/jHCP+Fq+ApixOYL9NvYYVDmgDqvE3jqTRtM1C9WKGQQFFiRsgEtIq8kezE/hV7UviDo2mLqEt68i29kjSPIilsqMZIHX1/KvLPiUok8F6ijDKuYlIzjOZUFcr4vuZG8Oa6qjdvtJ/lPujUAfVcUiyxpJGwZHAZSO4PQ06sLwHN9o8D+HptxbzNPt2ye+Y1rdoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqOu6pb6Jol/qt8221soHuJT/ALKKWP48VeqvqFjaalZS2eo2sF3aTDbJBPGJEcehU8EfWgD5X+APiTV7L4lwXGvf2pDF42t5p911bPHD9pEjyJ5LMNrr5bDGOMuB6Z7LwF8SvEuu/Fl/B17q2kNa6dPcmS+hhwdSVCu2KMH5VZcndgngHHTJ9suNB0i5jsEudKsJUsCDZrJbowtiAAPLBHyYAA4x0qC38KeHrZbJbbQdJhWxkaW1EdnGv2d25Zo8D5ScDJGKAPnvw7qB1TT/AISXLWtpak+JLxfLtIRFGMFxnaO5xk+9SeEfE13oPw7tbTSdTnstU1HxHfxQR29nFcPPtYkgea6IgBKksT7Aen0JB4c0O3js0t9G02JLOVp7ZUtUUQSN950AHyscnJHJzVa88HeGr3T1sLvw/pMtksxuBbtZxmMSHq+3GNx7nv3oA8V0j4n+MtQ8I+HNk+nR61deJ30Kaea3DI6hSQzKj4zkjOxsccHvWh4/+Ifiz4e6nLperTWup3WpaUv9jywWvlh7/wAxY2Tbk8YcPye2M817Bb+GNAto4I7fQ9LijguPtcSpaRqI5/8AnqoA4f8A2hz71meKfBVr4k8V+GdZv7iTZoUslxDahBtklYABmPX5SAQB3oAqfEHWdY8K/CbU9VWeCXW7GwV2m8v920wChmC+hOeK84b4ieMfDeqa3DrN1Y6zjwl/wklssNn9nED+YE8sgMSyDJYknOB2r3XULK11Gzms9QtoLu0mXbJBPGJEcejKeCPrUC6Npa3guxptkLoW32ITCBN/kZz5W7GdmedvT2oA8OT4leJvDk0DX2rad4ojvvD1zrKx2tssRs5I494UlGOYznbk88VjWOtay/xB8AeINZ1m01+7l0TUNRS1soFi8nNvv8kFSS3I2gkZyD9B75onhDw5oT3T6LoOl2DXQKzG3tUjMin+E4HK+3Sm6P4M8MaLdJc6R4e0iyuULMk0FnGjqWGGwwGRkccdqAPEfA3xN8c6nNpeqXLWlxpeo29y8qXK2trBbyLGzxiKQTtIwyuG3qCBk/S78P8A4h+J9Qu9asPEmsLYaumiXF/HFe6dHHaQMpG2ZJ43bfEvOdw5HIJ5r1u38B+ErfUpNQg8M6NHeyBg8y2cYY7hhu3cEg+uTnrUmk+CfC+jw3sWl+HtJtYr2MxXKRWiKJozwUcY5U5PynigC14Qup73wvpVzeXtpf3MtujyXVn/AKmZiOWT/ZPateoLK0trC0htLG3htrWFQkUMKBERR0CqOAPYVPQAUUUUAFFFFABRRRQAUUUUAFFFFABXh2lfHOaz1jXY/GHh+4s9DsNXuNLXWbJGmgiaN8BZhyVOCvzDrngDBr3GvJvg9FGvir4p6XNGjxf2607RuvDCaMHlT2OPxoA9N0jVLDWdPivtJvLe9s5RlJoJA6N+Iq5Xk2r/AAll0e/m1j4W6vJ4Z1Nzvlsfv2FyfR4jnafdenYDrRo/xak0jUYdG+KWkv4Y1OQ7Yr3O/T7k+qS87PXDHjuQeKAPWaKZDLHPEksMiSROAyuhyGB6EEdRVLxDrFl4f0S91bVZvJsbOIyyvjOFHoO57AUAeS/CMNqvxs+KOtsp2RXEOmxtjH+rBDD/AMcX869qryH9mdJ7vwhrfiC5gMJ1/WrnUIsgAmJiFHHblWr0Lxj4msPCehzanqT/ACKQkUS43zSH7qL7k/gOScAGk3ZXYG5Xk/xfG7x54EAZQQL9uepHlIP6iuI0X4qeKV8a6Xc6tLCdL1G8js309UUJbpI21WV8bmZSRkk4OTwOMdf8VGL/ABV8IpsyI9Pvnzz8uTCM/wBPxrOjXhXjzU3dCTT2OV+K8zW3w91qePO+KNHXjOCJFINc5chb7SnUjK3EBBH+8v8A9eui+LSGX4ceIEUZJt+AO53DArk/Cc63fhnSJgeGtoweMYIUA/qDWoz3n4C3Ml18HvCkkpBZbJY8j0QlR+iiu+ry39my4D/DCGxyS+m311ZtnttlZh+jivUqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooyMnnpQAUUUUAFFFFABRXB/GLxhqHgrQNMvtKhtZZbrVLeycXKsyhJN2SNrDnjjt7Vs+OPGGm+DdPtrnU0uZ5bqdba2tbWMPNPIcnaoJA6AkkkAetAHR0V53o/xd8PanLp8XkanaT3epNpLRXMCqbe5C7lSTDEDcPukEg4PoaLj4u+HY9J+3ww6ldCTUpdLtYIIAZLyWP7zRAsAUHPzMVHFAHolFeQ3HxXGsar4PXw4JbeG91qXS9Str2ALNCyR7ihwSAeRyCRW78cfFOveCfAl14i8PLpkn2Jk8+K+ikferyLGNmx1wQXyc54FAHoNZ/iG4ltNA1O5t22TQ2sskbYBwwQkHB46ivK/GvjLx94fuPBNtA3heSbX5Us5Ge1uCsczEncoEo+TaUGDk5Dc4IA9bu7UX2mzWl2flnhaKUx8feXBxnp1oA87+HnjmYfAqy8ZeLLh7qaO0lubqRI1VpNsjgAKoC5OAB0Fc74e+PKavJqECaDA93Dpkmp28Nnqsdz5qx8tE5VR5cm3nHPTGa6HQ/gxoek2i2C6z4mutH8mWBtLudTZrRkkVlIMQAH8RYYxhgD1FbfhTwDF4cu4ZU8ReJNQtreIwwWV/eLJBGpGPuhAWwOBuJwKAOcf406SIrm7isZ5tMtNCi1q6uEkBMTSkCO3245c565AFcrc/HB/EHhvxVZWlrDpmr2+hy6laXFjqSXirt42syqNkgJBxz9emfQPDfwj8KaB4e17RbW0mlsNaP8ApaTy7jtAwqKQAQFydvcHvSW/wusxpt7p194k8UalYXNm9j9nvL5XSKNgAdoCDLADAZtxFAG74da+1f4d6S66hLbald6ZC/20IrukjRKS+1gVJyc4IxXjXhjxN431L4G+JvFc/jCf+0rOSZoCNPtcIsG/K48vB35XJIyNox1Ne6JokMXhiPQ7W5u7aCK1W0jnhk2zIqqFDBscNgdcVw9h8GtEsfCeo+HLbWPES6VfyCSWP7aP9rcB8uAH3fMMc7V9KAOJ8XeIfG2l/CXwP4htvGNwL/VpbRbknT7UhhcoH6eXgbOQMAZzzXvenQzW+n20N3dNd3EcSpLcMioZmAALlVAAJPOAMDPFeeal8HdG1Hw3pGh3WteI20/S2D2yfbRkFcBM/L/ABhfQE16Hp1t9i0+2tfPnuPIiWLzp33ySbQBudu7HGSfWgCxRRRQAUUUUAFeU/D7/AEb46fFO25CTLplygHIH7hg2fcmvVq8p0ofZf2mtciOB9s8OQXIyOTsm8vj2oA9WqnrGlWGtafNYatZwXtnKMPDOgdW/A/zq27KiFnYKoGSScAV5X45+Ong/w0pt7C8Gu6s/yw2emnzdz9gXGQOfqfagDH1zwVrHwusrzW/h1r8dtoduGnudC1iUvabRyfKkPzRn2zySMntXAX/jfT/jxq3hzRrzW4fDulJKJNQ0qclXunHIEcv3XXsAdrAnOG4xtw+B/HPxl1SLU/iJJL4f8KpIJLfRYziSRf8AaHUH/abnk4UV6j4y8BeHl+G91o2n+EbPUYraBvsNggCMZSMAiQkFSTjc27JGetAG7oHiLQJtd1DwppE0KXujRRCW1jAVY0YfKF9gMA46ZHrXlH7R0dwvifwlPJuNg0dzCvPCzHYc49SgYfnXkvw5+GPxe8E+NrHxDa+HHlkifFxG2pW37+JuHQnze46E9CAe1dn8d9cvNY8aahpF7dPa2mlrbyWlvuxiZkDeawU/OctsAyRwccnNcmOaVCV+un3kz2KpWHUfFfg21gQEnVbYtgdQjbz+iGvRfHshl+NlpF1W38Pl+vQvc4/9krxfQ9T1bw74h0fxBMlpIbK4VTbYZ0KSHy3cE4IYBiR2HPXNe0eJnWf4w6y2Pmt9IsoBx2aSdz/MflWGVtew31uKnsZ/iqRotKjKqWJvbRcAZzm4jH9a8+8ORNb6c1pISZbW5uIHz13LM45r0HxSqPpttFIcLNf2UR5x965jH9a4yeL7J4z8Y2g6R6zO4HoJAr/+zGvSLPSv2bX26P4stTjdHrksnA7SRRMP616/XiX7P0wj8T+MbUnDOtncAY6gq6E/+OV7bQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFcB8KvFuo+Kb7xpFqa24XSNdudNtvKQqTFGcLuyTlvfisuD42+Hp/ENvYR2moGxuL/+zItTxH5Lz5wPl379hPG8rjNAHqdFee2PxY0S9TTFhs9U+2X+ryaKLMxx+dDPH/rGkG/ARRgkgk4I4rO0v42+HtS1+wsYLTUBY394dPtNSYR+TNNkgAKH3hWIIDFeTQB6nRXBfBfxHqXijwreX2szLNcR6ldWysqBMIj4UYHt3rG8E+JfFuo/F3xR4b1W90qTTdDWF28mzZJJhNHvQBi5A25APBzjtQB0vxT8E/8ACeeHrbTV1J9Nkt7yK9juEhEpDJuwNpIHf9K5nxB8KdU8T6PHb+KfF7ave2t0l1Y3E+kW4jhIBDI8IG2VWyMhv7ox3r1eigDyf/hT6zeDdQ0a51Syt7ue7hvLa80rSIbAWksRBVlRD8zdRktnB4xT9Y+DGl3vgjwzoNrdpDPoB329zPZx3McrsP3nmwv8rBydxGeDjBr1WigDyrRvhILK50S4uNUsfN0zUzqITT9HisYnzGE2bEPtncSx7dMV0PxY8FXHj/wtJoKaw2mWc7KbnbbLMZQrKyjkjbhlByK3vFWsjw/oVzqRtZboQgExxkA8nGSew9TzXI/DPx/J4nvryz1FIYLofvbdY8gMnQrz1I6++faueeKpwqxoyfvMlySdjP8AE/wx1vX5PDEs3jN459BKzQuNMjO+dWOJCN393au3kfLnua9SjDLGodt7AAFsYyfXFOoroKCiiigArh/ij4uvvCtjbGws1drklRcSHKRkdtvckdO3Heu4rI8WaJD4h0G606fA8xcxuR9xx91vz/TNYYmNSVKSpO0ugpXtoZXw18T/APCT+HUmnYG/gPlXIAAy3Zse4/XNdZXzX4G1m48F+MTHfho4d5truM9hnG78Dz9M+tfSasHUMhDKRkEHIIrly3FPEUrT+KOjJpyuhaKKK9EsKKq6jqNlpsBn1G8t7SEdZJ5VjUfiTXmXiP4/eAtGuTbQ6lNqtzyPL06Eygn0DcKfwJoA9XorxGz+JvxC8WOyeDfh69jbtyl/rcxjj29jswCfwJqjd/Cr4keMXP8AwnPxAFpab8/YtHjYIV7jPyf+PBqAPSPFfxS8F+FXePWvENlFcJ1giYzSg+hVASPxrwnX/iPqfiH4o6T4i+F2kTX2oX2kT6TDFeKI8hJhIZMbsFRkEZI9+mK9V8MfATwB4fkWYaQdSuV/5aajIZgT/u8L/wCO14R8SfjBrGg/FXS5ZfC1npl/4ZW5tFtPPMkUiSoApGFXAxhgR1BHAoA7WP4P/Ejx9Kj/ABP8Wtb6du3mwtHDc+m1QIx35+avZ/Anw28K+BoAvh/SoYp/4rqX95M3/AzyPoMD2rX8HXWq3/hbTLvxDbwW2q3ECyzwQBgsRbkLyScgEA89Qa0Lu/tLP/j7uoIOM/vHC8fjQBZorOGt6Uemo2f/AH+X/GsDU/HVn9vTTdCjfVNSkJXEI/dx4HJZuMgZHA9e1AGp428RQeFPDF9rNzG0q26jZCpwZZGIVEB7EsQM+9fNnxI8THx3p+gXl/oNlZahaaqbae7T52ysbSrGjkA7SME5716p8UdC8Tar4Qe/vbqFxYypenTYYN24Jndh85yAxOMH7uPevPPA3hiT4i6X4hFlcxwLbXtre2UxG6JpfKkV0JHQFCgJGSMg4PSuPESqOTpRWji/vJbd7GdcxLe614W0+2jEslxqVshUDIKiQO2R6bUYn6V6Fev53xX8aMFIWNbGHdjgkQlv/ZxU3wn+Hs2m+KpdW1nVdKvLqwRoobOxcy+Q7jBkdjghtoZQNo4Y1m6RKbvxl48vCV+bWTbgg54igiXr+fHalgKEqFK093qEFZakHjOQI/htT/Hr+nr/AOTCn+lZfj2D7L8X/FCKoCXEVpdfiYyhP/kOtTxejSXvhIKMgeIrAnnHHm074yQPbfFa3nwPLvNHUA+8Uxz+kortKIPhBefYfi41u7hY9S0lkVf70kMm4f8Ajrt+VfQtfMWg3A074meCr12wrXslm3H/AD2hYD9VFfTtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5dpnws1DR/EGr6jonjTVLC31TUpNSuLOO2hZGd33FcsCcY4qrp3wXt9J1rz9I1hINL+2/bRaS6XbTSod+8olwy71XPA7gd+9et0UAef6b8L9KsPijd+NY7mdp5g7JZkDyoZpERJJV77mVOfqfasTQPgvbeH9XtZNI1dItJt71byO0k0u2kmXEm/yxcld4XPH94DjNet1wnxU8Wal4XsrY6daxt9pJT7TJyI2Hbb6kcjJ7Hg1lXrRoQdSeyE3ZXZreAPCcHg3RZ9OtrmW5SW7muy8igEGRtxHHYVheFvh5d6H4/wBV8UyeJ7y9m1TaLu3ktYUSVUXbGMquRtGOmM45zWt8NPE3/CTeHI5Z3Bv7c+VcDGMns34jn65rrKdKrGrBVI7ME7q4UUUVoMKKKKAI7iGO4gkhnRXikUo6sMhgRgg181eIdPvPAfjUG1Zh5EgntZD/ABxnsfXup/GvpkkAZJwK4b4qeHY/Evh+SSy2SahYZkjCHJIxlk+pGCPcD1rzMzwrrU+eHxR1RFSN1dHUeHtWt9c0e11G0P7qdN23OSp7qfcHIrRrwj4J+J/7P1VtFu5MWt42YSTwkvp/wIcfUD1r0Hxx8UPCngfUIbHxHfz293NF50caWksm9ckZDKpXqDxmt8DiliqKn16+o4S5lc7aivIz8evDc+0aRpPiXVXbgC001jk+nzEVWl+MHiOeQjS/hd4llj52vc4gyB1zlSB+ddhR7LRXiVz4y+LmpApp3hDQdEViSs+o6mk2B6bUYHP4VWPgP4heIhu8R/FQWiuDm30eIRqB6BgVJ69waANL45+GMNH4gtE4OIroAfgr/wBPyrc+C3if+1NFOk3T5vLEAJk8vF2/Lp9MVp+BfBNt4e8Gz+HbrWLzXLed5GeW8cMw39QuOQM5bkk5Jrxn/Tvh/wCOe7PaSfQTRH/FfyP0rwsUngcUsTH4ZaP+vxMZe5LmO38U/Ejx42uX+k+Dfh1fXDW0ph+3ag4jhYg/eXkBlOQQd3TtVTTfD/xp8Qzs/iHxVpvhuzYjNvptsk0mM8gMQdv13GvZtNvYNRsLe8tH3286CRG9Qas17iaaujY8ji+AXhK5uvtfia41rxHeH70upXznJ/4Bt/Ku98NeDfDnhiERaBotjYjOd0UQ3n6seT+JrfopgFMkljiK+Y4XccDJ61y3xV8RXHhX4f6zrFj5f2yCILAZBlRI7BFJHfBYHHtXzRFpsOs3s974kvH1DUJf9Zc3mJCfZQeFX/ZUAVx4vGwwtuZXbJlLlPqDxz400PwRpSX/AIhuzBFK/lRIiF5JW9FUcmvM7vTvh/8AGPxXpPiGzvVF74emEl7BPCYnnhALIHV8HaHwd2CMbh3GPENSRbTxBpIa4neyQTQQo8rNHE7bT8gJwu4KRxjOK2PE2ltZR2etaRL/AKfajzI+ceZjkxNjqrdMVyrNYucfd919fnYn2iudf8RPit4h1C81y48KamdL0vRneKMrFG7XUicl23KfkPQAY45PoPavDPh6K506DUddVL3UrlFld2zhMgHaB7fT+Qr5x8YxeGtRuLXWNG1CeVdZSPUm0JITGFf5d++cjAj3DkAFicgEDp11n8WPHGmyteahaaZqtizbjbRQtbug9EfcwP8AwIc+tbrExo1JRrTWr0XZfoPms9Wez+IrTRtH0Waf+zLHcBsjBgU5Y9O31NJ4J0JNPtWvriFF1C6yzttAKqeQvAGOgOP8KxdE1F/Ht3purWkbpoCBZ4zKMGQ9enrngjtj1r0Gu8sKz5dMh/sy5sbJVsYpkdQ1soQozA5cY/iyc59a0K574geI4fCfg7VdZmPzW0J8lcE+ZKfljTA9XKj8aAPD/gDY/wDCNeP00iExh2s7+2vWjJxcyW10qpOwOfmw7Crnw9kW60/VtQQ7l1DV726Df3gZmUH8lFSfBDS7kfELU3n3Sf2DpC6fPKTnzLu4k+0z9h0bIqD4VA/8IBpBdWVmWRiG68yuaAJ/GYbz/DDKSETxBp7OR2HnAfzIrofj9bol74VvsDf509pnHZ49+PzirG8YkJoyXDdLa8tLgkdQEuI2P6A11vx/tI5fB1jfuzL/AGdqVvPkejkxNn2xKaAPIr8wxXGjXkwBW01S0n64xiVR/WvqgnFfJXi+HzfCesR/xrbNImOzKNw/VRX1F4Vvm1Twxo9+4w11Zwzn6sgb+tAGoKKO9efQ/EqNPFviTR9U0mbT7TQIftN5qEk6OixMCUcKuW+ZRnHUd6APQaK821j40eDrHQ9R1K0vpdQ+wvAssEMEiuRKwCsu9QCuMncDjjGckA7V18SfCdrd2ttcasEluFiZc28u2MS/6vzW24iLdg5XNAHX0Vxtx8TfB1u+qJNrkCtpbsl4NjnyGWVYiG+X++6j8c9MmltPiX4UvNOur2z1Ga4htbgWsyQ2Vw8qyEEgeUE3kEAnIXHB5oA7GiuI0/4i6bq3iXw7p2iKt9Y6zbXVwl6HKeWYGVSpjZc5ySDnBGOldvQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAQDjPaiiigAooooAKx/Fuhw+ItAu9OnwDIuY3P8DjlW/P9M1sUVM4KcXGWzBq582eANbn8HeMDHfhooGc214jfw8/e/wCAnn6Z9a+kwQQCOleK/HPw15NzFr9on7uXEVyAOjfwt+I4/AetdB8LvE91qvgy6s7cRza1p0JWBJW2rKNp8vcewyNpPYYPevFy+bwtaWDn6r+v66mUHyvlZ6JeXVvZW0lxeTxW9vGMvLK4RVHqSeBXkevfHTTpNRfSvAOjX/i7VFbafsalbdPcy4PHuBj3rmdP+G/iXx75Wv8Axo1SaOyU+Zb6BaHy0jB6B8dD2xkt6sOlexaBpEOjafFp/hnSLbSLAc8IAT74HJPuTXuGpwmz4z6+CZJfDnhS3Iz8oN3OOPfK1n3Xwt1S7fzPFPxV8RXLMOY7Fvsy/gqlh+lewDSopG3Xcstw/wDtMQPwA6VahtLeAfuYUQ+oHP50AeKn4NeG55AdT1DxhqRdSFS71Jj5g9wBkCu3+HfgLTPA811/YNhJaQ3gXzw95JNkrnBwxIzz1GK6Cxk26zcm4bDyfJGSeMA9Pr0raoA+ePi14bbw94kF9ZKUs7xjLGV48uTOWX255H19q9U8G6rD4y8OW145jTU7f9zNJ5asytxnGegbAPH9K1vGegweJNAudOlKiVhvhc/wOPun6dj7E14V8Pdem8H+LWhvw0VvI/2a8Rv4CDgN/wABP6ZrwZf8J+L5vsT/AAf9fgY/BLyZ74NGJP72/vHXptEm0fpTxoVhkFonYgYy0jH+tWLt7wFWtEhkj6kMxBP07VFHq1uCVut1tIBkrKMZ+h717xsOXSbBeltGKlWwtFAAt4wBx0qhJqsss5TTohcLxzggD8elWo5r/rJaxEeiyc0APj020jkV44VRwcggkVwXxp8Mf2poo1a1TN5Ygl8Dl4u/5dfpmu5k1IRNie2uEH97buH6VPBcQXsTeUwkTowI4+hzWGIoRxFN05dRSV1Y8j+BnifDSeH7t+DmW1JP4sn9fzr1sC7WU/PC8ZPAIKkD9c182+MbEeE/G0o0m5QrDIJ4DG4Yx852tjoQeMHtj1r0z4ZeMNW8V+J71r5o4rOG2+S3iGFDFl5JPJOAfavJy7G+z/2Sr8Sdl/XkZQnb3Wd9cak9tKwnsp/KB4kjG8Y9T6U2DXtMmlES3kayk4CP8pJ/GtOqd9pljfoyXtpDMGGDvQE/nXumxmePNM07WvBur2OtRGbT5bdvMVThuBkFT2YEAj3Arwzwj8DtT1Owt57/AMZ3K2BLARxWKCdlBIH70sfz216PrPw80nVrj7LpN3rGmRq379rS/lCN/s7WJU/lTLrwv4n0EJ/wj/j+RbZAAtnqtjDcL7AMgRhWdSlCpbnSdu4mk9zBn/Z68P8A9m6gkmsa3dXUkX+iz3Uwk+ySA5EiqoUE8Y57ZHGc15leeDfG4X7Ba6X/AGmZCbaHUbGTMHmdNzhsFAOueR6GvV7vUvirc2z282g6Pe2/8U+n3bW7yD0Cyg/zp1t8UdS0KGO21r4b+J7C1gXb5lrGt0igd8rWVXB0aySlHYTimZWu/A+4gtNGfwxf2qXNlp8djPFdRsEuChLeYGGSrEs3GCOR6VxWseF/HOkKtreeG7u6jfAV9NdblCfQ/dZfxAHvXp9r+0F4EkcJd3Oo2DdxdWUi4PocA10mn/FjwLfwGWDxPpqKOomk8pvybBqK+Ao13zTWvcHBMZ8FvDl/4X8A2ljq4Ed7LNLdSQBtwg8xy4jz0OAeccZzXdV4d4n/AGhNIgunsvCNidauFODcyzra2w5xwzct+A5rmNR8f+PdVRZ28R6TodtjldPtVl/8iSk8/QV1pWVkUfTBOOteN/GzU1vPFvgjQoVE8YuZtVmVSCCbaMsinn+8Rx7CvH7+/stXlMer+JNb8QTvkG3W6llGO/7uHAA/Co9Ctbaw8deHLjw94fvleO7Nveh7KRVEMq7WLk8jAOeaYHo3wg+Ingnw/wDDKFtU8SWUet3xnvb5Xc+a87sc7sAnONoH0pnwwkE3w/0KUDG+3DY9Mk1xFlpdjpM8nh+8gjfy3m+xtNCMTQ7s7eR95c4ZTyMZ6EV2PwnkR/h/pSR9IVkgP1SRl/pQBoePUL+B/EAH3hYTuvsQhI/UCuz+IwfxD8BdSuRgSzaQt8MD+JUWUcfVa5rxFGs3h/U4pPuSWsqt9ChBrnfhZ8Q518N6P4X8XNA+k6nYrY2epRJ5fls0e1YpR05HAcY5HI70AYauNS0wMvC3MHAH+0v/ANevfPhFcef8LvCjADI02CMgdiqBT+PFfOfgwyx+HbKC5z59qGtZB6GJ2T/2Wvav2dL1pvAE2nyNufStRubPpzt371+vyuOaAPUR0ry7U/hZd6jrXjK+uPEh8rxLaGzmhFio8lApWPDb+SoPPA3e1bvxk1rVPD3w61PU9AkEepRSW6xOYhJjfcRo3ynr8rNXm9j4o8c2Pie3gvdda/soPFaaHLG2nRR+fBJCX8xmUcbSMDbj3JoA63xH8JLfW49SSTV5oTeaVZ6aCkIJjNtKJVk5POWAyvp3qvrPwei1XxFNrdxq0Ml9exwC/NxpkMyyyRKFEkYb/VnAHHzDgGuF8OfE3xbea/qIF5cSWb6ZqM8dtd20azWk8AJQMqwqFP8AsF5OOpHetf8Ajb4i2WhXmoDXzK8GhadrixHS4hueZgr2/A+7gkk/ez0KjigD1S++GEN14O8TaAdUkVNb1h9XabyQTEWnSbYBnkfJjOR16VW8VfCZNe1jXNQGtSwHVL20u3t2tllhIghMXlyITiRWzuwcYIHWuW8T+KvGy+Nb+DTNY+y6fD4jstHjgOnxyDyriIbpCxG47WORyOeuRxWdqXj/AMW23g/ToZdUu49VbVdQsTqQtIo45FgPyeb+5kCsw+6qR/Ng8jGSAd94H+FMHhW+8P3MWqPcf2Ql6ip9mWMSfaHDngHC7cYAAx9K9Lrw/wCHXijxr4y1fTYJ9WTTYP7Dtr+4xp6uZJWkkRgCcbchQcc+wFafwW8W+KvFms6pFr+2GDQov7MvEESgXF+JX3yKw6KEVPlGBl/pQB67RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjEKpLEADkk9qGIUEsQAOST2r508Z+Mtb+L/ia68C/D5mt/D0b+XquuJkq0fIZV6DaeQADl8dlySAem6V428KfEa/8AEHhbS7o3v2WEefMqfu2ySMo3cqQpz05GM15JpF3eeAvHJFwGzbSGKdV/5aRHqR9Rhh+Fe5/DzwRo3gLw/FpWhQbVHzTTuAZJ37s57/ToO1cf8cvDX2mxi121j/e24EdzjvGTw34E4+h9q8nNcPKUFXp/FD8jOpHqj0dY49QmtbxJlltPLEkQXoxPIb8sVLeXbRyC3tk8y6ZdwUnCqOm4n0/WvNfgd4l+16dLod04M9qPMtyT96MnlfwJ/I+1epoyuMjGeh9j6V3YXERxFJVI9SovmVzOW21GVQZ75Iz3WGPp+JpyaZuYfa7qe5UdEYgL+IHX8a0aK6CijeabDcyB2+UnG8YyHHv/AI00afLEMWt7NGvZXw4H51oUUAUoLL7KhaJmkmLbndzy/qPavJPjl4Y8qePxBaJ8kmIroDs3RX/HofoPWvaKytZk0m9zoeo3Vt51/GyratIokkUAklVPJxjOQOMVy4zDLE0nTe/T1JlHmVjj/gz4n/tfRDpl3Jm9sVAXJ5eLoD+HT8vWvRGUN94A49a+ZUN/8P8AxxyCz2kmD2E8R/xX8j9K9h8W6RrvjKzsZ/CvjGTQ9KuLc+b5Nmsskm7GCrkgocZHHSuXK8S6kHSqfFHQmnK6sze8SeLfD/hhI28QaxY6cJDhBcShS30HWsmy+KHga9kEdt4s0VnPGGukX+ZFUfDXwh8HaJGXm0qPV76TmW91X/SppD6kvkD8AK6G+8GeGb+Hyr3w9pM0eMYezjOB7ccV6hobkEsc8KSwSJJE4DK6MGVh6gjrTLu3ju7WW3m3+XIpVtjlDg+hBBH4V5TqHg7W/h09zq/w2eS70vd5tz4YnYmNhnLG2bOY2x/Dgg/kK7zwN4s03xp4dg1jR2k8lyY5IpV2yQyLwyOOxFJq+jA8/wDEnwdDF5vD98QTz5F1yPwcf1H41d+DvhzVPD91rh1Sykhl2xLFnBWT75O1un93869Tri/it4zXwZ4aFxCqyaneSi1sY25UykE7m/2VALH1xjvXnrLsPRqqvHS33bEciTual/4pstKXdrMN5ZJ/z0aBpE/76QEfnUVv4x0HV9MuZtE1qwu3RDkQzqzIenK9R+IrwGx8T+MrXXdLXUfFV+1lql1HBO7RxkQl22h0AUbRkgbffPbm18bfh74W0SC31PUtYD69cSgZnmSGSVecsNu08HHJz1rroV4V488Nik01dHvmlWs09pGsm6G2xuCg/M+e5rVt7O3t8+VEoJ6k8k/jXhni+zs/ANhbuvxZ13SZXRXitLkpqLP0+7GRvI/HFYukfFf4iTSPHZ2enalYgYjvb+1awlk9/LV3/l+FbDPpKWWOFC8rqiDqzHAFYl94ltYsrZo90/cr8qD/AIEf6ZrwW5+L/k6pBaeLNGv21GT7kdjLHd5+iAqR+Iq3b/GLwfO7xXt9eaXKjFXhuLV/NU+mAMD8TxQB6Zqer3d6jLdTJDC3HlxcZ/E8muek8MaPvEz6DpYB5867iQdfQEFj+ApNJ8WaDqG3+w9W08u45ZLhZJiD6knj8BWihh847ZVklPU7t7H8aAKV34Z0K6tjDc6ZaXELDDJHbpEh/Ejcf0rm9W+FHgnUYwo0OC0I/itWZD+JzXcRQTyNxHsGcZc8/wCfzqWSzLxhWk75JPzfpwP0oA8m1j4MaXeWJtLDXNcggfgW/nGeMEdPlP8AjXF3PwQ8Y6VIBpeh2uqImTHdxTGyuE9/mcDP519J+VtUF7ifA4Codg/JcU826HrvP1c/40AfNeueIr610tNH+Jug6lp2qoQY9UiT5ZHUELLlePMUH7yk55yOa634G6taXPhNtOS8juLuzuJQ7AgearuXWQDqAQ3Q8gg5r1+TTrWXiWPfznazFh+RrktZ+E/hDVZfO/sxLG45/fWJMDA+vy8fmDQBY1ttujX7ZC4t5DkjOPlNeSeFbWG88B6XbXKLNBLaKrqeQRj/AD9K67UfhX4g0+yu4/Dfja+MEkbqLXUIxOMFcYDnp+VcR/wifi7wVbwalDokeoeHpo0SVNJkaQRyAAFyjZYMcEMANufTigC94N0ifw9pMlhLMk0S3MjwsM7jG2CN3vnPSvRPgVqcWnfEPxBozuVGqW0V/ArHguhKSY98FT9BXnCeLdFMogubh7C67wXsTQup99wx+tWpr5NI1vw/4rtn3LpN4jzSRHdm1kOyYeh+U5/CgD65opsbrIivGwZGAKsOQQe9OoA4vQ/ij4M1y+W00zXYZZmt3ulLxSRo0affYO6hTtwSRnIxTrP4m+D7vS9Q1GLWo0s7CJJ7h5oZIiI3OEdVdQXVjwpUEEkAZyK56x+DtjDovhfS7rU5ri10Wx1CwcCIIbhLtdrHOTtKjOOtV5PgxDeabcw6r4gu7u9+w22nWV0LdI/ssNvKJY/lHDncBknr7UAa2jfFnQ75tdmvRLY2GnXsNlBLJFKZbt5Iw4CweWJA3X5cEkDNacnxN8IpZWN0uqtNHeiRoUt7WaaUhG2uWjRC6BTwdwGK5XUPgymqw6lLq2vSXWp3eow6mtz9ijCJLHF5e1oiSGQg9OD0571BrHwQg1PSLKxfV7aD7OZW8y30qKJkMhBLRFSGjPHqwPcGgD1+3mjubeKeFt0Uqh0bGMgjINUdC0PTdBt7iHSbVbaO4uHupsEsZJXOWdiSSSat2FsLOxt7YSyzCGNYxJM253wMZY9ycZJqegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorwr45/EHVLvVYfh38Om8/xPfZS7kjOPssZXJG48BiDknPygepGADO+KfirWviP41/4Vx8PbwR2aKf7a1GPlUXOGj3DsOhwcsTt4ANey+A/CGleCPDdrouiQCOCJQZJCPnmkx80jHuT+nQcAVlfCP4f2Hw68JxaXZkS3ch828uSOZpSOf+AjoB6e5NdtQAVBdxQXMD2tyEeOdWjaNj98Ecj8qW8uUtYDI+T2VR1Y9gKrafavvN3eAG7cYwOka/3R/jQ1fRgfOepW154B8c/uSS1rKJIWJx5sR7H6jIP419A2V02o2tvq2jMkkF1EHMbtgH39mHQ/SuV+M/hr+19A/tG2TN5YAucdXi/iH4dfwPrXN/AvxL5c0ugXT/LJma1yejfxIPqBn8D614OGf1HFPDv4Zar+vw+4xj7krHrVrqCusi3Si2mi++jsOnqD3FOXU7Ful1D+LYqWa0gnkSSaFHdPulhnFOnhieNg8KSDH3SBz7V7xsSKysoZSCp6EHNKenFYUVmQhuNEkMD5w8EmdhPcEdjV6yvVvopYZE8q6QbZYWPI9x6j3oA8z1TxZrfj/X7vw54AeSw0izlMGqeISv3SOGits8F+2/t1HYnq/C3w38MeG79dRs7A3GsYw2pXsrXFyxIwTvcnBI9MVifs8boPhlbabO2bvTLu6sp1/uOszHb+TCvSiQDjvjOO9AHnHxp8Mf2row1a0jzeWKkvgcvF1P8A3z1+mawfgb4n2SSeH7yT5WzLalj0PVk/9mH416R4f1+38Q/aBbo8L2kj217ZXKBZoZOCM4JBBHIIyGDAg8V4V490OfwZ4vWWwLRQM4ubOQfw4Odv/ATx9MeteHmEJYStHGU9tpf1/WtjKfuvmR9Jk4FeX6l4vuLT4l2Ud/G1nZwXj6RKokLK6zxxyW0xHAG50kj74ORmu28I67D4k0C21GHCs42yoP4JB94f4exFed/HPw9NfBLi2cRLqdt/ZMspPEU/mCS0kPoBKCme3m+le1CanFSjszVO569XkXwduGPxJ+KtnGuy0i1SKRFHQOyHefqSoNdt8NfEZ8U+DNO1GZTHfBPIvYmGDFcx/LKpHbDA/hiuA+Ftl/wjnxw+I+jyMoGo+Rq9uO7IxYOfwZ8VQHs2PevN/jn4Wl8Q+F4b6zJ+26NKbxI8Z81NpWRfrsJI9wPWrfjj4p+H/C1zJp6vLquuhcrptiu+Qf77fdjH+8Rx2NeEfEbxR4v8V6ekut3EGnaKLhGm0i0XcDCCTumlJ+bBC5AG3GT2qKtuR3V9BPYxNX1I3ljpotp1ZnuIBA4YAZLqQQTxx159K0ZppPG2pX/iK9UedejzFWQA+XD/AMs4x7BcZ9Tk96pf2No5tRcrFbtcYxtKAjB64HTn2pnhyYJoyIjBRHGIyM/3fl/pXxzr8mH9nC9r3f8Al+BzXtGyOf0YwWerXsEb6daXUMwCzNby3l7KrDcoij+6AowuSVHAro7i01PUyVS31B0Ixu1a9ES/XybYK2fZpPzqHwleyPd61/ZVhdajdtKkflwR4UFVx80jYVeTjk9uldhpvhbxHqQWTW9Qh0qE/wDLrYgSS49GlbjP0FfXYZuVGDlvZHTHZHMGzh8P6ds1TxAdPtpODDYotp5vqCy5lk/FvSptItr2/QReE/DZS1c832or5MbZ/iwf3knrnqa9N0jw1pGkv5lnZR/aT1uJf3kp/wCBtk/h0rYrYZ5jb/COwvLgXPia6W+kHIhtIFtYwe+Svzt9Sa1G+FnhpJFk09dR06ZRhZLW/lVh/wB9Ma7l2VELOwVRySTgCuZ1Dx54csrr7L/aK3V2ekFnG1w5PphAefrQBVtfCOq6eM6X418QxHOQLl0uVH4OtSy23j+2GbPxXY3jel5pqpn8YyP5VZtL7xlrEKTaD4Evzbv92XUrqKz/ABKElsfhWlb+BfiVqDq15rfh7RYmHKWts9068erlQaAOVuPGvxC0KPGr+F7DWIR1m0yZlOP9w5OfoK1fDXxo8Kaswtr+eXRb8fK8GoL5YDem7p+eK6RfhBq1wo/tL4g6054z9ktobf8AkCfWuG134bSXPxCHhbWPFOsHTby3aSylm8qVmfH3WyvTAb06dcmgD1i0ube8t1mtbiKeJuVeNwysPYipd35V8+/ED9nnxF4Zit9R8Dahc6k4JE6QgW00Y6h1Cn5x1yBz0wD2o+APG3jxLm9srO5s/EjWJxNa3LGGcrx8yMwUkZ4IcZB4IoA+jy3NGlFLXUHtJT/xLtSyjp2SYjhh6ZAx9cVxHg74k6H4kujpztJp2tp8sun3i7JFYdQD0b8Ofautv4PtNrJDnaWHysOzdQfzoAxdZ8P2Woxy6f4hsLS9aBjGTLGG9ww7jII6V5v4i+DVoLW6/wCEQ1G40qSZGVrWR2ltpARggg5Iz684r1jU717yytNaZcGImx1JQP8AVyKflb6ZPX0YVheKtfTRLSCKKI3esXj+Rp9ih+e4lPQey9CWPAFAGn+zt4putS8MT+GdcATXvDbLYzjcCJIwP3bj1+UY/DPevWq8X8M/AjQbnQ5LjxxbtqHiXUH+03l1HM0Zhc5/dxlSMKucd84+gF22tPGPwzmW30+C78XeDVBIjMinUbIei5IEyeg+927cgHrdeKfGz4qan4U8SWGneG7c3Sacsepa8VQP5VoZFQJz0Zt2fUDB6ZI6pfi94Pm8Japr1nqkcqabCZZ7R8x3CMCFCGNsEEsVXPTJ61wXg+58PeHPAWr6x8Sr+3/t3xkDPfWifvJ2ikVhFAka5bAQ8ccE4PSgD3m0uIby1hubWRZYJkWSN16MpGQR9QaBcQmZohNGZV6oGGR+FfO/weXxb4n8NJ4RbXrjw/B4eY2l8iwbdQkhb5oMMciMbDt4GRs967HxD8DfC58L6jF4e08QeI2j8211Oad3nFyp3K7OSTkt1I9aAPXKK5H4YeKW8VeGI5b2P7PrNm5s9StSfmhuE4YH2P3h7GuuoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorl/iT4z0/wH4SvNc1MhhENsMO7DTyn7qD6+vYAntQBzXxx+JcXgTQ1tNOH2nxPqQ8nT7RBuYM3yiQj0B6DucD1Ip/AT4XN4G0y41XXJTd+KdUAkvJnO4xA/MYw3c55Y9z9BXI/AfwfqHi/wAQTfFLx2hkv7p92lWzj5IY/wCGRQegAOF/FuSQa+h6AA57U2R1jRncgKoySewp1ZGoO19qUenxk+Sq+ZcEenZfxoAWyV9QvBfSgrboMW6Hv6uf6VrUigKoVQABwAKWgBGAZSGAIIwQa+bPHWjT+DPGQksN0UO8XNm4/hGc7fwPH0x619KVxPxH0SDxb4WlbTys13ZszwMvO4j7yD6j9QK87M8K69K8fijqiKkbo19A1iTxFoFjqWmSQxGUfvkkQttYcMvBHQ/pW5D5nlJ5+zzcfNs6Z9q8H+CniT+zNafSLp9trfH5MnhZu3/fQ4+u2vZRokS/PHdXqz9fNMxJJ9weP0rTAYr6zRU+uz9RwlzIdfkafdpejiGQiOcdh6P+HT8adqlqxkjvrUA3UAPH/PRO6/1HvSWedT0qWC9AZsvDIQMZIOMj09aZ4anlksHguOZ7SVrdj/exjB/Iiu0o4GTRtc8Na/qPivwPHDq+mavtn1DR5H8qQygYMsDngOe6nGcdemOZ8e/EjQ9Tigl0y+1XQPHemOfJsZtOlkkckZa3lRQVaN8DkHggEV6/po+w61d6eDiGZftUP+zk4YD8efxq9phSWHzWCtcKTE8m0ZJUkUAeV6H4ifxHYxeN9HsLmz8QaZ/oWu6O6kSSxr8zRlT1ddxeMkZPK9zjsPG+jW3jbwakunukztGt3YzL0fK5A+jA/wAj2rmPiX53gTxZZePbBCdLuDHYeIIUTOYc4jueP4kJwT6ECuq8L79H1u50lG8zSLtWvtMdeVjUkebCD6BmDL/suQOFrOrTjVg4S2Ymrqx5R8IfEraD4iOn3rFLK9YRuH48uXop9vQ/h6V7n4j0m313Qr7S7wkQ3UTRFl+8hPRh7g4IPqBXi/xq8Mf2ZrC6xaJi0vW/eAdEm6n/AL66/XNd58P/ABLd+JfBksdtNGut2ieSzSjcCcfK5HuB+YNeRltSVCpLB1N1t/X4/eZwdnys830TxWfhr4yupvERnGla6j/aBFCSV1SD5JCiDnE4AcHuWHuawPGGu614w8Wx67pS3HhVVsn095VkV7q5gZw+DgYiORxgkjNd38Uvh/HqvhG4N7dfbNdmbdDdMf8AVzICRtI+6NwwcYwCRivKPB+unU9DMmoFYL60Yw3iP8vluvUnPTOM/nXtmppaNpNno9s0NhEVDtvkd2LPIx6szHkmrV1LBDbySXTxxwAfO0hAXHvmsOz1TU/El69p4QtElhQ7ZdTuMi3j/wB3HLn6V12l/DzT0nhu9fuJ9bvY8MpucCFG9ViHyj8cmgDz+PQ49e1GOPw2jxxOpIKzPbQ4B5cAKdw6D5QM561uz/Dy40LwxM0OqLNLbxs4AtyByc8ZcnAyeuc4rvr1QvizSyFHNvMv5bTTPFfiHTNHs5Ir64PnzKY0hiBeRiQew6D3OBWNTD0qitOKYnFPcf4Ltre08KaVDZpthECnrnLEZYk+pYkmta5uIbWBprqaOGFBlnkYKo+pNcd8M9G8X+JtMeDS7/SdL0i0mMRuXjM9yScMQI8hR97gn8q9PsvhD4X+0Q3WuRXWv3sfIk1OcyJn2iGIx9NtbDPPE8a2moXTWvhiw1LxFcqcN/ZsBeJD/tSnCD65Nb1p4R8fa4itcT6X4Xt26qoN9cgfX5Ywf++q9aurSG10S4trG3jhiWF1SKFAoHyngAV85fB7wJ4s0TwkvijS7K003UYtCureCyTeJ725LsY3uEdVUFcAKOc8ZIFAHo9t8EdCuGWTxRqWs+InBz5d5dFIc+0ce0V3+geG9F8PQGHQtKstPjPUW8Kpu+pA5/GvAdI134if2DeMl9rs6O9n9t3abM13YoXxcmLfborNj+BQ+3BI9a1ZIr6T4jeCdVs9W8ZXOkYurZJ7uwZSZN6FElHk7ljckqXcL8q8EYLEA9/or5w0/X/iIukanMsniGTU10W8m1GK6sNkdpfK/wC5W2/dgPkZ4UuCMHrWj8Q73xlpWg6HDa6n4luL65s57x72C3+VZtkZS3aOGBjkENjdtHLbiewB7rNqFnA0onu7eMxBTIHkUbAxwucnjJ4HrXDfGHTpE0yy8R2UQe90SYXIx1KAgkfTIGfbNeU6ofE9xpnibV3067k1a90Pw877rDeHmMqmYBGUjK5YkY+Xrxiuo0TUvFV18ZrvT9TOsajoct1dRmMW7wWtvbhGCLKskARweMOkpLcEjBK0AeueGNcs/EehWeqafIHguEDYzko3dT6EHgiub8YfDLQfEuof2n/pWl6zsKf2hp0vkysPRuCGHTqO1Uz4V1PwhczXPgjy2s5Tvm0+diVZvVe4OMc5HTnPGL2jfEPTrif7JqscunXanawmUhQffuvfrx70AeLfFL4S+KfsIuPKh8SSWo3QalZqLXUIMcjKcrKB6Agntiuc+HPxsksLo6L49JRoz5a3+xlZWHaVMZH1x9R3r7AikSWNZInV42GVZTkEeoNcz4o+H/hPxTcCfX9AsLy4H/LZo9sh9iy4J/E0AeOH4gQajq+saF4E01/FFxq1shYQPst7aQZXzJJCMAY2njuoFei/DT4ajw5dtrniK9/tjxRPEI2uWXEdsmP9XCv8I9W6n2yRXX+G/DWi+GLNrXw/pdpp0DEFlt4wu84xlj1J9zWvQAUUVy/xM8WweCPBeo63OBJLEmy2h7zTtwiAdeTjOOwJ7UAeZeNNE074i/GBfC9rZQLpGlpHfeIrmFNjXcvPkW7uuCcbmbr3PQqK9H8KfDbwh4Un+0aFoNpbXPadgZJB9Gckj8DVH4MeErjwr4QD6uTJ4h1WVtR1SZuWaeTkr/wEYHpnJ713lAHj/jf/AIor40+HPFS/JpXiFf7D1I9FWbrbyH3JG3J6Kpr2CuS+K/hUeM/AOr6MuBdSReZavnGydPmjOe3zAA+xNRfCDxUfGXw+0rVZ8i+2fZ7xCMFbiM7XyO2SN2PRhQBy3jyzv/AHi6bx74esZ9Q0++RYde0+AfNsUHbdIP7ygYI7g9uSPRfC3iPSfFWjQ6roF7FeWUvR0PKnurA8qR6GtavOfEnwttZb+XV/Bmp3XhTXX5eaxAME5/6awH5G+vB9c0AejVF9oiMxhEimUclAeR9RXhXgfVviZ8SdMEU+oaboWkWs72N7f2ibru7eP5XMYPyx5PcdO3TFew+GfDmn+HbMQWCyu5/1k87mSWQ+rMf6YFAGzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDe3VvY2k91eTJBbQIZJJZDhUUDJJPYYr5Uijuf2iPi6bj98ngTQiFwxKiXknp/fkI59EA74zuftH+L7zxX4gsvhf4QVri8uZl+3yRv8o64jbHQL99vTAHrXtfwy8FWPgHwfZ6Hpx8zy/nnnK4M0p+85HboAB2AAoA6a3hitoI4LeNIoYlCJGgwqqBgADsAKkoooARjtUn0GaztCjzavcuMS3LmRvb0H5Va1CbyLG4l/uISPrijT4zFYW8bDDLGoP1xzQBYooooAineMARSShGlyifNgk47e+OaqWaQaWtpp0AZsg4PfA5LN+P86tPbQvcx3DxK08YKo5HKg9cflWcnPimTeelqNg9t3NAHh/xc8Ot4f8TC+slMdpeEzRlePLkB+YD05wR9favY/h/4iXxL4at7tiPtSfurhR2cdT9DwfxqTxz4fTxL4cubE7RPjzIHP8Mg6fgeh9ia8T+FviB/DPio2t8Witblvs9wrceW4OFY/Q5B9ia8F/8ACfjL/Yn+D/r8GY/BLyZ9DW1utusgUkl3aQk+pNZun/uvEeqRDhXSKbHuQVJ/8dFbFY9sC3iq9YdFtokJ9DuY17xsJrX7vVdHn6HzmiP/AAJT/hRoc27U9agGMR3Cn/vpFNP8QBT/AGcWbDC8jK+/NVdCGfEviF1GFMkK/UiPn+dAGxqFnBqNhcWV5Es1tcRtFLGwyGVhgg/ga8w+B148VlqngvV2WTUvCd4baAuMM9qQfIk6/wB0kfTAr1O4mitoJJ7iRIoY1LvI5wqqOSST0FfJvi7x3bax8ZNL8TeHrS6t9GMi6Nc3/m+WLwlztcAc7VbHJPOB0xQB9E/Ei/0O38N3Nlr9xsW4QiKNBukLDoyj2OOTgV856bqd7pjTNp91NbNKnlu0TFSVyDjI+lepx+Nhd6xf6JrllFqUMUcUyx3CL9xtwypx1BU9eeetVP8AhDPDfilJpvC19LYTo21oLhS0Rb0V/wD65+leHmmCr15qpStp8mZVItu6MnxpcfZvAngXTrfzV1m48+709xwrTggiNjkcOJGHPUZ74rzzxDp1rPPa+N76yS7WC4W31rSyhzAoBAd1/idDjqMEEHpzXvHjXw3Dd+FtM0C8KLLDZRxrcRj5opVxiRD1BDLkV5Gmryadqt/f6nDHFq9oEtNcsBgpfQY+S5iX+I47emV9K9ehHkpRi+iRotEek6dcWt3YW8+nvHJaSIGiaP7pXtioL/VrOxube1ll33ty22C1iG+WU+ioOT9eg7kV5JDeal4Ot7WXSphaeA9Zux5GoSIJ205X6kLnG08kbumDxnr7JoupaRpZlsvhtpLa7q8q/v8AV5MMCxH33mI+Yd8DC+nFajOb0/RbzxZ4xnsPEs1x4fg062aeVLO8XzApZfkeUcKSCCdpOAMZ610Fnoula4R4d8B2CWfhkSB9T1JFIa5IOfLDt8znpkkn8ut/w/8ACUyXct/4s1KW9uLlvMnt4SVR2zn5m6sM9hivUbK0t7C1jtrKGOC3jG1I412qo+lAHnXwsii0rxh4z0WBDFBDcRzRRHoqsD09sba9Mrz7Tf8ARfjbqsaA7bzSo5m9MoyqPx5Neg0AMmlWGF5ZDhEUsx9gM15n/wALw8Gm3edH1doltheKw0ufDwbtrSr8v3FIwzdAeMk16VcxCe3lhYkLIhQkdQCMV43aeBvCL3q+F7LWtQvLyPQJfD0wt0Eot4WfzS8rqu2OTIwAxGc9DQB1d58S9I0zVNbTUruM2NkbFYzbQTSylrlWKZAXBzt42598cU6D4qeG59MN1GdRM/246aLA2MguzcBdxTyiN2dvOegHXniq1z8KNKuLy6uGv74NcS6bKwGzANkCIwOP4s/N+mKkvPhdp819eahb6nqNnqkuqnV4buHyy1vKYhGVUMpVkKjkMDQBZi+KXhaY6ULe6up5NTiaW3jhsppHIWTy2DKqkqVbg5xjBrT8Y+NNI8IyWMWqm8e4vvN+zQ2lrJcSSmNdzAKgJ4HPNZfhb4a6T4a1XSr/AE+4vHk0+zntB5zKxmM0oleRzgfMWz0wOelVvibN4TsNX0HXPFWvR6bLpP2nyId4Jl86IxN8mCxwDkYHXrQBo+D/AIjeHvF2p/YNGmu2nazW/iM9rJCs0JYKXQsBuAYhTjvxzg12Ir5itdT0XSrS3k8MReIkNtoMmiW+oX1xBpiCNpRIJVaXDFsgYKqRz0zWhN8XtcuIYLOx1nQbaTy8KbKC41i4cKACSUVE3HrQB9G1yXjDWvBVsrQeKtS0aJlXPl3U6BwPUAnd+VeLrq2u61bbtTufGerxynDIkMWmQlehBQsrYznv0qx4f8M2VgJng8KaXp1wuDFJJcCWV2zzufYzJ25DN16UAW7nxlpPh+T7V8PNWvtVVpDu0xLS4ljcd8MIyB35znnqa66x+MMd3pkNwnhXX/PYAtCyQxbcjI5kkXj8O9c/9l8S3E5PnaHbxAEguk1ywPZvvIMc9MfjVC78IarqE1vPc+JRFLEd8U1jpyxYzzj52fIz6cnp7UAdrp/xI1i91CKJvCv2S1LgSSy6nE7qp/i2Rhs8dtwr0eyuEuraOaM5DD0x+leD+HNAj8QQO8XifxUwiY28kfmRQEEY5JWIEDHP4+or3LRzENPijtwRHEBHycnjjn3oAu141c4+JfxoS3x5vhfwW/mSd47nUWHC+/ljP0II6NXU/FbxynhnwI+oaK8d7qeoutlpKQsJBNcSZCYxwQOT+GO9XvhX4QTwR4KsdJLCW9Obi+nzkzXD8yOSevPA9gKAOuooooAK8f8AC3/FE/HPXfD7fJpPimM6xY56C6XidB7kfP8AQCvX+p9q8v8A2gtKuj4VtPFOjpnWPC1yupw46vEv+uQn+6U5P+7QB6jVHXdQi0jRNQ1G4YJDaW8k7sewVST/ACpNB1W11zRLDVdPffaXsCXETd9rAEZ9+a5P463ZsvhB4slAyTYvF/33hP8A2agB3wPsG0/4U+HFkUrNcWwvJM9S0xMpz/33Xc1m+GrVbHw5pVohysFpFEDjGQqAf0rN8ZeNtB8H26Prd8kc0vEFsnzzTH0RByfr096AOkorA8L6nqmtQi9vdNbS7Rh+6gmbMze7DA2/TrW/QAUUUUAFFFFABRRRQAUUUUAFFFFABXAfHDx0ngD4f32pRSKupzD7PYqcHMzDhsHqFGWP0x3rv6+UtQe4+N37QsVpGDJ4T8NS5c/wuEb5j7mR1wP9kZ7UAdx+zF8Op9C0mfxd4jV38RayDIGlYlo4HIbkf3nPzH8BxzXutA4ooAKKKKAM3Vz5s1nZ9p5MuP8AZXk/0rSrNiUz67NNn5LeIRD/AHm+Y/ptrSoAKKKKACsqTT5Z9SkvGcwyJhISvPyjk5HfJJ/KtWigCEi4N0uDELcDnglmP8gPzrxD43+GvsOqx61api3vDtmx0WUDr/wID8wfWvdazfEmkQa9ol3p119ydMBu6t1Vh9Dg1x47CrE0XDr09SZx5lY5v4T+Jf8AhIPDaRXD7r+yxDLk8sv8L/iBj6g1u+HZBcvqN2ORLcsqt6qgCj8ODXgPhHVbnwR4123oZEjkNtdoM4KZ5I9ccMPX8a+i5J7Ww017hNi2qKZBs6EHnj65/WscsxTr0uWfxR0YqcroztVze+INPtYmGLf/AEiXvjBGB+NV/D15Db6dq+rX8sdvaNcyzGWUhVWNcDcSe2FNOic6doN5qV6VS5ugZXZjgICPlBJ6BR19MGvnjxT4hk+IWoW9tbll8FaaQLdCNv8AaEy8eaw/uA5wD/jj0izQ8a+MLv4l3UsUDz2vgtDtjhBKPqJB+/JjkR+i9+p9By/jTTopPBeoW8CLEtvB5kIX5Qhj+ZcenStfU9QtNJsHur2VYbeMAZx+QA7n2qDw/wCFdQ8V3kWpeKoGtdFjIktdKY/NMezzf/E/n7gFfSb1vEGo+FdcuxJDYajGdNlO7aZpChkxx/DvjYfjXsukG3S1hFh5X2Vl/d+URtI9iK8LuIZdK+HV/ZRIGuPCmvLchGIBMG7zEYfUOfyNbXhC81LUrW60nSJzb6ZZ3cymZyd7Ru5kRQOoG1xUTqRpx5puyE2krs9L1vVZGlaCwzNKg2vK5PlW4HPzN+Z2jmvLPiBFrOnNY+MtNmJ1KzcQyuygGW3Zscg/KoBxjjIzknIr0G5u7600eSwYxz2kkfkRxwwhGVzwvTqCeD35qK8utPubea0vSNsqmKW3kUhsEYIK9a4K+NlaMqC5k3rp+BlKo9HHU88FxaWOjT3l2kl/4RupG+02G3y2tJXzk7B0AdSHVcbThl6kVrfD/wAaXXwo1KCw1FZLjwFqDh7acEStYFjkHeo+ePB/w9DU0iwvfCXiDOoMw0lljjcyD5hG2Utrl/r80LHHBRCcbhVnxDaReF7W6R4Q/hi7YlkxkWMzHggf88mJwQOhJ7GreKlCpGnJbr7/APg/n5D52mkz6ksru3vrSK6sp457aZQ8csbBldT0II61NXzP4Xv9S+DGsLJILi8+HOoMu4bjJJpUjHqR12ZOM9+O/De36r430u1uVstNFxrOrOiuthpyiR1VhlWkYkLEp45cr7ZrvNTAudw+O9ngDB0lsnpxuP8AhXQaz400+zv5NM0yK41rWk4aw08B2iPbzXJCRD/fYH0Brzq2TUPFvxWurXxJ9l0yKxsN00OnTt5u0kYje44YD94c+WE7glhXTzfED4f+DETRNLurTzYyQunaRAZ3Dd8rGDg+pbnPWgDTbw/rXiRQ3iu/NlZNz/ZOlSsikf3Zrjh5PogRex3V0+laZYaPYR2Wl2lvZWcQ+SGCMIi/gK8m1r4l+K9SxB4V8NR6cjkAX2szLlRjqIEJbOP7xFcZqfhS61+RpfGXifWNbJbJtlk+zWuO48tOnfvQB7T4n+JPhDwzuXVteskuFO37PC/mzZ9NiZb9K4O9+Nl/qTyxeDfBupXgVT/pepOtnCDjgjdyw6ccGs7RfDFnpQMOmafb2MTcM1tEEcj0LDk9uSfxreisIUYK3J4ILk7jznr9aAPPb1vil4sgkGueKo9HspN2610mAKQuOP3hw2Oo+8eneq2j/CHQ7S7jup7nVZ7vq9xLdssh4OfuYIBBPc9Otepm3uAFEUaFd2Czk/KPXH59qebF94MtzwvOMcex/wAigDmLLwf4bsZRJHpFs845Mk0fnSHkHJZ8nP410ESRRII4YMZHyqqfdIq4RDAPvbyW5DHpU/2hF3OpCxKMkngD3z9KAKMFvLcTNvjeMKSMcDP0NWrbTlBbHcfN1Of1rK1HxloVm+JdW0yN8cL9pjLDjP3c5/Sn2viy1uokaxi1C73jcrLp9wqN24dkCfrQBvx2UUX3skHr2qvdXMGmwSTGMKqdSsbMef8AdBJPTtWVP4h1JpP9F8MajIR0a4ureFP/AB1pG/SmLqPiuR2MHh/QbRjyHub+WfPrkLEP50Ac/qWtzWviy01LSNP1u4gnPk30UWl3QAB434MeCRweOeD616F4Z8XWdxqMWnQ2mtxSPna11pVxDG2ASfnZABwD1x6Vymoarrpsr37d4g8M6dZCFt7xWEz4XHJJMyn8gc9Oc4rB+GfjO9Gp21jrPiO7dY5Wji0+LQ2m+0xD+NJIy7IoJHDcgDkYPEuSTUW9WB4T8N9E8aX3xOkfwNam5/srUZpEkvF3WkBJKlnzwCR6fNxkcivvSy+0/Y4PtxhN3sHm+SDs345255xn1pmm6fZ6Zai2061gtbcEt5cMYRck5JwO5PJPerVUAUE4oooAKg1BrZbGc37RLabCJjMQE2Y53E8YxU9V9RsbXUrGey1C3iubSdCksMyBkdT1BB4IoA+Zvhx8XtH8Apd+BY/N102+rtbaPNZyK0UlvK4KbpM/wsxzjPXA6V7h8W9S0fT/AADrEWvzBIL22ktI4gN0k8jqQqRqOWYnoBXjGqfs8p4e+J3h/wAReGZVbw7b6hFdXdpO/wA9oqNvyrE/OmVxg/MOPvDJHUaJ4h0S81e6+J3jG88nTPtD6b4cjdHkAhBIaZI1BYvIQ3OMhR6UAN8JaT8XPEHhzS7TVNTs/CWnw20UD+TF51/KqqFLEtlULYzxyK9A8LfDbw14c1D+07azku9YK4fUb+Z7m4Y467nJ2/8AAQK3fDXiDTPE2kx6lol0LqzclQ+xkIYHBBVgCD7ECtWgAooooAKKKKACiiigAooooAKKKKACiiigDyX9pD4gDwT4K+zWkxi1XVibaF0+9DHj95KB3wDgdOWHpS/s0eBz4N+HFvLdKv8AaWrbb2c4wVVlHlofovJ92NeP6wYvjR+0bb2iytLo2jyGNolU7PIhYl2LZ6vJheP4SOeK+uQAoAAwB0AoAKKKKACkd1jRnc4VRkn0FLWX4jldNNMUX+suHWBf+BHn9M0AP0JSbNrhhhrlzNj0B6foBWjTYo1iiSNBhUAUfQUk0qQxPJIdqIMkn0oAPNTzvK3DzNu7b3x60+qWmwsd93OuJ5+SD/Cv8K/57mrtABRRQSACScAd6ACmyyJFE8kjBUQFmY9AB3rHl1ieaZl0m0N3FHnfLu2qSOynuaqXt82pKkY06/fB+aFhsRm7bm9PagDgfjl4cV44PEVkoYELFcle4/gf/wBl/wC+a0/g9rcOvaCNG1LElzpzK8Qb+KMH5frtPH0xXe/YX1HR57LWIYfLnUxtHEThUIxjPqPWvnaJr3wB46+YFns5cNxgTRH/ABU/gfpXhYpPA4pYmPwy0f8AX4mMvclzGr8XfFt1421O78KaHIbfw/Zz+Tql4Mh7p1PzW8foo6M34dOvMapeWWg6askuI7dMRRRRryx/hRFHU+1e2adrvhObXL6XRbRbm++zyX8syxZVSACcZ/iJPOB1zk5ryjwV4YupriLX/FKA6lybWzzlLJD/ADkPdu3QV7VOpCorwd0ap32KnhPwnd6pqVv4g8VQiIwjdY6afmEH/TST1f27V22t6xa6PbLLcl3lkby4LeJd0s8h6Iijkk//AK8CqniLXTp89rpum27ahr1+dlnYoeWP99z/AAxjuxrqvD/hyw8C6YfFHjK6W98SGHbJPn5YyefIt06Ads4y3Un0sZ47Hot6PiN4htfG9tb2v9p6RHfCzSbesQDGBQxxh3AbPHGTWV4F1aLTNc0iJpCq3dm2n3UZU7hdWxPzYHXcprrviH/bVz488I+JfENlFZ6bqbvpMdvvw0auN8e8+pYZ/DtT7+1WLVPFdlbQq19ayW/ifTI+hYqoSZB9TE6Y/wBusa9FVo8ktiZR5lZm5LMX+yz3McsFn5iyruX55ipBChewLYGT+VWtZvtSvkeWVbVYh87W6qdzAc7fMz7f3ahvryLUNY06SOUSWE1mLm1zj5ixBB+u0g/jUt0klyptIHVJplI3scCNcfM7HsAO9eXVnLD1I4bDK36mMm4NQgWvHUUFz4Yi19rc3FrZwFb63A5uLCUATIfdQFkB9Y/esnwdYaHeRap4X8Qxi8u9PiXZK0rul/ZyD91cKucAlflYdA3Q81l6j4r1TVojpHgDyxoluDBea1PbiaJ1C4MUMbcS+7dOeuOTV0PwJqCwWI1PWNSvJrG2aygaGRLNVtyRiM7F3kYAz8x56Eda9lpPc6DO17xYPCuqHwpqOs3UOkWcCC1FixnvbuPcw8uSVQGjKgLhVCHHVz3reBb7xt4Zn11fCUEWm+Hb6Q3aLrS7pbVuC7KgdmOR/fPbn37vw/4L0zw9HK2mWkFrJI3zSqCXbPrI2WI9icVF43WPTPDt66HLOmzPrkgf1pgcR4c8MP4uXUdZ16e9uFv7xs2gd44JQhPzOqkFsuXxk4Fegab4YtrKI2un2lvYW7fKUt4VU5znqOv41q+GrKO18OaVbwKEKWsZzj7zFQWJHuSao6x450PRrn7LPfxT3rMIxaWSmeYnoRsTJH44oAvQ6DHECzpuGO52hep6D/PNaCWUG5DhVYHgKoyPx/rXNpr/AIi1FGXTvCtzaoTxJqdzFblfqg8xvb7tKdH8SX8okutbs7FgTlLKz81senmSnH/kMUAddG0EZU7AHHZjnFYepeKtH0zDXWqWNo524R5kjZueyk5/HFMk8K2N3Dt1GW9v1/i+1XT7T7GNNsf/AI7Whpmhafpi/wDErsLK2APW2t1T9VGf/wBdAHKaZ47Ouzyw+H9G1a7ijA3TzQi3gPOOGcgn8FJ46VpwjXbsBlFhY5GB+9ku1P4ARHv6mumEP70GViWPqaebdQ/Bz35J45oA5QaDqcrbdQ8QzhS3zR2cEcAI+pDOPwf0qVfCGj+cJbyOS8kU5LXk0l0D07SMy9h2roXjCyHbgcYyMDj8vrT7dASAclhjk847ZxQBStrG0spM21skbnALqu0nHuOwHar8UiByAg46DPU1PHEQTjkZwSBUn2dmbKR4zzg8c0AVHDs/yqoGBnjPNQSpdPjypQgHOMA5x7Vp3Pl2NuZ9QnjtbfgZc8dO3+FZMmrLfr5eh2V9fy/wybPKhHXkue34c9qAPPfi3dsunjTvs0c1wzxT3M0cWfJgWVSS7Z4ywUfgelZPhS7i/wCFgeGPslr5roZt6AkZUW8gY8dslfzFew6N4cS20+8TWPLv72/Ux3TOAyFCMeUBgArj25z9KwPA/hvRtE1HXLjTrSOOVLk2qSea8rRRqfuAuzFecZAx0HpXHVwrqV4Vb7EuN2meo6LeSXcUnmRCLYQoX04rSrH0BXBlcqwjYDBOcE+3+NbFdhQUUUUAFFFFAHnH7QWuXGifDHUVsTtu9SdNNibONpmO0n8F3V5X4xsrGPxTpnh6KQrp3hmxSwjUjA8woru/1IKD8G9a7/8AaZia88C2NlZI1zrEmpQS2NlGheS5dCSygDsF3Ek8DHuK8u+JXiDS9Y1qDU/7O1zwreyrt1E6npErwllwobMZzuA4z0IC9K5MbSqVaThT3Jkm1oev/AFJV8L6mx/49X1GQwH2CIp/8eB/WvTq8i8D/E74a6HoVjo1l4ptiYl+aSaKSIyyMSzucrgZYk46DOK9C0bxXoWtSbNK1W1u2xnET54rejD2dOMOySGlZWNuiiitBhRRRQAUUUUAFFFFABRRRQAV518fvGB8FfDHU76CQpf3IFnaEdRI4PzfgoZvwr0Wvln9o+5m+IPxa8MfDvSZGxA++7ZeVRnAJJHqkYJ/4FigDqv2P/CA0bwFPr91BtvtYlLRu33vs6cL+bbz7jFe+VW0uxt9L021sLJBHa2sSwxIP4VUAAfkKs0AFFBooAKzXdbnXEiHItU8xvZm4H6Z/Ort3OlrbSzyfciQu2PQDNUPD9tJFZvPcDFzdOZ5B/dz0X8BgUAalZkbf2hqUoYH7NaMAAejyev4fzqzeXUUUsFvIX8y4JRNnXpyfanafapZWcVtGSyxrjc3Vj3J9zQBYooooAZPKkELyzMFjRSzMewFYiJNrziSZWi0ocomcNP7n0X2pr7te1B4cMul2r4f/p4cdv8AdH610AAAwOAKAGoixoqIoVVGAAMACnUV5X8ZPiTN4bkt/DvhqNLnxPqCEqxOUso+nnSD8eB3x+BAOyl8YaMdcvdEttQtn1m1jVngkZkQMwO1WkwVBOOnJwc4rxP4nQ+JbjVze+IdOECKvlxvAmYguSQN4zk8nqc+wrDsLW20HS5XuLgtgtPdXc7fNK55aRz6k/4V2Hwx1rxL5c+oancSLpVwuy00qdQwEeeJGJ+YM390YAHUE9OLG4P63Dk5miZx5kRfBePbe69c/wDPPT2QH/eIP/stHinXpbBhY6WsMupNE1w7TNiK0t1+/cSkchF44HLHgV0ut63o+mWF5a+GdNii8V6wghtbFNwSdwfvHbwqruLEnbwDzXOfELwpB4H+EeotLI+o6/qt1bHULzZ89wRIrsir2RVVgFHYepowWHeFoezerVwhHlVjgvDPiLX9Ckvbvw61s13dHdPqWoWhlubj04DARR8cRjOO5zwPT/gwx8dz3mt+Lbhr3W9MufJW3C7YIQQGR0X3B79CPxryzTNZjSwkNu0cqSA/OpyD+Nes/s2abPHpeu6vIhW11G5Rbc/89FjXaXHtuJAP+zXDl2Nr4itKNTb02IhJyepL+1Pp01z8Lv7RtgTNo9/BqC4/2SVP/oefwrnfEF3BZax4W8XWjgWkcohuHwMfZboDazeyyeWf+BV7d4p0eLxB4b1PSLjHlXttJASRnG5SM/h1r5y8JRz6/wDBm/0S4Rhf2ENzpFxkbsSxfc6+gKflXtmpt+CbGznu9f0+9Alg0a7aCBJDwlsSZIT7AJxn/ZrKsrew+Iuqy3FvZS2ngK0kKqoOxtYnVs5f+LyVweO598heP1q8j1HxHpdnJqb6Ra6h4ftG12LYfOuGV2/cxovzl2+7wPun04Pp+mX+s3FtHZ+HfCY0vToYwkD6vL9mVVHQLCgZzj3x7mgDqrmaOVEihhjEUWFCIAFUAYCjj5R0wOgrJ1rXNP0G0D65qFnZNkYjeUbskcAL94/gDxVKXwrq+qMy614ruooGz/o2jxLZDHvId7t+YrY0Hwt4e8NuJNK023iuRw1yV8ydvcyMS2Tj1x7UAc9L4o1XUImPhjw5f38YO4Xd5ixhPXlTKN7fgv41594r1PxPeSvba/NZW6PHua0sEL+SvZmdurewwPzFen+NfEyWJW2twZ7yY7YIF5Z2JwP1P41iTeHG0fwJr13qDNNrN5CDM27iMb1OwHvyMk98AdACQDTtfh1o1xEkmrXOra2CPl/tK+do8Y7RqVUD2wa7DTNLs9LtTDpdpbWcbdY7aJYlP1CgfnVLwzcef4Y0eQHcHs4ThcAH5FyBx9aj8V+JIPDGgXOp3drJIItqpb5O+eVjhI19yfY+tAG2kSkKAGPuvJFNcJwoQ5HOOa5uz8L+PNcgt7rUvEsegLIu9tPsLGN2hzyAZZCSWHQ4UDqPerP/AAgvilF2j4hXxwuAW0u2J3A9zt6eo7880Ab8akAnoSc9aSQ7JUAXccYAHasVfh5fTSiTUfHHiiWQAjFrLFbRg9iERMfhzUQ8K+LvDyRyeHvE82tRq3z2GuBS0inrtuVXcpHJGQw9qAN4xzSnMULsfUj+dZmpX9npYJ1bVNOsVAP/AB8XSJkD0BPWuH13Q/EdjaSXfiDwtdeILZVJcW/iKSZ4kx82IAkSPx2A5rZ8GWfhXVdFttY8NaZpZt5DgMlmiyqw6qx25DD0z756GgCynjXwqqIItWtphnP+hJJc4GcdI1bBPpVxfGNplRp+la3dF+QE0meNT/wKUIo/MVqeTctHtSKUAdBzx+lWGsLhkBETjIz0b/CgDBPjHVBxD4L1h0kyC8r2sbA/7rT5Pf07VZl8b65E7Lb+D9UmAwPnns4lGeOD55/ya1YtPuQnzxtgdMkjP6Vy8eg6l4g8SSy3llLb6Tp02LeKZf8Aj5kXnzB/sg4wenA75oAZL4h1l9Ra+n8BXV3cHCo11qNntjGANqAOQOe/fPXtW1a+O/EHlg3Pga9DkHCx31mwXnjkzDP5CtcaZdHC/ZyxHI9PannTLzqbWRs9vWgDGPxF1ZHKSeDLtW/uHUbEN7cefn0pmm+KWgnuZX+G2rwNcs00j2ptJ2kbuW2y53HHT8s1rT+HlvmcXulwSggDE0KSAgdOo5rkYPCGhPrGu2114csxKm10KWqxkAjnYUAIxuXoaAO3sviFpct3bWl1pviDTpp5FhjF3pUypuI4BcKVH1JxXZggjI5FePWngtZrlItE1fxBpDnBxa30jxgepjm3rj2wK9W0i1mstLtbW5umu54YlR7hkCGUgYLEDgE9eKALdFFFABUN7dQ2VnPdXLiO3gjaWRz/AAqoyT+QqasvxXp8ur+F9Y023kEc95ZzW8bnorOhUH8zQB5/8JoZfF2s3/xF1IMY73da6LBJ1trNWwWxnAeQjJ9h711rT3kvxFW3S5dbGDT97wD7rOz4BP0Arn/2ftZh1T4YaVaCMQXukKdMu7fOWili+U5+oAb8a3dIcSfEHXskFo7eBR8v3RycZoA6aSCKT/WRRt/vKDTIrK1hkLw20EbnqyxgE/jU9FABRRRQAUUUUAFFFFABRRRQAUUUUAQX93DYWNzeXLbILeNpZG9FUEk/kK+Wf2W4rjxj8VfFnjfUELbd/lE9EkmboPoibfoa9Z/aZ8SR+HfhFrCmTbc6kosIQGwWL/e/8cDVL+zf4WPhb4T6TFPEqXt8DfT4HOZOVB+ibRQB6fRRRQAUUUyeVIIXllYKiAsxPYUAZmrZvLu209CNjHzp/wDcU8D8T/WtboPas7RoGCS3cw/fXTeZz1Vf4V/AUawXmjSygOJLg4Zh/BH/ABH+n1NADdOAvbuXUGGVBMVuT/cHVvxOfwArTpsUaQxJHGAqIAqgdgKdQAVj67czvJDp1g225n5eT/nlH3b69hV7U71LC0aZwWYkKiDq7HoBUGi2clvC812Q17Od8p9PRR7CgC3Z20dpbRwQLtjQYAqais/xBrFh4f0a71XVrhLaxtYzJLI3YDsB3J6ADkmgDB+Jnja18EaB9qkQ3OpXLeRYWan5riY9B7KOpPYfhXgen2slu15q2szpNrF4TcX92xwCeu0eiKOAOmBUxutQ8Sa/c+JtfBF1PmOyt2x/odtklU/3znLH8O1Vba1fxdrBsIgToVpJ/p83ad1PFuvqP7xHbjvQBY8Kaa/i25XVdRiI0GJ91jbuCDcsOkzj+7/dXv1Pauv8Va/HoNlEUhe71C6kEFlZx8vcSnoo9vU9hU3iDWLDw1ost9fusNrAuFRRgsf4UUep6AVu/CDwnfNcP4x8XWqQ65eRiOztc5+wWp5C/wDXRiSWP0HHIoA0PCmgWHgTQ7nxL4vu4DrUkIbUL5z8kK9fJiHZATgAcseTkmuQi+J+heKPiPpEV6s+m6XYrNPBJfLsS5kwArDGdpGSQGwfYVj/AB81n+1fiBZaAWc2ml26XUkeflaeQnaxHcqqnH+9XNWltDfeOfCFrZxKz/2lEWBHBUAs+fbYHrzauP5MTHDpevzIc7S5T3dvCnw+8XXD3o0rQ9Snz88kaIST/tbev412lrBDa28VvaxRwwRKEjjjUKqKBgAAdBXM6t4B0G+bzra1/s29XmO6sT5LofXjg/iKzbPxBqvhe6jsPGSiawZhHBrEQ+Vs9BKP4T79P516RZ3pr5d1Gz1S/wDHPj6PwZqsVn4VmuUlvr2OEM/2vYBLDAx4yScs3bjHv3mqa/rHxQWSx8Myz6H4QZ2in1onE96oOGS3XqqnB+c9ew61LcaBBpcGn+GfD6xRWSAYjXPyxg5JJ7knJJPJNAEXhrw3pugWVslhYQw3Ai2yXG3M8ucFi8n3iS3PJxn04rc8hsMUCAD07cZq2ulRxK3myTtu9Tkfzq3F/o/CnAwO54xQBmmwupslYpR6naR9O1VNStbvTtJvb+fKQ26FzuByw7Ae5JArphqsvKeZIDjr2rzHWr/U/ihrkujQyy2ngyyumhunQlJ9QkhI3qDnKxBsDI5J/QAwfDF/4ZsJZNf8XeILRNWuSVhs4wZp419fLQFhkZA46d+a0/GnibwvP8LNU1XRb9dR/eJapHErLIZWcfIUbDBsbjyO2a9T8MeHNK8P2CWui6fb2NuP4IUxk+pPUn3JJrjvijomkxeVrK6Xbtrc58n7Z5W6URKDkD3wxGeuO9AGf4N8N+OdV8Pac2payvhWxit444rHT4I5rlkCAbpJnB2sfRRx9aXRvCkkvxNS3m1rW9V0nQIo70x6pcicfbZN/lkfKD8sZZvqy+letI6PBF5Q2oyg49BjgVJt96AHQlnPIqYopHNRIhwWHpwKgg1SymuWt4ru3kmU4MaSgsD6YoAlZdp549/Wo5Bxnt3p97e2tqqfaZVXzG2IuCWdvQAcn8KZG6zsViinQDvJGUH680AVNSF62l3g0wwrfmF/sxmzsEm07S2OcZxnFeaaP8DPC+m6RHAZtUOo8tJqMN9LDJ5hIJZVVti8gY4PQZz1r1TJDEYxin8YGDQB4vF/aNv4mbwb4yu7nURJGb3SdTEslu11Gow0UvllQ0idec5ByR0rcs/A3h+4WSWTR7WaTd96cl2P4sTUvxrtlj0zw7q+dh0rXLSZ5efkid/Lf6g7xkVVvvEni3SmUOnhxLeWTy442uLl5WPQAKkfJ9QB+JoAyfEnh3w3Z6rY6bYeG7CbWbsgiNAyrHHkkuwQj0OP90+mD0beDNEjRvK0+52uSSFurgZz34fj8KqxHxRBqsuqP4f0Ga/niWJiurzqwQY+UB4ML05+lXxr3ixApn8HwMFXOIdajJ/ANGv88UAVh4J07yjHb3mv2CNkAQazdDHHOAzkVKnhW4t3LW3jHxahZQAr3sUoXHTh42q3B4t19GHneDtUCYyTFe2bkf8AfUqmr/8Awmgt42N14e16FQclvsAnyfX9yz5+tAGRFpni+3O238fXLKAQFu9Kt5cehJTZk1lXcHxAsLq/vLPW/DVzf3UISOWeGeFkC4yRHmRPToB2ya2b74o+G7OcLeSfZiDyt1ptzEx9eWjGPqaxPEvxG8PWGrQ6jp+mDV7zyVV4bTZgRMNykyNgZIYHaMnp0BFTKcYK8nZBsLpt78RruZluNZi0/Yu5ZDbwXcUpz90gLE4456fjXqnhS41K40O1bWxbHUAgEz2wIid8clQeQM+tZngrUvD/AIt0CDVtGtlWByY3iePY8TrwyOvYg/h3GRXUqqooVQFUcAAcCqvcBaKKKACiiigDxDxcNa8K/GGSX4c2EOpahrOnNearpU0ohiPluqJcByeHO4rgdeSau2nxG1Ww1O8l1P4Z61FqZiX7V/Z00N2xCjIyAwP8Q7d6u6Yzy/tM6yZORB4bhSP2DT5P6irGveLtA8K/E9YtZ1O2szeWwJ8x8AHAA3emdmOaAKn/AAudY28u78B+OYJicKh0vdnJwOQ3rW/ofxBOq3MUJ8KeKLLzDjfd2Hlqv1Oa7eKRZY1kjIZGAZSO4p1ACIdyg4Iz2NLRRQAUUUUAFFFFABRRRQAUUU2R1jRnc4VQST6CgD5f/aDm/wCE3+OXg3wNGWktLeRHu0Tt5hDPn6RJn8a+oIo0hiSKJQkaKFVVGAAOgFfMH7PEDeNPjZ408cztJLbQSyR2khyo+diqflEuMH1FfUNABRRRQAVjauzXupW2mxnCD9/P/uA8D8T/ACrSvbmOztJbiU4SNSxrP8OW8q2sl3dj/S7tvNfPVR/Cv4CgDVkdIkLyMFRRkknAAqG3jzK87qPMb5QQ2RtHTHpmny7zIiCNWhYHeSenoMd81KAAMDgUAFFFZmpTtLcx6fBnfIN0rD+CPv8AielAEVqh1PU/trn/AES3JSBezN0L/wBBWxTYo1hjWONQqKMADsKdQAjMEUsxCqBkknAAr5y8ceLf+Fia15NoB/wiel3BMLf9BC4XjzP+uac49Tz243Piv4xm8Razd+ENElMelWvy6zdocGQn/l1Qj1H3yOg461wWt3r6daWtjo1sj39ywtrG2UYUHH3iOyKOSf8AGgCPVZr3U9Vh8PaIzJdzLvuroDItIT/F/vnBCj8a9F06zsPDmhR20Gy2sLOLlmOAFAyWY+vUk/WqnhHw9F4e01ovNa5vZ3867un+9PKRyfYDoB2H41xHxD1h9f1g+HLGXbp0DAai6n/Wv1EOfQcFvqB61lWqxowdSeyE3ZXZV8K+N7PxD8RV1TWNNvLnSNPjdtGshF8txcZCiVs9TgsQADj69fcLYfELxIrXPn2vhy1Y4jhaPzJcepz/APW+leNaLFHpvj/wrFaFXYalAqhffIIH/Ac19X1jg8S8TT52raijLmVz5V+Lnh/UPCXjOx1bXNSfUItWgEEl88IjRJoydqHkgZUnHTOK1fgRb/2z8T5LyICWy0uydzKvKieQhEXPTOzzD+NfROr6XY6xYSWWq2dve2kgw8M8YdT+Br5D8KSappSXV/od7Lo97b3Eqm2g+WJMSMPLaL7rAYxyCffPNc2Kp0aFeOLqX7f8EmSSfMz7EuJ4raCSe5lSKGNS7yOwVVUdSSegrxrX/HGp/EO31HQPBGgS3Gi3ObObxDcyiGBFJ2u8KkZlwM4I74PpVHw9qA+MV2t74j82LwtpypA+mLlI7y+UZldyDlolJAUE4J69DXpc1nJbwg6c8Is4lAVI8KI0A4AHQDHpXqJ31NDjLLUv7DiOkaZaC402wbyIWDiPai8bVGPmx0ycVo+HJWvrm61Q/KWbyUXuoHUH3rk/D93DeaVDLBMkygsrOhyCwJBrpPCLhrnUI0GIxIhY9t5Xn9AtebhsZOrXnSktFf8AAxhUbk4s6hpZ1wwBK+uM043UexmcBQOS+RhfrXG6346K65N4e8H6bJruuQfLcbX8u1tDj/ltL0B/2Vye3BqlceBNf8RoqeOvEUDWDOrzaVo9uYYpQP4XmJ81lPcZGa9I2JP+E6m126lt/AOhNrqxhg2pT3BtbNJB/CrkEyY4yFGPetb4U+G5PDeiizu5vOvIcxTSqDtaRmMkhGeSN7nk9gK6mwgt7G1htbGCO3toVCRxRqFVFHQADgCq2hNsl1RW4/012654IU0AbQGVOPpXIeNwz6zokDYMMpaNh6BmRTj8GIP1rq0R3HXA9a5bx7vtJ9EvInRfKucMXAOclTj/AMdNAHQ6Y4t1bTpmAltsKgY8yR4+VuepxwfcH1qzPe2kDBLi8toSe0kqqf1NV9Wsre+Kpe20U6KcqGGSDnt+lNs7KytE229lbRKePliUEfpQAtzfQ6ncLYWU6yQiPzLiSFwcLnAQEd2IP4A069srOW0W2NtH5SjCqq42ehU9iPUVWv4k0+WK/toUjPmLFclV27o2OMnHUqSCD2GfWtAu2/ke2KAKmm2aWc5m8ye4mK7fNuH3sF/ujoAP8mtP7SGQ4qFl3j5RgkdfWo9hD/MMH0oAkAI3Huec0+FCwbBPy9PrSE7Uxxmsa68UWNjcNZwLcahqCD5rSyj810J/vHhU/wCBEUAZvxS0ptc8B6tZC9jsG2JMLiVN6oY3WTkZ6Erj8e9cPo3w+u/G4sfEPj6+mDspktdM00m2igRsHLOP3jFsAnkV2k9nqniy4jTWLP8As3RUcO9nI4aa5YchX25ATPbPOK6s4HtjqPSgDyfxN4HfwPokmueA7rUFawHn3OlXF288F3AOZFAcnY+MkMD2x3rp9A1+11/TrS9sWaW0uYlliYrggHseeo7/AENdhknI/Q14/wCBLZNG1XxVosHyxabqhNvFtxsgmUSoo9RuaTB9qAPSMLkjJAHoahPyNne20nAAGeuPSrlrafaEV1Yg8g/LXP66i6tcHw9o93M1443XVwo+SGPOCM9Nxz0H0oAw77xJH/aBs/D2n32qXIGJHgunigTr95s9e348Z5rzScS2nxA1W21qKCM3gW9j8pmZdrjaRluchkPX1Fe5+GYPCdvbnStGvrKd43PmIl0jSs/QllHQ8eg6cVhfGHwHDrWl2up6RNFYaxYMEWWdS0csTsAyPt7ZwQe3PrmuXGUPb0nBb9CZK6seb/DTTtRm1fxPBoV3q9qEa3uvN0+627GbepBhYMjg+WCTjPvivoOPxdp6Rf6Yl5bSKOVmgbOfwGKyvhn4Et/B+kSJ9te61S6cS3d0mUV2AwqqmSAqjgd+/eu3VcAAkt7mtMPCVOlGEt0hxVlY546zqV9ldJ0mVEPAuLz92o99vUinPpeuXAzNr/kf7NtaqBn6tuOK6CithnMp4UL5N7rer3HP3RPsGPTApkHhe8s9St59P16+jtkYGW3mxKJFBztBPAz64zXU0UAeNa62s6b+0DcvoMVrLLqHh1XKTH75in2nHI5Acd+leQaRpoudOvb2+3NfyPvumm5eSU/f3Z75yMV7l8cXn8Pjw744somd9BvNt6F5LWUw2SjHfB2H2xmuE+IfhnUrrxRbXfhCCO60zxGFnt7lZVWKORxli4PO05DjAOSxHFedmVCpWppU+/8AX3ETTa0PZfhduHw68OKxJ2WMSKT3VVAU/kBXUVQ8P6ZHouhadpcDM0Vlbx26s3UhFCgn34q/XoLRFhRRRTAKKKKACiiigAooooAK4P45+JB4W+FfiDUAR5725toQf+eknyD8txP4V3lfN3x9nn+InxQ8OfDTS2/0eFheajKrfcyD1HqqZIz1MgoA7P8AZZ8NP4e+EthLcwCK71N2vn4+Yo2BHn/gIBx7169UVrBHa20NvAoWKJBGijgBQMAVLQAUEZxRVHWb1rKyLRDdcSERQr6ueB/j+FAFO7I1XVUs15trVhLOezP/AAp/U1q3U8drbyTzHbHGpZj7CoNJsRYWaxFt8rHfK/8Afc9TUk8UN6hjch1SQFlB/iBBAP6cUAM0sXBske8JM0hLlTj5MnIX8BxVuiigCC9uUtLZ5pTwOg7k9gKg0u2aJZJ5x/pE53v/ALPov4VWAGp6qW3ZtLNsADo8n/1q16ACvJvi/wCO7q1uD4V8Ly7NVmQNfXq8jT4W6EesrDO0dup4xW/8U/GM3hvT4rHREin8Q34YW0bthYEA+ad/9lSQMfxEgeuPE9NsF023lMsrz3EjGa6u5j880h5aRyf8gUARM1j4d0QBEaO1gASONfmklcnhR3Z2P5k10Pg3w7LaXMmuawP+JzdRCPyg2UtIs5ES+p6Fm7ms7wdpf9u3MHiG/O6yjYtplt/DjJAuGHdmH3f7oPqa3PHHiRfDelJLHGJ7+5kEFrATgO5Gcn0UDJJ/xpNpK7A5v4t+OW8OwwaRpLKdbvwAhZsCBCcbyfU8gfQn6894L8D+K10oG00q41FHd3jvImUJPljyC5UjnI+bFZ2qaK1zoWoXV7ctcahc5kkuG4cyAfKR/dAIGAOgrudA0W9vLbRdX+Fza7puqNBFJfqp/wCJbLMVBlyjkDO4nO3j0HevNjUo5nCUNbJmd1UVji501XTfFGxYoRqumygn95uS2m4OCQPncAgEL8oyfmJ4Hrvh740ajYzxw+NdLhFuT819YBh5Q9WiYkkepVifavJ/HN5qOj/EC6XX7GPRL+//AHpeYlLO5mAAMkcmW27hjIJwDjJWujh8M+Mtda3EehTnzQNlxJJH5AU/xl1Ygr3+XOe1YyWKw1RQoRvDt+d3vcXvRdlsfUlvNHcQRzQSLJDIodHU5DKRkEH0r5O1TwvqkPxD1rwuIbm1k1G/uLq3uhGdotXbzGlVuhKhiuM53EV9ReF9K/sPw1pOkmXzvsNpFbeZjG/YgXOO2cVxHxnnTQE0TxY7hLfTp2tb0n/n2nAViO5KusTYHJwa9OvQhXSjPZO/3GjSe5zmlaRr+i6fZ6RpMml2mmWcaxRiTczsRyWJ2Ec5JPHOSeKsR+ENW1Hc3ifWpbyFmP8Ao1nmGMKT3I27uPb/AArc0jULTVbG3uba4hntZl3RTxsCjL05P9fwIqw4ntrhgu+LjleqsMVsM5q/t7Vtd0PRLK0a3toYWeZrZjG4hXgKSc5JbvwevNZPjFUbXIvB3gy6a0l1C3R764PJtYSzAsDnmVgGA/P3pNc8S2+h+JNf1XUYJJzaWsdnbW6feuJZChSKNgOCWB4ycDJ5wat6HoF74e/sWbVnim8QaxqhudQdRlY8rxEp6lUUKo98nvSUUndILHd+G9CsPDejQaZpFusFrCMDjJdu7Mf4mPUk9a0sb2G7JNOOCvAxTsdB0pgIUAxk1R012TWNThlACZjmTGTnK4OfxFXO+SOlZMlrcvq91qtnl3twtuYcj98mMsAcdQSMD1HvQB0SyK2Sc5rH8Z2X9peHLuKKMyTovmRovUkA8D8Cav2lxFc2qSwMWR+QSuCD6EHoRUrzeXG7nkKCxHsOaAMnwzrtrrenQyRTK12kYFxD0eN+jAj0zkZ6VpOxA6ZHpXBXPg+dYbXWtAuprTU1tw7QjlZiQGIAP3WPTJBB7iuj8J67Fr+nM5wtzFgSr3BI4P6fpQB0ZWOe3aOVN0cilWDdCCMEVz9xNqemanBbRIl9YyoRHvfZMhXkrno3y8jOOnJ9eigOEAPUcVmaw3+l6X03faDjJPI8p80AWtPvoboSCPcHjO143G1kPoRSXDFpAR1rN1WxS6vrCQPNDJl4/MhlMbD5dwzjhvunggjmrVg0pR4Lpla6hIDMuPnBztfHbODx2IPbFAGP4svbkxWWk2LPHdalKYfOTgwxDBkce4Xp7mtfQbO10q1jsrCJYbZOAo657knuT3JrLmthN42s3IP+i2Mjg47uwXj8Aa1QDnjqKAL87Yk+tMnYkqfUU1/mUPQrApknpQAZ5Brynxd4O03Xvijqdxq11qenWzaDDIt3a3LQKkqTyAsSOCygpgHjnp6enF87lA5PHWuanb/hLbo2cLA6FazA3MoPFzIpz5a/7I4yf/rUAeWeEPFPja8k1Hw/I1hcy2w8ozTrcW091A4JiuN6qyJuUfxDr1zmvR/D+sat4etvs9x4KvoY8jfcafcQ3vmH+8wJSQ9/4fpWL8UYl0jx14R162URm5l/sa52HAkjkBaMH/ddQfxr0aCYSQowHzNzjjigDDvPG3gvU4jbeJPscYbhodYs2t8exEygd+o4rPu/DXgq50a6uPDtxJbRiP5o9I1MrEQT/wA8wzRn8V7V2QdGTEhbaRyjdMfSua8U+GvCdzptzfX/AIf0i8dF3kmBY3OTzl1XcOpOaAKc3hvxzpUpvPCviWw1iMcfY9YtFidR6CaEKc8AYZcV3nhG/wBX1LRkn8RaP/Y+o72V7YXCzjAPDB14wfTrXLW3gux0xA2gazrmjBlyqQXhniAPP+rmDqPwArsNAg1C3sAmqajHqMu7KTrbiAlMDG4AkE5zyMDnoKANKiiigAooooA4/wCK/iO28NeDbia604aq95IlhBYEgC5llO1UJPQHnPsK8m8O6R8SPBPhWz0GXwlDrVvZXJurW6sdSTMILBvK2SYJAyw/L6nuPj8wg0vwfeSKGgtPE1jNLk4AXLrk546sK9Mu4jPazRK7I0iFQynBXI6igDg2+JE9vvF94H8YQ7VBylikwP02OfUf5FN/4WrZblUeF/GRY9v7Fl4rovAlw8vh+OCclp7V2t3LHJJX198EV0NAHK6V4yGqDMGgeIIecf6VZGH8fmNdLBK8qKzRNHkdGPIqWigAooooAKKKKACiiigDkPiz4wj8CeAtU10hHnhQJbRt0eZjhB7jJyfYGuF/Zl8K3Fp4buvGOvqZfEXiORrqSZ/vCEnKjHbJy3HYqO1cl4qul+N/xmsvDNi7yeEPDjG41CRfuTyg4I9Dk/IPbeRxX0pFGkMSRxIqRoAqqowFA6ACgB1FFFADZHWONnkYKijJJ6AVk6dA1/djU7kHaMi1jP8ACv8AePuf5VFOf7b1E2ynOnWrfvyDxLKOifQdT71ugYGB0oAqareCw0+e5I3FF+Vf7zdh+JpukWrWliiytvncmSVv7znk/wCH4VDc4vtShgUZitXEsp/28fKv65/AVp0AFZmuXUsccNraNi7un2If7o/ib8BWjLIsUTySHCICzH0ArI0WCS5uptUulZXlGyBG/gizx+J60AaVlax2dskMIwqjr3J7k1zvxE8XQeEND+0FBPqNy32extR1mmIOAfRR1ZuwFX/F3iXTfCmjS6lq8pSJSEjjQbpJpD92NF/iYnt+JwMmvB7iW/1nVLjXNcz/AGhcDakG/K2cOciFe2ehYj7ze2KAIVa5a4lvtTuje6vdAG5umGM46Kg6KgycKPqeSTVC0sW8V6xPZEn+wbNtt6wOPtMuM+SD/dAwWx1zt9aZqM1xqWrR6Bo0qxX8qebcTEZ+yw9C3+8SQFH49BXoGj6baaLpcFjYoIraBMD+ZYnuSckmgA1C8tdG0ma6nxFaWsedqL0AHCqB36ACvItRs9f17xX/AGrLZ3l8sdsUWztIGmNgWYfIdoOWIHzN65XoM1189td+MNc0q5hmMeiy3Ag0sDrczA4kusf3IxkL6thhxX0VomlWei6bDYadCsVvEMADqfUk9yazq01Vg4S2Ymrqx846L8NvFviaWOG6s5ND0t+Jbm6K+dt7iOIEnd7tjHXBr2zxb4h0T4XeAftVziOy0+Bbe0t93zzMq4SNfUnHJ+pNbvibXdP8NaFe6vrE6wWVpGZJHPU46AepJ4A7k182eBPDOtfHDx4PHHjGOSHwlaTE6dYScrMqtwgXP3eBvb+I8dM4zw2FpYaPLTQoxUdg8C+BNd+Nut/8Jl8S2lh8P5P2DTUZo96dtvdY/VurEelb+teGfG/wcuW1D4dyT654ODGSfQ7g+ZJAOc+WcbtvfK8+oPWvoWNFjRUjVVRRhVUYAA7CvHp/DNv4q+JPi7+19R1q1vLF7ZLY2F9Jbj7I8IIXC8HLiXJ6+9dBR1/w0+JPh/4hab5+i3O28jUG5spfllgJ9R3Gf4hxW54t0Cw8S6FcabqqyfZ3w4eJtrxOp3K6HswIBFeI+PPgiliIvEXwwnu9O8U2Tm4G+5aQ3h6sCzk/Meep2tkg9c16D8GviTbePdHlguk+x+JNO/dalYsCpRwSpZR/dJB+h4PbIB5d4at/FtlJL/wjXhVZtNErL9qmCaZDeJt4mNuRujkzgFkAVgOVHUdO+qfEW8srewg8I2GnyzHaNQuNTjuIbde7hEAc+w/PivXLjCznAxiuM1PxpZ2s07wWl5exwFg8luq7QV6gbmBbnjgHvUynGCvJ2E2luct4U8AabL4iudW1+ebXtcs5kxe3LbEjkUdUhTCLj3yfeun8RqJPFXhcHaXE0zc8nhB0/Edau+DYkXQILpTue+JvGcD72/kH8sVQ8Vh08T+E3UHabqRD1/iUCqGdSoPGSKUjBxj8cUL1HPtmkY5J4oAQYZ1HTnFQaLtFo8qqQZ55JTgY6sQP0AqdRhgFyTVbRJ45radYHDrDcyxHHb5icfkRQBUvZ/7J1OOZhIbO8bZIEUt5cmCd+PQjqB6Z9afc6nY3Wn3C2t/aSmSKRVCzKSTtPGPX2o8VRM+jSzxNtms2S7jPJ5jbceBzyNw/GtOS3guFkWeKKeKQYZXQEMPf1oAZYSb7C0bjmJGBHTlRXF28baN8ThCiqtpqcLsoBx82C3Ix2KN3PWus0JNmmpF5YjWCSSBFBBwiSMq/+OgcVyvxGtB/bfhS7icw3JvfsvnJjeobkHHcAr0PHzGgDvIRVCRxca+VUhltIDuA5AeQ8fjtU/8AfVVDqxsFxrRS0xn/AEkHEDY/2j9w+x/M0uhypJDcSwMkqyXUxLoQckOVHI9lA/CgC5fExXunKuSHlcdfuny2/Mdf0qK6vYba5CRwS3N66jMcCBn2AnG4nAA5PU9zis+6muLvxK1vbERR29sPMnzkoXY5Cjpuwg59Ca1rZLTSNPdz+5t0G9mOWJJPU9yST9aAMnS4r5vFd9dah5KD7LGscMbEmNSxO1j0Jyp59+K2WA3sQeM9cVnaNdPdy6lcyRNCz3Hl+WxBYKqjbkDoTnOK0MgHFAFiNcxkda52TxKqXE8dnpWo6hDASs09vGNgYHBVckFiO+Kt+J7uWz8M30tu/lTbfLR/7pZgufwzmrmnWcelWFnaQDEFvEkKfRRj+lAHLXV3feIJjaafbXdjpxU+fd3MTRs3OPLRTg59/wDJ6ewghs7OK3tEEUMY2oo7CnT8ykjnmkRue1AHnXxtdDL4FikKoreIIHMz8KuxWbG7sT0A74rsrC5iubBZYHV4z0kjIYN7gjineLtBtPFXhjUdGvkRobqJo8su7y2wdrj3U4I+leK/DnRLS5jWSCGTQtdsZjp9+2lTGAmeP5SzpzE4bhsFP4jQB7c8vIKncB6mqms7LjQtSiZRk27kjv8AdJ/pWDFea5plwsV/DHq8JAzJaqLe6X13Qk7JOxzGwPohq7r+safp3hS81S5n+z2v2dmV5VaJslDgBWAbd0wuM9sUAb3haWI6Fpn2hGYi3jDZJGMDB/lXYRENGpUEAjgGuG+FXiHQ/EuibtH1GO8ltMJNHtdHhJJI3K4Dc+uMcHrXd0AFFBGetFABRRRQBzHxM8Lx+MvBGq6I7mOSePdBIOqSqQyN/wB9AfhVH4O+K38YeA7C+uwE1ODdaX8WfmjnjO1gR2J4bHowrta8R+J2laj4I8U2/iPwFqH2fVvEN7DaTaNJAJLe+m5JkY5BjwoJZh6e5oA9D8KOIfEWvWuCu6Xzh1w3zMCR/wCOiurrxy28b+MbDXLi1uPhlFJqbjMslhq0B80D+IBgDjkdecHmtZvHXjoxK8Xwt1AliMB9Wtl4755yKAPTaK4PTfE/jS8H7/wDJY8kfvtVgbHvha6fTpNZmfN/b2tsmPuo5ds/yoA1aKKKACiiigAryf8AaM8eP4Q8GHT9L3v4g1rNnZRxffUNw0gA5yMgD/aYV6ndTxWltNcXMixQQoZJHY4CqBkk+2K+cvhRZz/Fr4tal8Q9Zic6JpMv2fRoXXCkqTtbHqoO4/7TD0oA9P8AgZ8Pofh54IgsnAbVbrFxfSeshH3R7KOPzPevQ6KKACszWbmUBLKyI+2XAIDZ/wBWvdz9O3vVy/uksrOW4lyVjXOB1J7AfWqWiWcq772+5vbgAsP+ea9kH0oAtaZZRadZRW0A+RB1PVj3J9zTr+5+yWzS7GkbIVUXqzE4A/M1O7BFLMQFAySe1VNMuZLyA3DIFidiYvUp2J+vWgCW0to7VHWPd87tIxY5JJOanoqK6nS2t5JpWCogySTQBnatKbm8g02LnzPnnI/hjHb8TxVzU7+00nTbi+1CeO2sraMySyyHCoo7mquiW3lQyXtx/wAfN1+8kJ/hHZfoBXivj/xKPHV55Fp8/hiymzGc/Lfzqcbz6xoc4HRjzyAKAM3XNam8Z+J4tcvYZILG1Vo9MtJBzGp6zsOzuMcfwqAOuaz9Z1V7YQ21lCLjU7tvLtLb++3dm9EXqTU19fW2madNd3TFYoxliOSx7KB3JPAHvWn4K0OW28zWdXQf2xeqAUP/AC6w9VhHuOrHufYCgCfwV4Yj8OWc7SzG71S8fzby6YYMj+g9FHYUmpw3Hi7xAPCWnSPBZiMT6zfoeLa3/wCeQPZ5MY9lyaseKNSvLaK307QoBdeINRbybKA9M4+aRvREHJP0Heui8MeB4bFLbw3FeS3dvGz3uv3QYqb65cDCMR0HGdvZQvrQBf8ACdlBrPiy31DTLcW/hzQ7Y2OnALhZG6Myf7IAAz7fWvSKZBFHbwpFAixxIAqoowFA6ACvM/2ifHUngX4c3NxYTiHV71xa2Zxkqx5Z8eyg8+pFAHh37QvxDtfGfxG0vwZHduvhi0voor6SAgmaUvtcg+iAkD3yeeK+ttLsLXS9NtbDT4VgtLaJYYY1GAqqMAflXx34w+FjeH/2cNM1ySFU11bxNRu5So8xY5RsVN3XAzGcepavqr4ba+vijwFoOsqwZ7u0jeXHaQDDj8GDCgDpK8x8e7/D/wATPCniCEulnqhOiai3VOcvbkjsfMLDd6NivTqxfGfh218V+Gb/AEa+ysVzHhZF+9E45R191YAj6UAWh1+lfPPxij/4VT8TNG+I+iW5NpqDtZ6tbodqykjOfYsFLf70ee5rqPAmseM7b4jQ6b4+tja/a9Ma3tGjuFeG6mt5MvMqD7hdHB55+X04Gn+0XoI1/wCEWuRqm6ayVb6Lr8pjOWP/AHwX/OgD0S4ljureK5t3DRToHRhyCCMg15Rbwm3iWFwA8eUcf7QOD+ua3vgVqza18GvDU8v+ttojZvnt5TFBn8FH51Bf6PJqPjXVYoL17O3W3hkIVA+XbOWGenAH+FcOPwssTBKD1RlVg5rQt/DmSWKxvNPbm3s5dsB/uow3BPoM4HtUXxEc276BfYyLe/XI25ODzx/3zXR6NpsGlWggty75O55JMFpG7scDH5ACs7xhpY1q2s7B7h4I5J97Mq5zsRiAR6ZA7iuumpRglJ3ZotFqdBgBiAaYSCcg/WuV03X5tKmOl+KjFbzxpuguw2Y7lB3xjhhxx/k60erRXSE6fDcXZzjcsZRR35Z8D8s9asZNrJf7FsVyvnyxwFgcEK7hWx74zSvGmkz+dDGEsXVI5VQYEO3hXx/dxgH0wDVW9kunspItQsJIIyNwmtpBMYypBVivBOCM4APStLRb1dQ0yK4LxSsQUcxkFCykq2PbIPFAE91CtxbSRbsLKhTcOeCMZqDQbwXGnoJc/aIcRTKV2lXA54/UexqjOsWiXImiEqafMdsqDLJA3USdflU/dIHGSp9ao+KtZttGMF/aK13fzjy1trf5zcqOccZ5Gcg/hQBraaskWoajbeUwgLi4il3A7/MzuGOowyn8CKw/HV3Zx6l4cWe4RJEvw/3wNoC/xeg56msu9tNQkt7fU/EerJbW1xcQo9taDyEWFicK8vEjfe55AGTx3rYj8MeEcDy9O0tzF+83EhmwOcsc5I475FADvEOuaLcaNqES6tpzsYTkLcIx456Z56dKntIYdLMUumSI+l3tx9xPmVHkydyEHgFuq9BnjFUpm0R7KWWbQkWyIz5psIwjjpnHUZ9SBWfL4RuJ7iK80trXQ5kYTLBArMruAdokXITqc5C596AOst7RIL2+mREX7TIjkqMFsIFyffg0lxm/1FY2VTbWTK7L/flxkfgoIP1I9KyNL8UR3Sm1nh8vW0JjayXLZYd89kz3PSt/TbX7JZbHYyzMS8r/AN9z1P8ASgCizrb+IoV3bTfQuWXnlo9uDn/dY/XFasqgBT1HTNc5rUl1N4k0+007YtzFG8kkzrkQI2B06FiAeD61oSWF6gDQ6tK8mfm8+FGQ/QLtI/A0AV/GTD/hHZUP3TNDu4zkeYtbUsnzFQeM1yWvJql9JpumTi2SOa8WR7iFz80cR3ldhGQTgDqa6ZwTg475NADm5FCnDDvmmhweKcoyeM0ASRuVPArxLxPoM1h8a530rVLvSv7a0w3r+SVeMzxyKhLxuCGBUjGMEHuOa9d/tnTxIyC4yytsYiNiob0LAYry3xprumTfGDRJ0u1NvZ6NcP5kSNJ5jNOsewhQeAVJ9MigDr5J9fsLNW1OxsNatUTfJcWj/ZZQmMlvKkJU456Sj6V42HTxdqVxr93I6xSgvaRytu8iHqiqCeCRgsR1JPtXsmpXNt4i0aTRtNu1lW+jME1xEd6wRkfOWI6Ng4C9TmvAPDdvqlzex+D9Oi3eIoGaykhIO2IxnaZXPaPADZ75AGSa8zM41ZwjCmr3ev8AXYipdrQ9X/Z0tll8UeJb+PiOCGGzLY4dyWcjPcgbP++q98rznw38OpfCWiW0PhzUGXUUXdcTSj5buVuXdxzyT09AAPeuhtPFAhcW2uW8lldDgnaWRvcEdq7cPS9jSjT7FRVlY6WioILu2uF3QTxSL6o4NOnuoLdC888USju7hR+tbDJaKwbvxZpVu21ZmnY9PJQsD+PSqv8AwlVwzFotC1BocZDleSPXFAHUV5nfA6v+0Hp1tM5NvoeiPexR9R508hiJP0Rf1rq7HxOlzqVvZPp1/DJNnDPGNqkDJzzkD3xXlfjXXpPDPxn8ST2tvdTXVx4USSLykLBGSWQbj7Dj9aAO18O6xpmp/FDW7exvbae5tIyk0aOCyEbFOR7Hg+/HavQK+PtDhk0ePw7rOmSudWgliEZViGl3MoZG9Q+cHPrnrX2COlc2GxKxEXJK1nYmMrhRRRXSUFFFFABRRWR4u1+z8LeGtR1vUm22tlC0rDPLEdFHuTgD3NAHjv7R+u6lruoaT8MvC3z6prBEt6wJAitwScMfQ7WJ5zhcY+YV6/4N8O2fhPwvpuh6agW2soVjBxgu38Tn3Y5J+teZfs96Dd6gNU+IviOIrrXiKRngRv8Alha5GxRnnnA/4CF9TXs9ABRRVTVbxbCxknI3MMBE/vMeAPzoAz7kHU9bjhH/AB62LCSQ/wB6T+Efh1rbqnpNobSyVJCGncmSVvVzyauUAV760S9hEUrOItwLKpxvH90+1WAAAABgDoKKKACsPVA2pazb6eo/0eAC4uD2PPyr+ma3K8s8f+KLnw4smi6RPHJ4o1UtcPNjcljB90SEdyMbVB6tk9AaAMv4s+K5dcvLnwjokjJYRny9ZvUPYjP2WM/3mH3z/CDjqcVyUzRwRbF2RQQpgAcKigfoAKSxtYtO06K1iaR9uSzO255HPLOx7sSSSfU1kW9ovjLVpdPj3nQ7Nx9tnVuLmQc+Qp9O7EemO9AFzwtpR8RavDr94rf2Van/AIlsLjHnP3uGHp2QH69xXYeItZttB0ma+ugzhcLHEgy80h4WNR3ZjgCr0skNpatJIyQ28KZZjwqKB+gAqP4Y+HpvFmr2fjXWVaPTbcudFsWH3gcj7U/uw+6OwOe9AG/8KPBV1pUlx4l8TBW8TalGEeNTlLKDOVgT6dWPc16JFFHECIkRAzFiFGMk8k/Wn0UAFfK2sXC/Gv8AaLtdLgcSeGfDYMkhBys2xxvP/AnKp/urkV7D+0B42XwR8N9QuYX26leqbOzAfawkcEFx/ujLfUD1rlP2UfAz+HvBr6/fxeXqGsqrIhXDJApOzPqWzuJ9NtAHrHjfQo/E3hDWNElIVb61eAHAO1iPlPPocGvE/wBjnWpf+Eb13wtfttvNJvCwiY8qrcMPTh1b/vqvoevli2H/AArf9rV41Ux6b4jO1QwwCZznjjHEy4/GgD6nooooA4D4yabeSaBZ69pEPnal4eul1KOILlpo1BWaMe7Rs34gVpaLqul+NvCn2rSrlLnT9Qt2jyp5XcuCrDswzyD0rrHYKjM5AUDJJ4AFfJHjrXfC2na1e618PV8RxypeRXjxWhEemXUsUgLEp94ggMMgbcnNTKcY/E7AdJ+yFqgt/Dfi3w7duPN0y8Nz68Mu1seoBi/Wusj1bU5NbvNXtnt44bpEVbeSIklFztLNnOSD6cZ71418K9dt7T9oLWn0Ere6d4hilEQVsbTMBMqt6FSGUj2NeszyHR3ks9WxazWw2ln4V1HRlPcGuPH1K1OClR+fUyquSV4no2k6hHqdmk0QKnkOh6xsOoP59e9LrJEVvDcs21baZZmP+zyGP5En8KwfAkb/AGO6vmysF26vCD3ULjd+P8sV08ieYDuGVI2kdMiuum5SgnJWZotVqc945jJ0qPUrZN9zpkoukxjJQffAP0Gf+A10NtNHNGkkb7o5FDI2OqkZB/Ksuxxtl0y6Ad4UCjd/y2iIwG/Lg+9ZFjBr+ggWtlb2+raapxDun8maIHnaxbggdARz/SxnbIowOpxWTJE2mXs9xDGzWVx88yRKWaOX++FHJBHUDnIzzk1myTeKbmPFtb6bprZBBmlM59+gApvh3xJJcyarY64kVrqGlYNw6k+XJGRnzFyOBj/PagDTOsQeUZoYr2ZACSyWzgADqeQM/hmuW0tobgHxrIdivIduBtAss7dxHdv4s9cCneOZ7i60yCB5bmJ9Rcx29rAWSRxjozAjls9DwBnOSK0BFdXD2eh3tilpYm3Ysbe7J8xEUJs4UEcsp49PrQA/Rbi1e9S41GG4h1W6dxB9qRguzJKrET8o+XkjhuuRxR4u0yO/sbeyt7WM3TXEc8RGI1j8tgzMxAzj+E9Sd1QzaFaWT20esW8erQyTIiXF0d00R4C5DE7gOOVwR1IPJqm3iHTdGN/cPPNfWWkSvYubOJ7qVC+xwjBQSNmxgSf9nnPFAFq6/tPxFeT6W5k0q3SANdlAkjSF3YKsbHoMITux3x1HFtReXd2NHuDIFt0WW4uApX7TGchVB6AkqdwHTHH3hWXoer6F4jt18Q6dr7I1w5gjkhmxsVCSImiOQSAxYgjI3npxSWNhDf6VJqVrf3FzqskgF/JA+DPGGIaIxg4HyZC8Ajr1NAD9d0Vf7Rtm8Jw2VnrsDCV2X5QYQCCrgddxwBn3PatDTdbn1yJ4bS2uLFo28u7lkIBhcfeROpY9OcY565pPM8OhQLc2ULoSVNv8kyE9SMDfn1/WsXRtRstM8X3UMutPcw39qs/mXZRHjdDja3C9QcjIzQB2kEKWlusFrGqRL2HU+5Pc+9WlJKbvbH41l3eqwJiO2eO8u2+5BBIrMx9T/dHqT6Gsu9l1NbqMaxPBb6O6bW+ybtwkPaRzyFI4yAOR24oAs32o2sOuW8EiTyTw20krCG3kk2qxVQflU9Sre/HSpW1/Sosme8SA/wB2cGIj8GAqawgtLe3AsEiW34wYzkHHHXvx3NUyF1mVN5J02GTO08rcMOn1QH8yKAJ5tZ02NmY31ucdkkDHr2AyT+FMmnutQRoLWF4rOT5XuZSY3KnqETGenc4q7GqRjEaIgXoFUDFSlscsTgn0oAmtxHbwJFDiOCJcKucBVA/QV5H4DlHifxf4l8XF5HguJ/sGmyZ+U2sXGR7M+4/hXR/Ga+vLH4b6vLYTLAZBHbzz4JMMEjrHI4HqFY/zqXwbp8GnaZDp1igitbNVjjGQxUAdyOM9T+OaAOmdiiRB1JRgF6Vz3gsFL3WdYinZ5L+8dUYdooj5aKM844P4mulv5hFpl3NyWihaQYHOQpIwPwqn4X0qK18P6aJFLqYEdhuIIZhuPf1Y9aAOr0u/+1qVdSsg5Iq1c28NzEY7iJJYz1V1BFVNKtbeFS8G/ceDvPIrQoAwpPCejO5b7JtJxna7Ace2aZD4O0OLpZBj/tOx/rXQUUAV7KxtbKPZZ28MCekaBf5VYoooAp6zqdpo2k3epalMsFlaRNNNIeQqqMk+/wBK+cPGnjzT9U+I3gzxJFpup6bpN9a3GmT3mqWxht54Jk/dneCRtDEnnHr05r1P9oxS/wAGPEgBAAjiJB7gSpkfjXbLpenXugwafdWFtNp5hRPs0sQePaAMDaeMCgDwD4R+CNWuPGNmuuxWsdjou2cNBcrOtzIAPLZSOic7+eeBX0jXkNt8MNGF9qDeAdZ1rwpdwSlZEs5t9s7+phfII4xxjpWza6f8TtIhCLrXh3xAqIQDeWslnKx7ElCy+3QVnSowox5YKyEklsei0V58/ifx5ZyFb3wDDdRhcmXTtYjfJ9AsiIatWXjq6lmSK88IeI7RjjcTbq6rn3VuelaDO3oqhpmpC/j3i0urfnGJ49hq/QAV4Z8SXX4l/FjSvh9ExbQ9JxqetFTw5A/dwkj/AHhkf7Xqte51w/ww8AQ+CRrlxJdtfalq99Jd3Fwy4OCxKIO/APfuTQB2sEUcEMcMKLHFGoVEQYCgcAAdhT6KKACsG53aj4phgAzbWCedJ6GVvuj8AM/jWzdTpbW0s8pxHGpdj7AVl+FLeWLTGuLkYuLyRrmQEcjd0H4ACgDZooooAKKKyPFuv2vhjw/d6teh3jgX5Io+XmkJwkajuzMQAPegCj458W2vhbT0Zx5+o3JKWlop+aVsdT6IOpbt9SAfDLfzlku7y9uGutUvJPMubhhgu2MDA/hUDgKOAPxqb7JfXOrXWueISsmtXyjzApyltH1WBP8AZXue5yaxr++mttcGl2LQSX+qW5NlFM+0Rzxk8k9lZWb6tGgHU0AR6jPdaxqsfh7SWYTy4a+uI8f6Lb9+ezsOFH416PpOnWmkadb2GnQJBaQLsjjXoB/U+p71n+HNHtfDOiGN5VMn+uu7uTgyyn7zsfc9B2GBVbxLPqWqaja+FfC8qpreoDdLN1+xWoOHmPv0CjuT7UAS2GkTfELxcdKADeEtLkB1WQN/x9Tj5lth7D5Wf64r3qKNIYkjiRUjQBVVRgKB0AHpWV4T8Paf4V8P2ej6RF5dpbLtGeWdurOx7sTkk+9a9ABRRXlf7RHxC/4QXwRJHYSD+3dSDQWaD7yDHzy/8BB49yKAPJPF3m/Gr9oe20ODMvhrw+xW5OfkZUYeacj++wCD2Ga+rY0SKNI41CIgCqqjAAHQCvK/2cPAS+Cfh/bS3UZGsaqq3d4WHzLkZSM5/ug8+5avVqACvnv9r7Q3Gg6F4usX8q+0a7C+aAchW+ZT+DquP96voSsDx/4fTxV4K1rRHxm9tXiQnor4yjfgwB/CgCfwfrcXiTwrpOswYEd9bRz4BztLKCV/A5H4VsV4B+yH4kkuPCuqeE9RLrqOh3LDY/URsx4/Bw4/EV7/AEAZPi6wn1XwprWn2bhLm7spoImJwA7xsoOfqRXyZYTxadbPpl1amG7t0ETwyDa8RUYwR/Xv1FfYd7dQWVnPdXcqQ20CNLLI5wqKoySfYAV84+NviXL4o1Ozm0/w7aXOi2NwLiI3jlZbsAEYI2kIhznByemcV5uZUKVaC9rPlsZ1EmtTwnTLldA+MOg6jZAx2x1CCXK8I3zhZCp6Y+8Prmvu/wATJp32GX+1mgW2ZSpabGASMcHsfpXyP+07r+n+Jbfwfq+hwSw+TasJ4zHtW2YyELGSONwaKYYHGFz3r3rV9TbXtC8I62wPkX1gsq85CSMisR9cZ/I11OXsKF173KvvKb5Y3KngnxfDsj0eWKW6mtwY4JrUBlmROvBOQVGOOSRziu9t7uC6hEtu6yR5wSDyD6Edj7GvKNWsZJrqyuLAFdRjmUxMnDE9QPxIA/E16JZzR6taQX9q4huSmC687T3Rx/EAf/rUYXELEU+dKwoT51cbriytJbNZS+TfM+yNmXchXqwYZHGB9R2pxub6wKPfrBPbFiGmtwymIdmZSTx6kdOvSprW1k+0/aL2dJZlBRFjUqkanrgE5JOBkmr20HtkY6EfpXQWKrcjoR2PauZ8VeGpNQvoNU0mWG21WDCkypujnUHIV/oeQef0GNG0mj06ePT7hnUM221kYEh1xnYW/vDB4PUDvVq/aYtDb2jrHJLkmQjOxBjJA7kkgD60AcpoWpa3e+Ore016ztbd7e0eUNDIGDnjGOTj7x/KtfxXc2cep6etzZXGoOscjPBbKWkiQlf3vBGBlcdcnPAOKztdsmsNX0K+GpXqqs7WrSSMj7fMQ7Sfl5G5QDn14xWvCZtP1W4m1KSMi78tUuETYqlcgRtycdSQScHcRQBxHjiLRtR1Hw5odnYS/ZtS1ILPeKSEmjjR5JIg27cxYIFJxjBPPNenhjGuyJRGo7IMV5p49sdTnjs9U8MR3c48PXn21IDKrJc4+WSGMY3f6t3A5xxgA9nR/GvwRJAnm6hew3TEbrR9Pn82MkfdICEZ7cEigBdTtIvDPxc8P6hpscdrb+II7iyv1RQqSSxp5kUhx/GfmBPcV1XimG4t7WTUNKyuoSbYCqKMzgnAHP8AEOdp7Z54rzaTXIfFHxB0vxBf6Xcx+DtJEtlBNeQ4aS9kX73kH5ioUAZI4znjt6DJoQtrG31CztcX1rI1ytoZtsRBLHy8cqGVWwGA4I9KANawe2ktLeWxAEQQIhAwyjup75BHI9awddspr7xdpz2M8MN5bwszvNH5iMmeY2XI656jkU7R0ttcuptT+zzxQyRxZjMroBPgl/lBHzAFRu70eG4VPiXXLqJ7hraIpZxiWRnUMoBYqW5xnHegDZjlvLclIdItQScEw3Cqv/oIP6d6ivdS1Wys5bltF+0hVJaO3uw0mMEngqAfwOfatMHoT1p43hl4zz0oAxLDSrW4WW+nVXkvVVmWKR1i2Y+VdoIB4PJI579q1EVUCogVFUABVGAB2AHaqWhHOj256MNwYc8Hccj8OlXxyc5GKADkHjPWpAckZ/OowCCfzqSMevT1oAz/ABPpcer+GdW0xwCl5aSwHIzgshAP4E5ryj4U2GmeJPC+jajeWjJfSWuyS6ti1vOXiPl58yMqx4Qd8V6t4u1JNG8K6rqU0gjitbaSZm9AFPT3JwB7mvPvgbpN3pPgbR4L6Iwz+SZWjJGRvdmGcd8Mv8jQB0Gt6N4itrGe3s7mXXdJuYWhmsbtliulUjBaG4ACscc4lGT/AHq3/BvifR9Wt3tbVpEls/3FxZXClLm2I4w6dce4yD2Jq34huJbTREkjkKZkjBKthsZ6A+p4qPxf4P0/xL5LyJJHe22Tb3lrJ5Vzbt6o47eqnIPcUAdhbpCEBg27T3HNS1578P38X6drM+keKrRb60EZa11u3AjWbGPlmizlH56j5Tg4r0KgAooooAKKKKAOR+Lmiy+Ifhp4j0y2VnuJrNzEq9WdfmUD6lRT/hX4ih8U/D7Q9VgkLtJbIk2eqyqNrg++4GurrwK0l17wh8WvFlr8PdIj1rQSsN9qenCUQm2uZAcrASdu5lAcgjpxxxQB6l4XyvibXkJU/vckA9MnI/Q11deQWPxO8JaT4nvZPEy6x4b1e5Cq8GqW7rEBgDKsm5CMr97PNejaN4q0DWwTo+t6bfYGSLe5RyB7gGgDZooBBAIII9qKACiiigAooooAKKKKAMjXAbya10xWwJ282b/rkhGR+JKj8TWuOBgVGIIxcm42DzigQt/sgk4/WpKACiiigArM1jQ7PWLrTpr4O4sJjcRR5+QybSoZh3K7iR6HnsK06KAPFPiS0OhWuo3qxvcWtrjEcSktJIzbVjXjqWIH5+lcxpHg65j0a9m1R/J8R6hsnMwGTZupDxIntGwB9yCa+jkgij3bI0Xc25sLjJ9frXmPjO7tbLU7u5mkWG1hjMkrscKgHUmgDjPEOtQXfw81K7nMNrc3GnXY8hj9y5iikZ4l91aJsH0APevTfhf4H/4ROzurzU51vfEepMJb+7C4Ge0Seka9AO/X2Hk2kabJMdU1bXNNig0/xDaXv9hM6kvBKbYKXZegaeJCwHXEWOrHP0B4bnF14d0u4GMS2sUgwcjlAetAGjRRRQAjEKpLEADkk9q+W9Ls1+N/7QFxrJXzfCXhvZFGxPyzlWJUD13PuY/7IA716B+0v4yudH8MW/hjw+Wl8R+IX+yQxRcusTcMw9M/dH1JHSuw+EHga3+Hvgez0WJllucme7mAx5kzAbiPYABR7AUAdrRRRQAUUUUAfNeoQJ8NP2pbS/8AMWPSfFaGNhtICySHB56H94qHP/TSvpSvFP2s/Dsmr/DL+07NCbzRblbsOvDLH918H2yrf8BrvvhR4nXxh8PdE1rerzz26rcYPSZflce3zAn6EUAVPjdDcT/CnxIlqHZvs26RU6mIMDIP++A1fO9vqEcGlMsewq4zvzxj1+mK+v2UMpVgCDwQe9fMHx08MeGrHVrLw94f0z7DNIpvbuWGV9oVmIWNUJKjJ3HpwFHrXlZphY1oqpKXKo7mdSN9TkNJ0Y+Jfgl4pnG4tNezXtqQvVYtpA/Ha/4mvTfht4nl1f8AZohuxafbJtEH2eeNW/eLFCQS6f7axEEA9cYPWuX+HV5NoeoW/he8Pm6bdCRYRJyySHLlcjqrDf15B74OAfs/SyeGLj4peFGba1rDJdW+77xVVdd35GM/jXdh6kKtNOGxcWmtD1DwbYJrVrb6wl2kttE4eIRpjzDjgk5OMZ6eorTwdH8QONuLLUzuBA/1c46/gwrg/C1kvgXRfCniJbq7h0bVLlrTVLV5ibaMylhFcBTwhDKikjAw1eo6xp6X1tNaTAbz80bHoGHQ/wCfWtKdKFJcsFZAoqOiJ1Y5I9KkRhgADr1FYnh+6llshDdALdWuIZBv3E44BPA5/wA961lIz8vNWMbqUEV1AYZAVGQyuOqMOQw9way4pbqy1CWfWjAInURwXCNhFHUhgcbSxwc8jtxWxJnHfNNYB1KsAVPBDDII96AM6+htvEOkXlrAyyDokhQ7BIOQQejYOOQax4NXsvEnh+OweVJrudhb3VvGcllV8Pk9gQM59+ua39XlWOw8sSBPtDLbBs7QNxwcfhmszVtJm0+U3/huaGzZVHn2ki4t7hFXABA+4wAGGHXGDQBD4g03+zdDmGmTx2emq8TS2uzCbA67whH3AVzng98Yqxd695mv6elvb3SWqkyXVzLA0agMGSMfNg/ePXGAKwp/EulTzmLxVBNYAxCD7DdxkrJI2dxXA54AAbPc9Oa3IIWs9BZrxpbu6u4li2yAOWyMJHxjIAPJ+pzQBHrE1vdatDp9jqgil1NHSdYSHDKq8uGGdsmBgeoHtU13q0dtZHStUlia8eWK05womSRlXzMf7rHI9RVK2jvtMstEi1U6VbpBMiyTWzFA7bGQcMB1yMnNUdU12S9h8QafoFu+p3rj9wYW/doxiXLmTBAwwGB3IoA0PGN8/hqK51LToVnmucKbMHaSygkyJ1GQuMgjkKOQcA6eg2CWGlW8SsWZl8yRyMF3bkk/57VU8P6dK5j1LVb7+0r949qkII4oVP3lVPUnqSMnpwKbYaxYW13fWW+ZLa2kAjmZHaM7l3FVfGDg57/yoA39pqTBBGDzWNba6NQXOjWlxdryPPdDDEp+rAE/gKnFjLcxMNWnWZWz+4hBSIDPf+JvxOPagDNj1WK1vriGwtrjULWRvM3WKeYIpCcOp5Ax/F19avnXLWBlW+jubPe4VTcxFUJJx94ZUde5FXoVSKNY41WNFGFRF2qB7AU90WSJ45UV43GGRxlSPQjvQAu35iTxUvHfOKy40uNNYokb3OngFk2cyQj+7j+JfTHI6c1La6pYXUyQQ3Ufnt0ib5X4z/CcHsfyoA8z+J0194o8a23g5jFa6JaRQ6teljukv0EmFiVeyBh8xP17AH0LQrfdEeqhm/75GO3tXn/jCX7R8ctJjttjNaaLKbrHLAPINin0O7BHfrXqGlJ5UQGMZGMmgCrq2qaffXy+HZ7o6dqTurwrcxELcqpyfLOQG+incMciuwaMrkgA9+K5XxXa2moeHruHU7G3vYFXzTHKpOcEcjBBVh2YHIrA/trVvh/Ikmpy3Os+DXUOLraZLrTFPTzMcyxAfx8uMc560AekWt0ZZGR0ZSOQcVaqno+qWOtadBqGk3cF5ZTjdHNC4ZWH1FXKACiiigAooooAK8r+DmyDxh8TrWRdt6Nd85wepieNTGfXHDVJ8dNR1Saz0Lwn4dumtNU8R3v2Zp4zh4bZFLTOpzwQMfgT3rNn+GGpeCLtdb+Fl2TfGMJqGn6nO0qamBnDGRjlJOTgjA+gzkA7HTraO/8AG2t/aY1mgWNY2jkAZDnb2PH8J/Omav8ACzwNq5Y3vhbS9zdXhhELH/gSYNc78KfG2m6jrGsWOrbtG8Sy3OX0q+bZMM8/ITw4yzYK9gDgZr1agDzO1+CvhWxbOmTa5Y9sW+qzAY4wMFj0xxXSw+ERBFHHFrmubE/vXe4k+pJFdPRQBR0zTzYxbGu7q5Pdp33Gr1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFee+Nfh+3i3xZpsuo3Ef/CNQDz7qyXIa7mU/u1ft5Y5JHc/p6FRQBz3jzw//AMJH4VvNOgcQXgUS2c3TyZ0O6NvoGAz6gkd6rfCu6+1fDrw7uws8FlFa3EeMGOeJRHKhHYq6MPwrqq42x3eHviDc2RGNM19Td2/YR3kagSp/wNAsgHqkp70AdlWd4j1mz8PaFf6tqcgis7OFppGJ7AZwPc9AO5IrRr5k+Muu3nxV+JFn8MfDbSLptpcB9WuUxjKkb/wTJGO74HYUAXf2edM1Hx1441n4o+JIjslZrbSo5CGEa5wSvoFUbM45JfvX0dVDQdJs9B0Wy0rTIhFZ2cSwxIOygY59z1J9av0AFFFFABRRRQBX1Czh1CwubK6QPb3EbRSKejKwwR+Rr5y/ZmuLvwX4/wDFvw21QviGVry0LLjdjALD/eQxsPoa+la+b/jfcp4K/aA8CeLirLbXcZs7nYduQCUJPrhZVP8AwGgD6Qrw39oDw7cQalbeK7WNpLVYBb3u0Z8oKSySH/Z+ZgT2+X3r3KquqpbyaZdpelRatC4lLdAm05z+Gayr0Y16bpy2Ymrqx8gaPqUM/izSbws8lrazebPNGpdYhsYDcR0yxHHXrWh8T500TxdpHizR7iF7fU7eTSL1lcbSJEIUkj2JPP8AcFZPhTU5pPhZ4msLOWRUi1BI0kK7WNvKyAHHOMjJ7/erD8TeE7I+EpJbWOKJ0jLptHOQM4PrnGOfWuGE6WXKFB3d+pCtDQ+0NJ0W3Pg2z0bUbeKe2NmlvPC4DK42AMD696808Hwv4L8V6h4GvLieazkB1DQpJ5Gc/Z8YktwT/wA8yMgZ5DZrU/Zx8cL41+G9kbiXfqumgWd2CfmJUfI5/wB5cHPqDV/40aFfXuhWevaBEsmveHp/t9qneZAMSw5HOHTPHcgV6ZoRayg0y+i1WNdsLsI7th/CpwN59uBn35rbiYSIrKwKsAQy8gg9DmqehalZ+I/D9lqlkVezv4BKqnkYYcqfcHIPuDWZZaJfaXug0rVfKs95Zbe5t/O8oH+FW3A49AaAOgI9M1SuTJdTNaW8jxKgzPIn3hnogPYkc57fjVE2Guo+8a5buQCRG1iFVj9Q2QKf4evXmuNShu1Ed8ku+RR0wQAuPUYXrQBaXSLEy+ZLC9wwG0C5dpFX6KeM++KY2kphI0uJRYo4k+zHkZHIG4nIXPO2tIfdbB5HNJ0HJzQBn63YLf20RaKOea3fzY4pQCjnBBUg8cgkZ7VzA0XRLsv9lt/ENmBKTJHbSSosb45HBIzzjiu3IPB4+lZVzOtprIy0hS5g3FEQtl1YAEYHUgn/AL5oAybPwtp09+t5e2MtwIkKxHUpDM7MeN2DkKMcDPPNdbENkYSIBUXoqjAH4VmLd3skxWDTWWP/AJ6XEoT/AMdGTRNbX93Hsa7jtULfN9nQlmXPQM3TjHOKAK32D7bq91IZGGnfLuiX5VnmwQxJHOANvfBP051LudrOyzEFDblRF6AlmAA4+tZhsm02eIaOoQTyESRSszRrheZB6HgZxjJPPPNXbexlM8c9/ci5liJKIieXGh5525OTg4yT9MUAN1WGZd91pSp9vRT8jcLcD+4xHf0PY+1S2V5FfwCW3Y4ztZWGGRu6sOoIqyRzxVC6gljuvtlkpaYLskhL7RMvr6Bh2PfoaANBQR1PHenKuAB0zUFlcRXUfmRbxg7XV12sh9GB6GrAxn8aAFXJ5HBrn/HPiyDwnpSXEsT3V/dOLawsUPz3Mx+6g9B3J6AfUZ6VVBGeleF3bzeOPiLrWr6feeTbaJjTNLnMYlQTKQ08mw9c/cyMHBGCCAaAL/g7wpr+nS3F2us2banqMwub83FmZAZcZKI4cEoo+UenPrXpGk6jfpexaVrtrbwXMoLW9xbyfu7jHJAVvmVupxz0PtXP+EddDaw2ka3CLDWFBZYi4Md0mfvwscbh6rgMvcd66D4h6LPr/hC9j0iRo9WgjaawkSXyyk4U7fm7Zz3oA5vxj8Q9F09L7SrZ7rUb6JTFMLOMOIW4zudmC7h6Akg9QK9C8C69p3ifwvZX2my+dEF8mQOm145F4ZGU9CD/AEPIr5msfD/jHRfD5C+E5bdVARmuLqAcnjJO4tyc845/Gvof4R+Ff+ER8FWtnNKk97cO15dyx52NLJyduedoGFHTgZ71y0Klacn7SNl07kpt7nSaLo2m6HavbaPY29jbvI0zRQRhFLsclsDuav0UV1FBRRRQAUUUUAeX+JXU/tCeDI5WGF0m+aIEfxkoDj3wDXf+Iro2eiXs6vsdYyFb0Y8D9TXlv7RT3Wjr4R8S6AofxNZ6qtpZQlNwuRMrB4m5HBC9e3tnNRQ/FbTfFemXnh+8EWjeLEna0k0+5myjyr1WOYfIcngcg+3TIB2kfgvRPEXgvTtP8S6fHqKiBSHuOZVyMgh/vKfoRXMv4F8ZeD903w+8TvfWa4xo2vMZo9vpHN95fYdPU16pZxmG0giIAKIqkA5HA9amoA8+074gX9oRD418L6lokw4NxDi7tW9xInIz6EV1Wn+JNH1BFe01CBwem5tp/I4rXPPWs+40XTJ23S2NuWJznywD+YoAvqysoKkEHuDmlqO3gjt4xHCu1BwB6VJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3jvRZ9a0B105lj1ezkW90+Rui3EfKg/7Lco3+y7V0NZPivxBp/hbw9fazrE3k2NpGXdupPYKB3JJAA9TQB5p8WPi1HovwztNT8OgtrOrwM1pEwBa3CrmV3U948EEH+Lj1qf8AZ3+Hy+EvC39sakkreI9aUXN5JM5Z0ViWWM+/OWPdifQV5N8IbSy+JvxEi1/xJpZs7Rb+6vtJj2/urkgozxE9yjsJeOGZ5fQgfWdABRRRQAUUUA5oAKKKKACvnv8AbP08yeBtE1VAu+x1ELkk5w6H8OqLX0JXlH7UVg9/8Fdd8tSzW5huMeyyLn9CaAPTtNmNzptrORgyxI5HpkA1wn7QWsSaJ8I/EE8JYSzRLaqV7eYwQn8mNdD8Nb19S+Hfhi9lOZLjTLaRz/tGJSf1rz39rMuPg/cFc7ftsG7HpuP9cUAed6no0GleL7Kzc+TpHiLTRpzMD/q7iJR5bD3xjHuK47UprzSjPpWp28zXsJMW1Ym2znsyHGCrcH2zz0r2TU9Ni8XeCYYJW8prq2inhlXkxSbQyMPocU/w/er4j8MSWupcXsYNpfRjgxzqMMR7E/MD6EVy4nB08Tbn6Eyipbnn3g+Cf4JeL/D2pXU0n9ha5Cllq4LArBdYyH+gOTn0319aAhgCOQa+fdes7TWvD83hrxYpjWRQkN7j5GYfdcHs/qD7+tT/AAJ8bXmh6k/w68cXJGqWxH9lXUrfLdQfwoG7kY4z1HHVeeoon8SW9x8IvEo1O3LyfD/VbjF3By39lXDn/Wp3ETHqo6du1ehi4tpLWO8iuYHtZFDJOsgKMD0IboRXWXdtBeWsttdwxz28qlJIpFDK6kYIIPBBrxH4k/ArwvH4a1DUfCOhRQ63bEXcMXmO8c2whmi8tmK4YAjGO9AHpAUkZP4Vh3BSz8WWr7Qv26Foi3YsgyB9cYqXwnrll4m8NafqumlFtbmJXWJSP3JAwYzjoVOV/CrOs6XHqlmImcpNGwlilGcxuOh4Iz9KAL2DnGeaTkHiufTVNW01Aus2DXESjm6sVL5ORyU69/QfQ0XPiVlkiWPStQjikOPtV1EYoUOcAOeSM/THuKANq6uFt4TIxzyFRR1Zj0H8qh061aEPNcMHvpQPNcdB/sr6KOlSQWxjZpZmEtyw5fsg/ur6D9TU68Hp1oADwTnGPalXHQD8aReTgc/U1QL/ANqgBSRpwPzN/wA/BB6D/Y46/wAXbigCpaarZX3iCdI5yfJiEMe5SquxJLlSeG6KK2z8owMcUSRpLEYpkR4WG0xso249MVkXU91pbxWsMRuI7h9lvPNKMRMf4Xzyw6kY5PT0oA1S8caPLM6oi8lmOABVT+2bEFf3khUnhvIkK/ntqxaWBSRZrud7udRtBdQqrznKqOAenPJ96vFSpJz8x70Ac5I1/eXUmoaXbqqxqiL5q+W14ATuXnooGNrEZznt12bO5guLBbsNshKl23kDZj7wb0I7+mKssQAWbA9STXjvxB1mbxDr154E8MvGsd5sl1q8RsfZoTxJGOOZHGO/fnHJAA3X/iTfeNY5dF+GsN2okyk+uTxeXBbx5IJj3cs55xjnnI55HQ+B/DFtoWkWdhaqwgtVAGQFaRupdv8AeJJx/QVseH9KhENvZ2kYhtbdRGkajhVA4UewFdXeWem6bZG7vbqCyhTky3EoRCfck4oAwNS0Oy1yxFpqlr5qrIJYyrFXjcfddHHzI49Qc1z8/iDVfAsqL4pmOoeHncRx6sseJbfPRblV429hKuBx8wBOa6jQNf03XDPN4fvotQggIDzwKWjBORw2MHoeh/nW9bSRXkmydArn7ki/xexoAhW0ste0aQ21wstvcxZSSKQOjdwysOozU/g69+16HDG5/f2v+jyg9QV45/DFReGvB2ieGru/uNFsltHvpFlnSJiIy4BG5UztXOTnAGadquiypdtqWiyCC/6vGf8AVz+zf4//AK6AN+isHTvEkElwLPVI207UP+eUp+Vv91+h/n7VvUAFFFFABRRVXVbsWGl3l4wyLeF5SP8AdUn+lAHifxe8WWl94x0W3tbO8udP8KapDe6zfwx74rTcjBQQOSRncSPugd+leS6Folnf6Dd6df7ZZYXdHyc72DE7wf8AayGBHZga+j/gVpgtPhlpl1cBXvdYDanduefMknJc5/AgfhXmXxP+Emo+Hbu71/4d2a3NnLmW60hW2sh7tD6jvs6jnGcgDix2HlXp+5undEzV1oV/g+PiI3haW68NeJY9WfTL2WzuNH1hQVdFwU8ub7ykqwwCcZ+len6R8VrBJ2tPGum3vhG+U7c6mALaVsciOcfI36VR/Zx020tvAkmpW+o29/datcG7uTBnbA+1VEJB5DKAAcgHP4V6fd20F5byW95DFPBINrxyoGVh6EHg11w5uVc25SG2N7a39us9jcwXMLdJIZA6nv1FWK88vvg94QlvTe6XZ3Gh3xOfP0m4e2P/AHyp2/pWrp/h/wAQaVCkVr4llvYkAAW/hV2IHq45P1qgOuoqK3MxjX7QEEmOdh4zUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzx8eLHxF8QfiboPgDT0ksdGSP8AtG4vGj3K+MgtjoQuQoH95+e1fQ9GBnOOfWgDidc8JppngawsvCtsiXmgbLnTE6bnjBDIT/00QyIT/wBNCa6jQtUttb0ax1OxYtbXkKzR7hggMM4I7EdCOxrj9d+J2maP8SdM8IT207y3nlo94pHlQSyBzFE3fc/lnH1HvUujeIvCmgzXmj6fqmbuTUrhRYSB98c7AzSKqBdyx8l92Co3HnGBQB3NFeT3PxgWG0edNJguVXw1L4hDwXrFH2SiPylLRA4Oc7yB6be9dQvxF8PRXOm2mo3Utpe3wgCI1tM0QklUMkfnbPL3HI4LA+1AHYUVxw+Jvg4zzwjXIDJbzfZ5v3b4jk8wR7WO3A+cgc+uenNdBo2tadrX206XcrcCyuXs5yqkBJkxuTJHJGe2RQBo0Vxlt8T/AAjcRX0g1R4lsrb7ZMLizngIg3BfMUOgLLkgZXI5FU7T4s+F77xdp+gafczXUl9E0kVzFC5i3BwoXOO5PX7vHJ6UAd/XLfFPT21X4beJ7JAC82nThQRn5ghI/UVTi+KfgyUXjJrcfl2sLXLyNBKqPErBWeNiuJFDHGULU9/iH4PvbO7Ua3btCLKa6dijhTAh2uwJGGwT0GSe1AGJ+zZqQ1P4L+HHy26CN7ZsnP3HZR+GAK2PjNoTeI/hh4h02GMSztbGWJT3dCHX9VxXnv7H14H+H2qab5gb7DqUgUYwQjqrDI69d1d58c9Rl0z4UeIpreTy5ZYBbB/TzXWM/o5oA85+E2qLq/w80WdTloofs7/WP5f5AUzxJC/hzWG8U2SNJbOqxarbqfvRDgTAf3kHX1X6VW8H6fbeDvEU/hy1Vo9PvYVvbPcSR5iqEmTJ74CP+JrunjWaNkdVZGBVlYZDA9QaAIWW2v7QbhHcWkyhhn5ldSMg1xnjH4ep4gsVgtLhra5tf3unXW4+ZayAghd3UoTz6qRkVc0RZvCuoxaNMHl0G4bbp83LNbOefIc/3eu1j9D2rtrf5HoA5z4SfGF7/WE8F+O4Dp/iu3/crMxHlXjDoR6Mw5A6N264r22vEPiB8NNK8d2rSzL9l1qNcWt9ESGRhyN2PvDP4jtiuR8E/FPxL8Mtd/4Rb4vC4msOFtdV2mQqO2WAzImO/LDvnsAd5q/gbxF4O1vUNZ+HX2e/0+/lNxeeH7uTyl8wn5pIJOiE+hGPrwBS0L4mi78Rafoet+Gtb0C+vHkhRr6MCEyoudiPxvJ7EDuPWvYNE1fT9c02HUNHvIL2ymGUmhcMrfj6+1YPxM8HQeM/DUlnvFvqVu4udPu+9vcpyj9OmeCPTNACjpgEcGmth1ZHUFWBVgRkEdxXl8XxH1PwgpsPijot7p93GQBqllAZrO4H94FeVPtg/QdK9A0DXdN8RaVHqWg3kN7ZOxUSxZxuHUEEAg+xHegBUtrm0wlrJFLaqMJFNuDJ7BxnI9Mj8aVJNTeQ/wCj2UQ6bjM0mfoAo/nV49fSlBHH86AMybTrm6Ux3moyeS+N8VvGIwRjlS3LYPPcda01RVVERQqKoVVHQAcAUEjGc4/GkSRWY4G72UZoAfsYt0GKZdm2aCSC7AeJlO8HjA65z29c1yfi34i6J4dl+xea19rD/LFpliPPuZG9No+59W/WsCLwx4s8cObnxhfy6Jo8uf8AiQ6dJ+8kX0nnHPPGVXj6HNAG1B8RvCtmZIbnxfo1wIyBGfOQOBj+JgxDnpyAPejU/ix4M0+z+0SeI9PdMZAhlEzn2CJk/nVqDwHoke1LXQNLWJcKoWwjOAOmTjk/XmtXTfAGk210s8Oj6fbSjpLDZxxsv4gZoA85Hivxh42jdfDmnHw9pUoYLqmpJunkXsYoB06ggsSPxFbHhn4eyafo9pBosuL6Cf7TLqFwvz3btkSGTHLZBPBPHHPevULbQraA+bKPu5JZz0H41498SPj/AKPodydE8DQf27rcknkiSIFoY3JxgY5kbPQDj3oA9D8Z+KNB+Gnh032qMS5Oy3toyDNdOf4VH8z2/KvNvBvga9+Lt7a+OfiPMx01n36XoMTgwxxA8GQ9yT1HBOOePlHN+H/C/iFfF0GteOtSFx4vurdZtKnu1D21pKGJ8lkHy5IGPl+7uJGWwa6fTtcvdO1x/wDhHpLXQfEsrM954Y1J9trqUh/5a20nQMx6MnDfxAEEkA98tLaCztore0hjgt4lCRxRKFVFHQADgCka1gMokMS7wc7gMGs3wlq91rmhW99f6Td6RdsWWWzusb42UkHBHBU4yD3GDWxQAUUUUAUtU0uz1SDyr2FZF7Ejlfoa5zSri78PazHo99J9osrgk2s56p/stz64H4/l2FYXi/SzqOmB4QftVs3mxEdfcfl/IUAbtFcxJ4y0nTvC39s61dpaW8WI5SwJJk/uqo5YnsAM1l+Cvil4e8X63LpOmi/gvFjM0a3ds0ImQEAlM9cbhwcGk5JOwHd1geONf03w54enu9XWSaGUi2jtol3yXMj/ACrEi92bpit+vNvHEH2v4wfD2G7ANlEt9cxq3RrhY12/iFLEfSmB2/hnTodI8O6Zp1rHLFBa20cMcczBnRVUAKxHBI6VpVjeLvD8PibRZNOuLu+s8usiXFlOYpY3U5VgR6HsciqHhu51vTrmPRvEYe+fB+zarBDhJ1A6TAZ8uT/x1u2D8oAMHXfAd1peu3Pif4f3Cafq8x33unyf8empEc4cf8s3POJB3PIOTWl4K+IFn4gvpNI1K0n0TxNAu6fS7z7+P78bdJE/2l/IV2lYPi7wjovi2zS31uzExiO6GdGMc0Df3kkXDKfofrQBvUV5YkfjrwDMAjT+NPDYPRsLqVsv14Ew/Jq7Twt4u0fxNAW0y6/fodstrMpjnhYdVZDyCPyoA36KKKACiiigAooooAKKKKACjNFFABRRRQAUUUUAFFFFAHkniD4KWeuT65f3Ou6kmt6hqCX8N3G7KlsYyBEvk7tjlFDKGbn5j0rUPw0lbxzN4tk15zq84a2lAtVELWZQKIQuchgRu8zOc8YxxXo9FAHksHwZt4tJSxGtSkL4bl8O7/s4+68ok83G7qMY2/rUWq/BSLUfEFrqcmuyMLeWzmRJrNJXj+zhRsjkJzGjbclR3OeelYfxl+IPiXw94xnttAu7i3jso7SQ200CGK7Ekm1vL/dMz4BwT5kYXHGTwZZfFnjRfEL3i6sf7Mi8ar4fOnmwjw9q+z5zJjdkbuCPTnNAHV6v8PTbfCvxb4dtN2qXGqSXd3Ah2w4mlcugyTgbX2nPt0re+HfhRvDXw9sNCnnk+2eQzXdyj/O1xJlpHDdzuY4J9BXjvgnXdY8S/FTwHe+IL6eXVY/7XW6002YhTSztCrEGCgtkKDlmY8Dpnnsvif4m8YaL43stE0NiYPEEUMOn3H2ZXFlOs6idm45XyWLc9xxQBnWPwDgt7fVI5NfMj3+kvpLSrYIjkNKknmyMGzI/yYJbrntjFd5qngk3fizQ9ct9Te3k0+zewmhMIdbmBipZc5BQ/L1GeteZXHjjxmfiTf6bd3dvaWUWpSWiaZcW5/0i02kJKmISzMeG3eZs6ggdaztC8ReL5fDmj2Oi6imiRQ+D5tYZYNNiZTPHMVCBSuFBB6Afh3oA6WD4CWVtpF9pdvrCLZzW0lrDI2mxG4jRyD80owXxj/ZzxnNa3xc+Hc3jK58F20ERNvY3W2/ufNCf6JtHmRlc5beUQdwMc13XgfUbnWPBXh/U79Qt5e6fb3M4VdoDvGrNgduSeK26APnn4EyjRfjn8T/DzMF8+5a+ijA4C+Yx/wDQZVrtv2lYHm+D2sugJMElvOceizITn2xmuB8WN/wiX7W+gaivy22v2y28mV+87AxgA/7yRH8a9o+JulNrfw88R6cg/eXFhMqcfxbSV/UCgDyrxpp9xq2gQX2lDGq2Lpf2WeMuoyUPsykrj3rZ0HVrXXdHtNSsWBhuIw2O6N/Ep9wcg/Ssr4camNX8D6Ndh9zG3VHP+0o2n9RWJcQzeBvEVzqMCvJ4Z1OXfdov/LjMTzMB/cbv6HmgD0AHFXLYLKyoD83bNUYnSREdGDxsAVZTkEeoNR3l6LBY5sAAyxx8nGN7hR/OgD0DR9OMSBpgCOwp/iTw/pXiXSZtN1yxhvLOUYZJFzj3B6g+45q/Zgi2jDHJ2ipqAPlXxL8EfG3gHV21b4R6vdS2pO82RnCSr7ENhJF+vPsetWfDv7S+paLetpfxK8Nz213EdkktqhjcH/aic/qG/CvqEc+1ZuuaDpOvWpttb02zv4CMbLiFXA+mRx9RQByvhX4t+BvFTrDpfiC0+0PkC3ucwSE+gDgZ/DNYvif4UtLrE3iD4f67J4b1e5+a5WOMS2l0fV4umfce5xnmuY8YfsweE9WdpdAu7zRJWOfLX9/CPorEN/49XGwfBr4s+BpHbwN4pjuLZSWWJLhot/A6xOCmfxNAHVeLLf4t6Dp8L6jq2kNpjSst5qem6eZprSPHEjRHAKjJztBIAzzVux+HLajZW91e+PvE+oSOiulzZX6xROP7yhVII+pNc23jX9oDR4VivfCVvfGJfmlW2Ehf3/dPjP0FOX4+a/otoLXX/hZdW7IWwI98MeScthWiPrnqetAHTP8ACzfvFt448a27sNvzajvx/wCOjtipIvhJb3pMGt+LfFuswj79vLqBSJ/UFVGccetccv7UWmRbRJ4FnSZh937Uvrjg+Xk96WP9qdQwSw8CTsCCyhb3BOASxwIu2PyzQB7b4a8GaX4dtRb6Bo9rp8LfeMSBWf8A3mOWb8Sa6aLTUHMp3H0A4r5xj/aA8fasIm0D4bzvHOA8LlJ5lZT33BVBHTnpVJPFvx18W3l3ZWcWnaFJaMIrldscboWAIYhy74wchlGDzjJFAH1BfXtlpVlJc39zBaWkQy8szhEUe5PArxH4kftI+GvDxS38MFdevlkXzPLJWAJznEndunQEVws3wF8T+I7mO58ceOJLtsAskfmXBHspcqB+Ar0Lwh8HvB/hCWK5tNPN9fKPludQYSlW9VXAQH3xketAHkJHxM+O7NcXd2mk+F2lMflqxSHKnkBAd0rDPVuM9xXsfw2+Fvh7wKizafFJc6oyFJL645kIPUKOiA+g5x1Jq3rmg6rbaw+veEJ4BqMwAvdOucrb35HAbI5jlA4DjOQADXpejWLRxJNdLicrymchD3weM/XA+goA5vWPCz+IdMa2djbgESQzdSjjocd/QjjgmneG7Kw1C3TSfEthaXOq6fIsoFzGJMkYxKm4cdun9a7esLxH4fXVZIbq2na11G35inT+R9uf/wBdAG7RXLWviaWxuBZeI7ZrWYAAXKDMMvuD2rpopEmiWSJ1eNhlWU5BHsaAH0UUUAFFFFAHzN8YdMit/i5bIAy2k1mZ1jLkospkIdwCeCQVFanwXsEu/itdXVvGDa6dpzgt12ySugX8dsclRfFvS/EHi34gpdeE9KGpwafA1jNidI9jsysGJYjIyuOMkde9eo/CLwW/gvw08F7Ks+rXkxubyVfulyAAq/7KgAD6Z74rzvq0pYz2z2S0/Ijl9653Nct481DxDo9pDqfh/TrfVoLYlruxOVndOMtC2cbgN3ykfNng54PU0V6JZjeE/Euk+LNFh1XQbtLm0k4yOGRh1VlPKsPQ1s15p4n8DX+j61P4q+HEkNnq8g3X2mOMW2qAc4YdEk64cdzz1Jro/APjKz8YaZLLFBNY6lav5N9p1yNs1rKP4WHcHqG6EfiAAZ/hbw7q3hLxBc21lcyal4a1GeW6IuZczafK3zEKSfnjY546qT3BJHcUVheNNZvtA0N9R03RbnWnidfNtrZwsgj/AInUH7xH90cmgDdrJ1nw7pesENfWiNMvKzp8si/RhzUHhLxZoni3TlvNBv4rlOjx52yRN3V0PKkehFbtAFDS7GexTymvJbmEDC+cMuPq3er9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHz3+1fC2lXXgXxbEv/IL1RVkYE9MrIv4fu2/OvoCNo7iBXUh4pFyD1DAivNf2k9IOr/BvX1Rcy2iJeJxnHlsGb/x3dWt8ENYXXPhP4YvFcOws0gkIz9+P5GHPutAHm/hXRj4L8S674TklDQiT+0rE4xmCXggf7rKR/wDrrqpoo54XimRZIpFKujDIYHggirfxo0G7mtdN8T6LAZtU0SQu8SDLXFq3EsY9Tj5h7r71n6ZfW+padb3tlIJbW4jWWNx3UjIoAw9A8Mazoep+T4dIv9Ak5OnzzbZLUk9Ynbqv+wT9DW7qeieIbkz2a6IQ0M1vPDOLlGimVZkYjnkEBTwRj0JrR0a/+xa7pyyBjFcyGD5R91ipZSfb5SPqwr0kHIBHQ0AIoCgAdBS0UUAFFFFABRRRQAUUUUAcv418DaJ4vt4RqcDxXtsS1rfWrmK4tm/vI49+xyD6V5r4kbU9At47H4lWy6hokbj7N4isYypgYcK8yr80L/8ATRPl7YHNe5UEAggjIPY0AfOdtDqfhALqWgXceqeHJyZmEcgEEinPzEICsT/9NEHlH+NUPzVvS6x4d8RaaupzXN/pOo2CoEuIo2+1W4kOExtDLNGxzgfOjY9endXHw/sYPEcGs+H5jpEzShr23hTNveJ33R5AV/SRcHrnNdXZWMFkhS1jEadlHAH0FAHBeE/+Esi1f+yfEOmwz2wj82PWbVgsU4BAw8R+aOQg5wMg84wK7QaTFvyzuR/d6VpUUARQW0MAAijVf51LRRQAUUUUAQ3drBeQNDdQpLE3VXGRXLnQr/QGkm8NSmW2Y73sZ2yuf9gnp9K66igDmbHxfaGRLfV0fTbw9UmBC/g2P510kciSxq8Tq6MMhlOQRUd5aQXkDQ3UKTRN1VxkVyl74J0qASXFrdXOnAHezJKQBj/9XrQB2Ncn4v1qc3MegaI//E2ulyXAyII84LH0P+fSuRu9LbU5HstK1bUtS353O7sI1+vzc/oPrXeeEPDlv4d01YIz5lwQBLMRy2P6UAWvDmi22g6XHZ2m5sfM8jHLSN3J/wA8CtSiigAooooAK4Hx14JnutWj8VeEZksPF1sgQOxPk30Q58iZehB7N1HHoMd9RQByvw78ZWvjLR5J0iaz1O0kNtqFhIf3lpOvDIfUZBwe4/EV1Ved/EPwlf8A9sW3jPweWTxLYR7JLUMFj1O3By0D/wC112t2P4EdZ4S8Q2fijQ7fU7DeqyDbJDIpWSGQfejcHowPH/1qAPKfjB8J7m41mLxp8P5X03xJbMZLmO1+Q3i9yO3mYzweG6Gu1+HXiXUtY0a2nvvLvYWXaLyFfLfcOCssX8DjuBxnpxXc1zNxor6Vrr6zosaj7UwGoW44Eo/56D/bH60AdMORRQCCAR0NFABRRRQAUUUUABOKKKKACiiigAooooAKKKKACiiigAooooAKKDRQAUUUUAFFFFABRRRQBQ8QabHrOhajpk5IivbaS2cjsrqVP868S/Y/vZ4vB2teH71WSfS799qspB2PkZ5/20kH4V75Xz18PV/4Rf8Aan8ZaKoMVnq9r9tiQH5WfKvn/wAemoA+hSMjB5FeM694av8AwPq1xeaPbS33hS9mMstrCuZNNkY/M6KOWiJJJUcr2GK9moIyKAPHNTiOpabImmzI14vl3NvtYZ3owdD7AlRz6GvX7dt0EbbduVBx6VWGlWIu2uvskH2llCGXYNxUHIGfTJP51dAAAAHFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZeo6wLe5FpZ2s17eHrHFgLGOxdjwv8/agDUJCgknAHc1hXfiazSUwWCS6jdD/AJZ2y7sfVugFNXRrrUgW8QXIkjPIs7clYl9i3DP+OB7U/WrqHw/o4Wwt40lciKCJFABY9OKAMe51rXrzUk06xtre0uGG+TefMMK+rEcfQdT7da0ovC8cjJJqt/d38wO7532Jn2UdKu+HdKGmWbGU77ydvNuJTyWY9s+grVoAjt4IraJY4I1jjUYCqMCpKKKACiiigAooooAKKKKACuR1S2HhnWZNcs0/0C7ZU1CFRgK2eJ/qOh9c5rrqbIiyIySKGRhgqRkEelACoyuishDKRkEHIIpaq6ZZpp9otrCWMMfEYY52r2X6CrVACKABxS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfPXx3kbwt8bPhz4uwqWrOdPuZfRSxByP92Vj+FfQteIfte6TLf/Chb2BSX0y/iumwuTtIZD9OXU/hQB7fRWX4V1Iaz4Y0jU1GBeWkVxjOcbkDf1rUoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAr3SzS/uoW8pT96Qdcei+/vTrW2itYRHAgRM59yfUnufepqKAEZgqlmICgZJPauX0rOva42qSIPsFrmK1z/ABNnl/px/nFSavdyazeSaLprlUHF5cL/AMs1/uD/AGj+ldBa28drbRQQKFijUKoHYCgCUUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQMgdc0AFFFFABRRRQAVl+KdHt/EHhzU9IvIxJBe27wMpOPvAjr25rUooA8j/Ze1O4vPhZFp9+xN5o13Np0gPVdpDKPwDAfhXrleO+AVXwx8ePG/h8r5cGswxa3aKPuk8rL+Jcn8q9ioAKKKCMgg9KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKx9Tuby5ufsGlFUcf8fF0RkQg9gO7nrjsOT1GdikAA6DFAFXS9OttMtRBaR7VyWZics7HqzHuTVuiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKD0460UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABGQRQAAABwKKKAOY1PwjFeeP9G8VR3bwXFhbTWkkSoCLmN8EBj2Ctkgc8+ldPRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lymphatic drainage of the breast flows toward the axillary and internal mammary lymph nodes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, Second Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8744=[""].join("\n");
var outline_f8_34_8744=null;
var title_f8_34_8745="Open globe injuries: Emergent evaluation and initial management";
var content_f8_34_8745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Open globe injuries: Emergent evaluation and initial management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Christopher M Andreoli, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Matthew F Gardiner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8745/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/34/8745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A traumatic breakdown in the integrity of the wall of the eye (sclera or cornea) is known as an open globe injury. Prompt recognition of open globe injuries and referral to an ophthalmologist are essential to maximize visual restoration and outcome.",
"   </p>",
"   <p>",
"    The approach to the patient with an open globe injury is summarized in a rapid overview (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open globe injuries are described by mechanism and then by anatomic site [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Open globe rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open globe rupture occurs following blunt eye injury, typically at the site of greatest structural weakness near the equator and directly behind the insertion of the rectus muscles. (",
"    <a class=\"graphic graphic_figure graphicRef79392 \" href=\"UTD.htm?14/41/14994\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Open globe laceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open globe laceration refers to a penetrating injury to the eye by a sharp object or projectile and is further subclassified as penetrating (entry wound but no exit wound) or perforating (entry and exit wounds) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/1\">",
"     1",
"    </a>",
"    ]. Open globe laceration may also be complicated by an intraocular foreign body (IOFB) (",
"    <a class=\"graphic graphic_picture graphicRef82383 \" href=\"UTD.htm?8/10/8354\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80118 \" href=\"UTD.htm?13/27/13745\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Zone of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic region that is lacerated or ruptured provides additional information that is important for injury prognosis (",
"    <a class=\"graphic graphic_figure graphicRef66823 \" href=\"UTD.htm?39/61/40913\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zone 1 injury involves the cornea and limbus (junction of the cornea and sclera).",
"     </li>",
"     <li>",
"      Zone 2 injury refers to a rupture or laceration located in the anterior 5 mm of the sclera that does not extend into the retina based on operative evaluation.",
"     </li>",
"     <li>",
"      Zone 3 injury describes a full-thickness scleral laceration or rupture found more posterior than 5 mm from the limbus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of open globe injuries worldwide is estimated at 3.5 eye injuries per 100,000 population, accounting for 203,000 cases annually [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/3\">",
"     3",
"    </a>",
"    ]. Overall, males comprise approximately 80 percent of open globe injuries with an estimated incidence six times higher than females [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Males age 10 to 30 years are at greatest risk. The chance of blunt globe rupture also increases after ocular surgery such as large incision cataract removal, corneal transplant, glaucoma filtering procedures, or LASIK (laser-assisted in situ keratomileusis) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observational studies identify the following patterns of globe injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/4-7,12-16\">",
"     4-7,12-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injuries in young children tend to involve laceration of the eye with sharp objects such as scissors, knives, thorns, or writing instruments [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/6,12,17\">",
"       6,12,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Teenage boys often suffer penetrating eye injury from air powered pellet (BB) guns or blunt injury during ball sports, motor vehicle collisions, or fights [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/5,7\">",
"       5,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Young men frequently sustain penetrating or perforating eye lacerations at work, especially in construction settings that involve hammering on metal or stone [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/18\">",
"       18",
"      </a>",
"      ]. Safety glasses would prevent many of these injuries. Blunt facial trauma during motor vehicle collisions and assaults are also prominent etiologies in this group. Illicit drug use and alcohol consumption commonly contribute to the circumstances of the eye injury [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/7,19\">",
"       7,19",
"      </a>",
"      ]. Gunshot wounds to the eye and orbit are less common but typically cause severe globe injuries with poor visual outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Globe rupture is more common than globe laceration in elderly patients. The usual mechanism involves a fall with subsequent open globe injury at the site of prior eye surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/4,21\">",
"       4,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intraocular foreign bodies (IOFBs) occur in 18 to 41 percent of open globe injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The majority of IOFBs are small projectiles resulting from hammering on metal or stone, machine tool use, firing of weapons, explosions, motor vehicle accidents, and lawn mower accidents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. Up to 90 percent of IOFBs are metallic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/15,22\">",
"     15,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p>",
"    The eye is composed of three layers (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      the external fibrous layer (cornea and sclera)",
"     </li>",
"     <li>",
"      the middle vascular layer (chorioid, ciliary body, and iris)",
"     </li>",
"     <li>",
"      the internal layer (retina)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The junction of the cornea and sclera is known as the limbus.",
"   </p>",
"   <p>",
"    The lens demarcates the anterior structures (iris, anterior chamber, and cornea) from the posterior structures (vitreous, retina, choroid, and optic nerve).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Blunt injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The orbital bones provide rigid structural support and protection for the eye. High impact blunt trauma can overwhelm bony protection resulting in orbital fractures as well as open globe rupture. The site of rupture commonly occurs where the sclera is thinnest and weakest: near the equator directly behind the insertion of the rectus muscles (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/23\">",
"     23",
"    </a>",
"    ]. Other potential regions prone to rupture include the limbus, insertion of the optic nerve, and sites of prior eye surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Penetrating injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open globe lacerations involve the cornea in the majority of patients. Scleral or limbic lacerations account for about one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/15\">",
"     15",
"    </a>",
"    ]. IOFBs are present in many globe lacerations and are most commonly found in the vitreous cavity followed, in decreasing prevalence, by the anterior chamber, retina, lens, or subretinal space (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Extrusion of ocular contents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any increase in intraocular pressure risks further extrusion of ocular contents after an open globe injury. Avoidance of this risk involves measures to prevent external pressure on the injured eye (eg, placement of shield, quiet environment, no manipulation of the eye, except by an ophthalmologist) and to avert Valsalva secondary to vomiting or crying (eg, antiemetic therapy, sedation, and pain control).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endophthalmitis (internal eye infection) rates have been estimated between 2 to 7 percent for all open globe injures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/14,24\">",
"     14,24",
"    </a>",
"    ]. This rate is as high as 13 percent in patients with open globe lacerations complicated by IOFBs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/25\">",
"     25",
"    </a>",
"    ]. A standardized management protocol consisting of a dedicated eye trauma service and 48 hours of intravenous antibiotics was associated with a rate of posttraumatic endophthalmitis of 0.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors associated with infection include open globe laceration, retained IOFB, injury inflicted by organic material (eg, thorn), disruption of the lens, and delay in primary closure beyond 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/14,28-30\">",
"     14,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacillus species and coagulase-negative Staphylococcus accounts for up to 50 percent of endophthalmitis after open globe injury based on intraoperative cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/2,28,31,32\">",
"     2,28,31,32",
"    </a>",
"    ]. However, Streptococcal species, S. aureus, and gram negative organisms are also common. In addition, up to 12 percent of infections have mixed organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with an open globe injury is summarized in a rapid overview (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history consistent with a high risk eye trauma such as a high velocity projectile, high impact blunt trauma, or injury from a sharp object should raise suspicion for open globe injury. Essential components of the history include exact time and mechanism of eye injury and composition of any possible IOFB, if known.",
"   </p>",
"   <p>",
"    History should also include medication allergies, time of last meal, prior ocular surgeries, preoperative functional status of the eye, and tetanus immunization status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a high likelihood of an open globe, the clinician should avoid any examination procedure that might apply pressure to the eyeball, such as eyelid retraction or intraocular pressure measurement by tonometry.",
"   </p>",
"   <p>",
"    In young children, the extent of ocular injury often cannot be assessed due to poor cooperation. In these cases an examination facilitated by procedural sedation or anesthesia should be performed by an ophthalmologist when the mechanism of injury is highly suggestive of an open globe injury.",
"   </p>",
"   <p>",
"    Examination under sedation by the emergency provider after discussion with an ophthalmologist often suffices in situations where the risk of open globe injury is low.",
"   </p>",
"   <p>",
"    In cases of obvious or high likelihood globe rupture, the examiner should avoid placing any medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    ) or diagnostic eye drops (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    ) into the eye.",
"   </p>",
"   <p>",
"    Any protruding foreign bodies should be left in place. Removal should be deferred to the ophthalmologist.",
"   </p>",
"   <p>",
"    Physical findings of globe rupture or laceration include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markedly decreased visual acuity",
"     </li>",
"     <li>",
"      Relative afferent pupillary defect (",
"      <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eccentric or teardrop pupil (",
"      <a class=\"graphic graphic_picture graphicRef67579 \" href=\"UTD.htm?20/19/20787\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased anterior chamber depth",
"     </li>",
"     <li>",
"      Extrusion of vitreous",
"     </li>",
"     <li>",
"      External prolapse of the uvea (iris, ciliary body, or choroid) or other internal ocular structures",
"     </li>",
"     <li>",
"      Tenting of the cornea or sclera at the site of globe puncture",
"     </li>",
"     <li>",
"      Low intraocular pressure (checked by an ophthalmologist only)",
"     </li>",
"     <li>",
"      Seidel sign,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      streaming in a tear drop pattern away from the puncture site (either observed at the time of fluorescein installation by an emergency provider for a presumed corneal abrasion or when specifically performed by an ophthalmologist)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross deformity of the eye with obvious volume loss is clear evidence of globe rupture (",
"    <a class=\"graphic graphic_picture graphicRef59152 \" href=\"UTD.htm?1/46/1775\">",
"     picture 4",
"    </a>",
"    ). Obvious corneal lacerations can be noted by direct illumination with a penlight (",
"    <a class=\"graphic graphic_picture graphicRef82383 \" href=\"UTD.htm?8/10/8354\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The presence of subconjunctival hemorrhage (SCH), particularly with 360 degrees of bullous SCH, can mask a scleral laceration and should raise suspicion for a posterior globe rupture (",
"    <a class=\"graphic graphic_picture graphicRef65379 \" href=\"UTD.htm?15/57/16287\">",
"     picture 5",
"    </a>",
"    ). In addition, intraocular hemorrhage such as hyphema (blood in the anterior chamber) or vitreous hemorrhage can limit the ability to examine the eye completely for evidence of globe rupture (",
"    <a class=\"graphic graphic_picture graphicRef71507 \" href=\"UTD.htm?41/26/42415\">",
"     picture 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases of ocular laceration, intraocular contents can plug or tamponade the wound, hiding the extent or depth of an injury (",
"    <a class=\"graphic graphic_picture graphicRef59152 \" href=\"UTD.htm?1/46/1775\">",
"     picture 4",
"    </a>",
"    ). The presence of uvea (iris, ciliary body, or choroid) prolapsing into or through the wound is diagnostic of an open globe injury (",
"    <a class=\"graphic graphic_picture graphicRef59152 \" href=\"UTD.htm?1/46/1775\">",
"     picture 4",
"    </a>",
"    ). In cases of injury posterior to the limbus, uveal prolapse may appear as a dark black, blue, or brown structure trapped underneath the conjunctiva. This is in contrast to SCH that typically appears bright red. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The iris should be carefully examined before any mydriatic (dilating) drops are placed into the eye. A noncircular, peaked pupil should raise suspicion of rupture (",
"    <a class=\"graphic graphic_picture graphicRef59152 \" href=\"UTD.htm?1/46/1775\">",
"     picture 4",
"    </a>",
"    ). Iris tissue prolapsing through a cornea or scleral wound is pathognomonic for an open globe (",
"    <a class=\"graphic graphic_picture graphicRef82383 \" href=\"UTD.htm?8/10/8354\">",
"     picture 1",
"    </a>",
"    ). If an open globe is apparent or strongly suspected then the clinician should not place dilating drops in the eye.",
"   </p>",
"   <p>",
"    In addition to careful inspection for obvious injuries, visual acuity and evaluation for a relative afferent pupillary defect are the two most important physical examination findings for the clinician to elicit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Visual acuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual acuity should always be checked in each eye separately. Care must be taken to ensure that no pressure is applied to the injured eye while it is covered during vision testing. A standard Snellen acuity chart can be used at a distance of 20 feet. Alternatively, a near card can be used at the distance indicated on the card. Gross visual field deficit may be assessed by direct confrontation.",
"   </p>",
"   <p>",
"    If the vision is not adequate to read from an eye chart, the ability to count fingers, detect hand motions, or the presence of light perception versus no light perception should be noted. One should consider that patients over the age of 40 are likely presbyopic and may require the use of reading glasses in order to adequately assess their near vision. Vision assessment varies by the age and developmental capability of the child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link&amp;anchor=H19#H19\">",
"     \"The pediatric physical examination: HEENT\", section on 'Vision'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Relative afferent pupillary defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relative afferent pupillary defect is assessed using the swinging penlight technique: a bright light source is directed back and forth at each eye. The eye with the afferent defect will paradoxically dilate when exposed to the light because it has previously constricted consensually to the same degree as the unaffected pupil when the normal eye was illuminated (",
"    <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;More subtle or partially self-sealing corneal wounds may require the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dye. This technique is usually reserved for the consulting ophthalmologist. After topical anesthesia drops are placed, a fluorescein dye strip is moistened and applied to the ocular surface. In cases of full-thickness laceration with aqueous flowing from the anterior chamber, a clear stream of fluid parting the yellow fluorescein dye (positive Seidel test) is noted by illumination with a Wood's lamp or blue light from a slit lamp or ophthalmoscope.",
"   </p>",
"   <p>",
"    The ophthalmologist will typically assess color vision using color plates, if available. Alternatively, a red object can be used to test for red desaturation. This finding presents as a graying or washed out perception of red color relative to the normal unaffected eye that indicates optic nerve damage.",
"   </p>",
"   <p>",
"    A full ophthalmic examination including motility, color vision, IOP, anterior segment, and dilated fundus examination should be performed in the uninvolved eye to provide a basis for comparison, to ensure no traumatic damage from the event to the \"good\" eye, and to monitor for preexisting pathology in the fellow eye that may be pertinent to future vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Injury to adjacent structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open globe injuries are commonly associated with traumatic hyphema (anterior chamber bleeding) or orbital fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9783?source=see_link\">",
"     \"Orbital fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PRIMARY EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with an open globe injury is summarized in a rapid overview (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Initial emergency assessment and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard trauma evaluation should be followed to evaluate for life-threatening injuries in multiple trauma patients before attention is focused on the eye.",
"   </p>",
"   <p>",
"    In patients requiring intubation, an open globe is a relative contraindication for the use of \"high\" dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    due to the potential increase in intraocular pressure with risk for extrusion of ocular contents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Doses of ketamine &lt;3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    do not appear to increase intraocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/35\">",
"     35",
"    </a>",
"    ], but emesis is a common adverse reaction to ketamine, thus making other sedatives (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    ) better choices.",
"   </p>",
"   <p>",
"    Safe use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    in 73 patients undergoing open eye surgery has been described in one case series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    can mitigate increased intraocular pressure if rapid sequence induction is absolutely necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the administration of other paralytic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    ) avoids the risk of intraocular hypertension entirely when emergent endotracheal intubation is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H25#H25\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Succinylcholine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If an open globe is strongly suggested by history or gross inspection of the eye, the clinician should make every attempt to avoid sudden intraocular hypertension with extrusion of ocular contents and further wound contamination. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Extrusion of ocular contents'",
"    </a>",
"    above.) Specific measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye shield placement over the affected eye",
"     </li>",
"     <li>",
"      Avoidance of any eye manipulation",
"     </li>",
"     <li>",
"      Bed rest",
"     </li>",
"     <li>",
"      Avoidance of any eye solutions (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"       tetracaine",
"      </a>",
"      , cycloplegics)",
"     </li>",
"     <li>",
"      Antiemetic therapy (eg, IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose: 16 mg)",
"     </li>",
"     <li>",
"      Pain medication",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      (eg, IV morphine, 0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum single dose: 10 mg; or IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mcg/kg).",
"      </span>",
"      Nonsteroidal antiinflammatory agents (NSAIDS) are discouraged because of their platelet inhibiting properties.",
"     </li>",
"     <li>",
"      Sedation, as needed (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.05",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose: 2 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blunt force with an object larger than the orbital rim is often associated with major orbital injury in addition to open globe rupture including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blowout fracture with ocular muscle entrapment",
"     </li>",
"     <li>",
"      Orbital hemorrhage with proptosis",
"     </li>",
"     <li>",
"      Orbital compartment syndrome, a rapid retro-ocular hematoma expansion in the rigid compartment of the bony orbit, leading to elevated orbital pressure with optic nerve or central retinal artery ischemia and permanent vision loss within a very short time period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9783?source=see_link\">",
"       \"Orbital fractures\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ophthalmology consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an open globe require emergent evaluation by an ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial and coronal computed tomography [CT] of the eye without contrast, utilizing 1 to 2 mm cuts through the orbits, is the preferred modality for further assessment of suspected open globe injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/33\">",
"     33",
"    </a>",
"    ]. CT is superior to ultrasound in assessing the location and size of IOFBs and requires no direct contact with the eyelids or globe. CT is faster than magnetic resonance imaging (MRI), has less motion artifact, and will not cause movement of metallic foreign bodies.",
"   </p>",
"   <p>",
"    CT findings of open globe injury include IOFB, intraocular air, eye wall deformity, volume loss of the eye, and irregular scleral contour (",
"    <a class=\"graphic graphic_figure graphicRef79392 \" href=\"UTD.htm?14/41/14994\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Sensitivity and specificity of ocular CT in detecting open-globe injuries varies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 142 CT studies for ocular trauma with 80 confirmed cases of open globe injury found that sensitivity and specificity of ocular CT was 75 percent and 93 percent, respectively, with a positive predictive value of 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study focused on 48 eyes in 46 patients undergoing surgical exploration for occult globe rupture and excluded patients with obvious physical findings [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/40\">",
"       40",
"      </a>",
"      ]. In these patients, ocular CT had a sensitivity of 56 to 68 percent, specificity of 79 to 100 percent, and positive predictive value of 86 to 100 percent for open globe rupture depending on the radiologist performing the reading.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings indicate that ocular CT has limited ability to demonstrate an occult open globe injury and should not be used as the sole determining factor for decisions regarding surgical exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Additional emergency treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a globe rupture is diagnosed, treatment focuses on providing antibiotic and tetanus prophylaxis, and preparing the patient for definitive surgical management. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Definitive management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     NPO (nil per os) status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should receive nothing by mouth (NPO status).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no trials have evaluated the benefit of prophylactic antibiotics in patients with open globe injury, endophthalmitis is clearly associated with poor outcomes. Thus, we suggest that patients with open globe lacerations receive prophylactic antibiotic treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose: 1.5 grams) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg:",
"    </span>",
"    maximum dose 2 grams) to cover organisms commonly associated with posttraumatic endophthalmitis (Bacillus species, coagulase-negative Staphylococcus, Streptococcal species, S. aureus, and gram negative organisms). Patients allergic to penicillin can receive a fluoroquinolone in place of ceftazidime. This initial prophylaxis is typically augmented by topical antibiotics postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/2,28,31,32\">",
"     2,28,31,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Endophthalmitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Tetanus prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus status should be determined in patients with open globe injuries and tetanus prophylaxis should be administered based on the nature of the wound and the time since last immunization (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/24\">",
"     24",
"    </a>",
"    ]. An open globe rupture is typically considered a clean wound. Ocular lacerations, especially those occurring in rural settings or associated with IOFB, are considered tetanus prone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any significant ocular injury resulting in altered vision should prompt urgent ophthalmologic evaluation. When there is suspicion or definite evidence of globe rupture or laceration, immediate ophthalmic consultation is indicated, with prompt transfer to another hospital if ophthalmology consultation is not readily available.",
"   </p>",
"   <p>",
"    Many community based ophthalmologists may prefer transfer of ruptured globe patients to a tertiary trauma center if they are not experienced with surgical globe repair. Transfer should not delay the institution of antibiotics.",
"   </p>",
"   <p>",
"    Rapid primary closure of an open globe injury by an ophthalmologist promotes the best visual outcome for the patient. Many factors determine optimal timing for surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/10\">",
"     10",
"    </a>",
"    ]. In general, closure within 24 hours of injury is ideal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial preservation of vision has been described in up to 75 percent of patients with open globe injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/41\">",
"     41",
"    </a>",
"    ]. The extent of initial injury, mechanism of injury, and initial eye findings at presentation are important predictors of final outcome. Rapid primary closure (ideally within 24 hours of injury) and antibiotic treatment to prevent endophthalmitis are the focus for ophthalmologic intervention.",
"   </p>",
"   <p>",
"    Factors associated with poor visual outcome defined as visual acuity of",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    <span class=\"nowrap\">",
"     (6/60),",
"    </span>",
"    no light perception (unable to see the brightest possible light), or enucleation following open globe injury, include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/2,14,39,40,42-45\">",
"     2,14,39,40,42-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open globe rupture from a blunt mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Initial visual acuity of hand movements or worse (eg, no light perception or gross evisceration) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Relative afferent pupillary defect on initial examination [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/41-44\">",
"       41-44",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Posterior wound location (Zone 3) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Metallic IOFBs caused by BB or pellet injury [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Associated injuries, especially lid laceration, orbital fracture, hyphema, lens damage, vitreous hemorrhage, or retinal detachment [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/41,43,44\">",
"       41,43,44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The degree of injury present on ocular CT, especially moderate to severe scleral deformity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elapsed time between injury and primary closure [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Development of endophthalmitis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/2,14\">",
"       2,14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two scoring systems have been developed to provide prognostic guidance to ophthalmologists and their patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Ocular Trauma Score, derived from analysis of 2500 eye injuries, is a point score based on initial visual acuity and the presence of globe rupture, endophthalmitis, perforating injury, retinal detachment,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      relative afferent pupillary defect. This system has not been prospectively validated [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/3,47,48\">",
"       3,47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A separate model, developed from analysis of 214 patients with open globe injuries, found that variables most predictive of outcome were initial visual acuity, relative afferent pupillary defect, posterior wound location, and associated lid laceration. During prospective validation, the model predicted blindness with a sensitivity of 86 percent and identified patients with vision survival with a specificity of 92 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traumatic cataract is the most common complication that limits vision, and it can occur at any time from one day to years after an injury. In addition, zone 1 injuries may lead to corneal scarring (typically weeks to months after initial injury), and zone 2 or 3 injuries may develop retinal detachment either immediately or weeks to months later due to retinal scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Zone of injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with an open globe injury is summarized in a rapid overview (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open globe rupture occurs following blunt eye injury at the site of greatest structural weakness [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open globe laceration refers to a penetrating injury to the eye by a sharp object or projectile and is further subclassified as penetrating (entry wound but no exit wound) or perforating (entry and exit wounds) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8745/abstract/1\">",
"       1",
"      </a>",
"      ]. Open globe laceration may also be complicated by an intraocular foreign body (IOFB) (",
"      <a class=\"graphic graphic_picture graphicRef80118 \" href=\"UTD.htm?13/27/13745\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history consistent with a high risk eye trauma such as a high velocity projectile, high impact blunt trauma, or injury from a sharp object should raise suspicion for open globe injury. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a high likelihood of an open globe, the clinician should avoid any examination procedure that might apply pressure to the eyeball, such as eyelid retraction or intraocular pressure measurement by tonometry. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases of obvious or high likelihood globe rupture, the examiner should avoid placing any medication (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"       tetracaine",
"      </a>",
"      ) or diagnostic eye drops (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      ) into the eye. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gross deformity of the eye with obvious volume loss is clear evidence of globe rupture. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Inspection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to careful inspection for obvious injuries, visual acuity and evaluation for a relative afferent pupillary defect are the two most important physical examination findings for the clinician to elicit (",
"      <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Visual acuity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Relative afferent pupillary defect'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Evaluation and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard trauma evaluation should be followed to evaluate for life-threatening injuries in multiple trauma patients BEFORE attention is focused on the eye. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H8#H8\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Initial approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If an open globe is strongly suggested by history or gross inspection of the eye, the clinician should make every attempt to avoid sudden intraocular hypertension with extrusion of ocular contents caused by Valsalva (vomiting or crying) and external eye compression. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Initial emergency assessment and treatment'",
"      </a>",
"      above.) Specific measures include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Eye shield placement over the affected eye",
"     </li>",
"     <li>",
"      Avoidance of any eye manipulation",
"     </li>",
"     <li>",
"      Bed rest",
"     </li>",
"     <li>",
"      Antiemetic therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      , intravenously)",
"     </li>",
"     <li>",
"      Sedation and analgesia (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , intravenously)",
"     </li>",
"     <li>",
"      Avoidance of any topical eye solutions (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"       tetracaine",
"      </a>",
"      , cycloplegics)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a known or highly suspected open globe require emergent evaluation by an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Ophthalmology consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Axial and coronal computed tomography [CT] of the eye without contrast, utilizing 1 to 2 mm cuts through the orbits, is the preferred modality for further assessment of suspected open globe injuries. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with open globe lacerations receive prophylactic antibiotic treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose: 1.5 grams) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg:",
"      </span>",
"      maximum dose 2 grams) provide empirical coverage for the most common organisms. Penicillin-allergic patients may receive a fluoroquinolone in place of ceftazidime. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tetanus prophylaxis should be administered based on the nature of the wound and the time since last immunization (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ). An open globe rupture is typically considered a clean wound. Ocular lacerations, especially those occurring in rural settings or associated with IOFB, are considered tetanus prone. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Tetanus prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid primary closure of an open globe injury by an ophthalmologist promotes the best visual outcome for the patient. Many factors determine optimal timing for surgical repair. In general, closure within 24 hours of injury is ideal. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Definitive management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31330445\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/1\">",
"      Kuhn F, Morris R, Witherspoon CD, et al. A standardized classification of ocular trauma. Ophthalmology 1996; 103:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/2\">",
"      Al-Omran AM, Abboud EB, Abu El-Asrar AM. Microbiologic spectrum and visual outcome of posttraumatic endophthalmitis. Retina 2007; 27:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/3\">",
"      Schmidt GW, Broman AT, Hindman HB, Grant MP. Vision survival after open globe injury predicted by classification and regression tree analysis. Ophthalmology 2008; 115:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/4\">",
"      Casson RJ, Walker JC, Newland HS. Four-year review of open eye injuries at the Royal Adelaide Hospital. Clin Experiment Ophthalmol 2002; 30:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/5\">",
"      Koo L, Kapadia MK, Singh RP, et al. Gender differences in etiology and outcome of open globe injuries. J Trauma 2005; 59:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/6\">",
"      Blomdahl S, Norell S. Perforating eye injury in the Stockholm population. An epidemiological study. Acta Ophthalmol (Copenh) 1984; 62:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/7\">",
"      Parver LM, Dannenberg AL, Blacklow B, et al. Characteristics and causes of penetrating eye injuries reported to the National Eye Trauma System Registry, 1985-91. Public Health Rep 1993; 108:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/8\">",
"      Zeiter JH, Shin DH. Traumatic rupture of the globe after glaucoma surgery. Am J Ophthalmol 1990; 109:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/9\">",
"      Lambrou FH, Kozarsky A. Wound dehiscence following cataract surgery. Ophthalmic Surg 1987; 18:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/10\">",
"      Colby K. Management of open globe injuries. Int Ophthalmol Clin 1999; 39:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/11\">",
"      Vinger PF, Mieler WF, Oestreicher JH, Easterbrook M. Ruptured globes following radial and hexagonal keratotomy surgery. Arch Ophthalmol 1996; 114:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/12\">",
"      Rostomian K, Thach AB, Isfahani A, et al. Open globe injuries in children. J AAPOS 1998; 2:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/13\">",
"      De Juan E Jr, Sternberg P Jr, Michels RG. Penetrating ocular injuries. Types of injuries and visual results. Ophthalmology 1983; 90:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/14\">",
"      Thompson WS, Rubsamen PE, Flynn HW Jr, et al. Endophthalmitis after penetrating trauma. Risk factors and visual acuity outcomes. Ophthalmology 1995; 102:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/15\">",
"      Williams DF, Mieler WF, Abrams GW, Lewis H. Results and prognostic factors in penetrating ocular injuries with retained intraocular foreign bodies. Ophthalmology 1988; 95:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/16\">",
"      Khani SC, Mukai S. Posterior segment intraocular foreign bodies. Int Ophthalmol Clin 1995; 35:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/17\">",
"      Lesniak SP, Bauza A, Son JH, et al. Twelve-year review of pediatric traumatic open globe injuries in an urban u.s. Population. J Pediatr Ophthalmol Strabismus 2012; 49:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/18\">",
"      Kanoff JM, Turalba AV, Andreoli MT, Andreoli CM. Characteristics and outcomes of work-related open globe injuries. Am J Ophthalmol 2010; 150:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/19\">",
"      R&uuml;fer F, Peters A, Klettner A, et al. Influence of alcohol consumption on incidence and severity of open-globe eye injuries in adults. Graefes Arch Clin Exp Ophthalmol 2011; 249:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/20\">",
"      Ben Simon GJ, Moisseiev J, Rosen N, Alhalel A. Gunshot wound to the eye and orbit: a descriptive case series and literature review. J Trauma 2011; 71:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/21\">",
"      Andreoli MT, Andreoli CM. Geriatric traumatic open globe injuries. Ophthalmology 2011; 118:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/22\">",
"      Luo Z, Gardiner M. The incidence of intraocular foreign bodies and other intraocular findings in patients with corneal metal foreign bodies. Ophthalmology 2010; 117:2218.",
"     </a>",
"    </li>",
"    <li>",
"     Duke-Elder S, MacFaul PA. Injuries: Part 1 Mechanical Injuries. In: System of Ophthalmology, CV Mosby, St. Louis 1972. Vol 14.",
"    </li>",
"    <li>",
"     Albert D, Jakobiec F. Principles and Practice of Ophthalmology, 2nd, WB Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/25\">",
"      Mieler WF, Ellis MK, Williams DF, Han DP. Retained intraocular foreign bodies and endophthalmitis. Ophthalmology 1990; 97:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/26\">",
"      Andreoli CM, Andreoli MT, Kloek CE, et al. Low rate of endophthalmitis in a large series of open globe injuries. Am J Ophthalmol 2009; 147:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/27\">",
"      Faghihi H, Hajizadeh F, Esfahani MR, et al. Posttraumatic endophthalmitis: report No. 2. Retina 2012; 32:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/28\">",
"      Duch-Samper AM, Chaqu&eacute;s-Alepuz V, Menezo JL, Hurtado-Sarri&oacute; M. Endophthalmitis following open-globe injuries. Curr Opin Ophthalmol 1998; 9:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/29\">",
"      Reynolds DS, Flynn HW Jr. Endophthalmitis after penetrating ocular trauma. Curr Opin Ophthalmol 1997; 8:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/30\">",
"      Zhang Y, Zhang MN, Jiang CH, et al. Endophthalmitis following open globe injury. Br J Ophthalmol 2010; 94:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/31\">",
"      Brinton GS, Topping TM, Hyndiuk RA, et al. Posttraumatic endophthalmitis. Arch Ophthalmol 1984; 102:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/32\">",
"      Affeldt JC, Flynn HW Jr, Forster RK, et al. Microbial endophthalmitis resulting from ocular trauma. Ophthalmology 1987; 94:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/33\">",
"      Harlan JB Jr, Pieramici DJ. Evaluation of patients with ocular trauma. Ophthalmol Clin North Am 2002; 15:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/34\">",
"      Rich AL, Witherspoon CD, Morris RE, Feist RM. Use of nondepolarizing anesthetic agents in penetrating ocular injuries. Anesthesiology 1986; 65:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/35\">",
"      Nagdeve NG, Yaddanapudi S, Pandav SS. The effect of different doses of ketamine on intraocular pressure in anesthetized children. J Pediatr Ophthalmol Strabismus 2006; 43:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/36\">",
"      Vachon CA, Warner DO, Bacon DR. Succinylcholine and the open globe. Tracing the teaching. Anesthesiology 2003; 99:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/37\">",
"      Libonati MM, Leahy JJ, Ellison N. The use of succinylcholine in open eye surgery. Anesthesiology 1985; 62:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/38\">",
"      Mowafi HA, Aldossary N, Ismail SA, Alqahtani J. Effect of dexmedetomidine premedication on the intraocular pressure changes after succinylcholine and intubation. Br J Anaesth 2008; 100:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/39\">",
"      Joseph DP, Pieramici DJ, Beauchamp NJ Jr. Computed tomography in the diagnosis and prognosis of open-globe injuries. Ophthalmology 2000; 107:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/40\">",
"      Arey ML, Mootha VV, Whittemore AR, et al. Computed tomography in the diagnosis of occult open-globe injuries. Ophthalmology 2007; 114:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/41\">",
"      Rahman I, Maino A, Devadason D, Leatherbarrow B. Open globe injuries: factors predictive of poor outcome. Eye (Lond) 2006; 20:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/42\">",
"      Pieramici DJ, Sternberg P Jr, Aaberg TM Sr, et al. A system for classifying mechanical injuries of the eye (globe). The Ocular Trauma Classification Group. Am J Ophthalmol 1997; 123:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/43\">",
"      Cruvinel Isaac DL, Ghanem VC, Nascimento MA, et al. Prognostic factors in open globe injuries. Ophthalmologica 2003; 217:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/44\">",
"      Pieramici DJ, MacCumber MW, Humayun MU, et al. Open-globe injury. Update on types of injuries and visual results. Ophthalmology 1996; 103:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/45\">",
"      Lee CH, Lee L, Kao LY, et al. Prognostic indicators of open globe injuries in children. Am J Emerg Med 2009; 27:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/46\">",
"      Ehlers JP, Kunimoto DY, Ittoop S, et al. Metallic intraocular foreign bodies: characteristics, interventions, and prognostic factors for visual outcome and globe survival. Am J Ophthalmol 2008; 146:427.",
"     </a>",
"    </li>",
"    <li>",
"     Kuhn F, Pieramici DJ.. The OTS: Predicting the Final Vision in the Injured Eye. In: Ocular Trauma, Thieme, New York 2002. p.9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/48\">",
"      Unver YB, Kapran Z, Acar N, Altan T. Ocular trauma score in open-globe injuries. J Trauma 2009; 66:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8745/abstract/49\">",
"      Thakker MM, Ray S. Vision-limiting complications in open-globe injuries. Can J Ophthalmol 2006; 41:86.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6513 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-E03BC582ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8745=[""].join("\n");
var outline_f8_34_8745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Open globe rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Open globe laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Zone of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Blunt injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Extrusion of ocular contents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Visual acuity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Relative afferent pupillary defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Injury to adjacent structures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PRIMARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Initial emergency assessment and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ophthalmology consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Additional emergency treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - NPO (nil per os) status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31330445\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6513|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/41/14994\" title=\"figure 1\">",
"      Zone 2 blunt injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/61/40913\" title=\"figure 2\">",
"      Zones of open globe injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2150\" title=\"figure 3\">",
"      Cross section of the eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/15/42239\" title=\"figure 4\">",
"      Afferent pupillary defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6513|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/10/8354\" title=\"picture 1\">",
"      Corneal lacerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/27/13745\" title=\"picture 2\">",
"      Intraocular foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/19/20787\" title=\"picture 3\">",
"      Open globe laceration with a teardrop pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/46/1775\" title=\"picture 4\">",
"      Peaked pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/57/16287\" title=\"picture 5\">",
"      Scleral rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/26/42415\" title=\"picture 6\">",
"      Hyphema grade IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6513|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/28/16845\" title=\"table 1\">",
"      Open globe rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 2\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9783?source=related_link\">",
"      Orbital fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_34_8746="Surgery in the treatment of exocrine pancreatic cancer and prognosis";
var content_f8_34_8746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Carlos Fernandez-del Castillo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Ramon E Jimenez, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Michael L Steer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/34/8746/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/34/8746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 45,220 people develop exocrine pancreatic cancer each year in the United States, and almost all are expected to die from the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of these tumors (85 percent) are adenocarcinomas arising from the ductal epithelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection is the only potentially curative treatment. Unfortunately, because of the late presentation of the disease, only 15 to 20 percent of patients are candidates for pancreatectomy. The prognosis of pancreatic cancer is poor even in those with potentially resectable disease, and despite progress in surgical techniques and adjuvant therapy, there is little evidence that outcomes are improving over time. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Results'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical management of cancers of the exocrine pancreas will be reviewed here. The clinical manifestations, diagnosis and pathologic features, adjuvant and neoadjuvant approaches are discussed separately, as is the management of tumors arising in the endocrine pancreas (islet cell tumors). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several diagnostic studies are available to determine the tumor stage. Disease that is limited to the pancreas and peripancreatic nodes (stage I-IIB disease, (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/2\">",
"     2",
"    </a>",
"    ]) is most likely to be cured by radical resection. Absolute contraindications for resection include the presence of metastases in the liver, peritoneum, omentum, or any extraabdominal site. &nbsp;Other indications of unresectability include encasement (more than one-half of the vessel circumference) or",
"    <span class=\"nowrap\">",
"     occlusion/thrombus",
"    </span>",
"    of the superior mesenteric vein (SMV) or the SMV-portal vein confluence, and direct involvement of the superior mesenteric artery (SMA), inferior vena cava, aorta, celiac axis, or hepatic artery, as defined by the absence of a fat plane between the low density tumor and these structures on CT scan. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumors with limited involvement of the major peripancreatic vessels such as the superior mesenteric vein, portal vein, or superior mesenteric artery may be technically resectable. The impact on long-term prognosis is controversial. (See",
"    <a class=\"local\" href=\"#H445902151\">",
"     'Vascular evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H436301373\">",
"     'Vascular resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Staging laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently available imaging techniques are highly accurate at predicting unresectable disease, but they fall short in predicting resectable disease, mainly because of limited sensitivity for small-volume metastatic disease. Radiographically occult metastases (&lt;1 cm in diameter) on the surface of the liver or peritoneum which are rarely visible by CT, MRI, or transabdominal US may be visualized laparoscopically.",
"   </p>",
"   <p>",
"    A selective approach to staging laparoscopy maximizes yield by limiting the procedure to those with the highest likelihood of occult metastatic disease. This includes patients with a tumor of the body or tail of the pancreas who appear to have potentially resectable disease by computed tomography scan (one-half of whom will have occult peritoneal metastases), large (&gt;3 cm) primary tumors, any patient for whom high-quality imaging is in any way suggestive of occult metastatic disease, and those with a high initial CA 19-9 level (&gt;100",
"    <span class=\"nowrap\">",
"     units/mL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H1618421#H1618421\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Staging laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TUMORS IN THE HEAD OF THE PANCREAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445902203\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Role of biliary drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pancreatic cancer who are jaundiced at presentation are at risk for associated coagulopathy, malabsorption, and malnutrition. The development of percutaneously-placed transhepatic and endoscopic stents has spawned efforts to drain the biliary tree preoperatively to improve surgery-related morbidity and mortality.",
"   </p>",
"   <p>",
"    Although experimental studies in jaundiced animals suggest that preoperative biliary drainage improves surgical outcomes, clinical studies have not consistently shown a benefit for preoperative biliary drainage in jaundiced patients who then undergo resection. In fact, some report deleterious effects (eg, increased risk of cholangitis, longer postoperative hospital stay).",
"   </p>",
"   <p>",
"    Multiple prospective randomized trials have been conducted in patients with potentially resectable pancreatic cancer and malignant obstructive jaundice, with one suggesting benefit for preoperative biliary drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/3\">",
"     3",
"    </a>",
"    ], five, no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/4-8\">",
"     4-8",
"    </a>",
"    ] and three, potential harm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/4,5,9\">",
"     4,5,9",
"    </a>",
"    ]. A Cochrane analysis concluded that stented patients had significantly fewer postoperative complications but similar postsurgical mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this analysis did not include data from the largest and most recent randomized trial of preoperative biliary drainage (10 Fr plastic stent) versus no drainage in 202 patients with cancer of the head of the pancreas, which showed a nonsignificant trend toward more surgery-related complications with preoperative biliary drainage (47 versus 37 percent, relative risk 0.79, 95% CI 0.57 to 1.11) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncertainty as to the benefit of preoperative drainage has led to differing approaches. Some surgeons advocate an endoscopically placed stent prior to surgery while others reserve decompression for selected patients in whom surgery will be delayed for longer than two weeks or in the presence of cholangitis. In practice, jaundiced patients are often initially seen by a gastroenterologist, at a time when resectability as well as the time frame for resection are undetermined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445902151\">",
"    <span class=\"h3\">",
"     Vascular evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom vascular resection is thought to be beneficial, preoperative consultation with a vascular surgeon is ideal to assist with the preoperative vascular evaluation, identify appropriate vascular conduit, and allow coordinated operative scheduling. The experienced surgical oncologist may undertake vascular resection and replacement without assistance, but having a vascular surgeon on standby is prudent. (See",
"    <a class=\"local\" href=\"#H436301373\">",
"     'Vascular resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436301891\">",
"    <span class=\"h2\">",
"     Pancreaticoduodenectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Conventional pancreaticoduodenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conventional operation for pancreatic cancer of the head or uncinate process is pancreaticoduodenectomy (a Whipple procedure). The conventional Whipple procedure involves removal of the pancreatic head, duodenum, first 15 cm of the jejunum, common bile duct, and gallbladder (",
"    <a class=\"graphic graphic_figure graphicRef82519 \" href=\"UTD.htm?16/57/17303\">",
"     figure 1",
"    </a>",
"    ), and a partial gastrectomy. Pancreatic and biliary anastomoses are placed 45 to 60 cm proximal to the gastrojejunostomy. This assures that the gastrojejunostomy is bathed in alkaline secretions, reducing the risk of stomal ulceration and preventing reflux of gastric juice and food into the anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Perioperative morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although previously associated with high morbidity and mortality rates, modern series show that in experienced hands, the conventional Whipple procedure is associated with a five-year survival of 20 to 30 percent in completely resected patients, and a perioperative mortality rate of less than 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. This relatively low perioperative mortality rate represents a decline from over 15 percent in the 1970s, making the Whipple procedure a much more attractive option now than it has been at any time in its long history.",
"   </p>",
"   <p>",
"    One of the most important reasons for this is the greater experience of a limited number of surgeons who perform the procedure regularly in high-volume institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. The relationship between surgeon and hospital volume, and postoperative mortality and survival after pancreatic cancer surgery was addressed in a meta-analysis of 14 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/23\">",
"     23",
"    </a>",
"    ]. There was a significant association between hospital volume and postoperative mortality (odds ratio [OR] 0.32, 95% CI 0.16 to 0.64), as well as overall survival (hazard ratio for death 0.79, 95% CI 0.70 to 0.89).",
"   </p>",
"   <p>",
"    Clinically significant postoperative pancreatic fistulas occur in approximately 5 to 10 percent of patients, although in some series the incidence is as high as 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/24\">",
"     24",
"    </a>",
"    ]. The development of a pancreatic anastomotic leak may be signaled by increased amylase in drainage fluid or radiographic documentation of a peripancreatic amylase-containing fluid collection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/24\">",
"     24",
"    </a>",
"    ]. In one report, risk factors for pancreaticojejunal anastomotic leak included the duration of preoperative jaundice, decreased renal function, and intraoperative blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/25\">",
"     25",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    can decrease the incidence of this complication in patients who undergo pancreatectomy for nonmalignant disease, it does not appear to protect against pancreatic fistula when surgery is performed for pancreatic or other periampullary cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anastomotic dehiscence, liver failure, or bowel necrosis are associated with a high rate of mortality. Ischemic complications after pancreaticoduodenectomy can be related to a preexisting stenosis of the celiac axis or superior mesenteric artery, which, in our experience, is rare. Arterial injury can occur during dissection of the uncinate process of the pancreas from the superior mesenteric artery, or from failure to recognize anatomic variants of the hepatic or superior mesenteric arteries intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/28\">",
"     28",
"    </a>",
"    ]. Preoperative spiral CT can detect hemodynamically significant arterial stenosis and anatomic variants. Arterial stenosis can be treated with a stent to minimize the potential for postoperative ischemic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/29\">",
"     29",
"    </a>",
"    ]. Besides preoperative spiral CT with arterial stenting as indicated, intraoperative maneuvers that can help decrease significant ischemic complications after pancreaticoduodenectomy include meticulous arterial dissection and intraoperative assessment of hepatic arterial flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for pancreatic cancer remains poor even with surgically negative margins. Large series show five-year survival rates of only 10 to 25 percent and median survival between 10 and 20 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/14,30-35\">",
"     14,30-35",
"    </a>",
"    ]. The most important prognostic factor for completely resected patients is nodal status. Five-year survival after pancreaticoduodenectomy is only about 10 percent for node-positive disease, while it is 25 to 30 percent for node-negative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/15,30,33-36\">",
"     15,30,33-36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Prognosis and prognostic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the increase in the proportion of patients undergoing surgery at higher-volume teaching hospitals, diminished surgical mortality, and greater use of adjuvant chemotherapy and chemoradiotherapy in more recent years, it was hoped that outcomes from resection would improve over time. However, there are conflicting reports in the literature regarding progress in the prognosis of resected pancreatic cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 396 Medicare patients residing in one of 11 SEER (Surveillance, Epidemiology and End Results reporting) registries who underwent resection of pancreatic cancer with curative intent between 1991 and 1996, the three-year survival rate was 34 percent, a rate that compares favorably with published reports from the earlier literature [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/37\">",
"       37",
"      </a>",
"      ]. In multivariate analysis, one of the strongest predictors for survival was the use of adjuvant chemoradiotherapy; both median survival and three-year survival rates were significantly higher among those who received it compared with those who did not (29 versus 12.5 months, and 45 versus 30 percent, respectively). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link&amp;anchor=H3#H3\">",
"       \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\", section on 'Chemoradiotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to these data, a lack of progress in long-term survival over time was noted in a large series of 1147 pancreatic resections performed over three decades at Memorial Sloan Kettering [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/38\">",
"       38",
"      </a>",
"      ]. Although patients treated between 2000 and 2009 experienced lower rates of operative mortality and had greater one-year survival, long-term survival rates were nearly identical for patients treated in the 1980s, 1990s, and 2000s (median 23.2, 25.6, and 24.5 months, respectively). The corresponding five-year survival rates were 17, 20, and 8 percent. These data underscore the need for earlier detection and more effective adjuvant therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436301993\">",
"    <span class=\"h3\">",
"     Modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications of the conventional pancreaticoduodenectomy procedure have been developed in an attempt to improve outcomes or minimize the morbidity associated with the operation. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pylorus-preserving pancreaticoduodenectomy, which decreases the incidence of postoperative dumping, marginal ulceration, and bile reflux gastritis that can occur in many patients undergoing partial gastrectomy",
"     </li>",
"     <li>",
"      Subtotal stomach-preserving pancreaticoduodenectomy, which aims to preserve as much stomach as possible while minimizing problems related to delayed gastric emptying",
"     </li>",
"     <li>",
"      Minimally invasive pancreaticoduodenectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Pylorus-preserving pancreaticoduodenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pylorus-preserving pancreaticoduodenectomy, a somewhat less aggressive operation that preserves the pylorus, is being increasingly performed in the United States. The procedure preserves the gastric antrum, pylorus, and the proximal 3 to 6 cm of the duodenum, which is anastomosed to the jejunum to restore gastrointestinal continuity (",
"    <a class=\"graphic graphic_figure graphicRef60689 \" href=\"UTD.htm?5/43/5810\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several randomized trials have directly compared a pylorus preserving with a conventional pancreaticoduodenectomy in pancreatic or periampullary cancer, none of which enrolled more than 130 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/39-44\">",
"     39-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis from the Cochrane database included five trials that provided quantitative data on 465 randomized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/45\">",
"     45",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was marked heterogeneity among the trials with respect to methodology and outcome parameters.",
"     </li>",
"     <li>",
"      There were no significant differences in in-hospital mortality for pylorus-preserving versus conventional Whipple procedure (odds ratio [OR] 0.49, 95% CI 0.17-1.40) or for overall survival (OR 0.84, 95% CI 0.61-1.16). There were also no significant differences in the comparison of pylorus-preserving versus Whipple pancreaticoduodenectomy in rates of pancreatic fistula (OR 0.86, 95% CI 0.41-1.81) or biliary leakage (OR 1.35, 95% CI 0.10-18.55).",
"     </li>",
"     <li>",
"      When all five trials were considered, there was a nonsignificant trend towards higher rates of delayed gastric emptying after a pylorus-preserving procedure (OR 2.35, 95% CI 0.72-7.61), but when the analysis was limited to the three trials in which delayed gastric emptying was specifically defined, the OR decreased to 1.14 (95% CI 0.35-3.68). The lack of precision of these estimates is reflected in the wide confidence intervals.",
"     </li>",
"     <li>",
"      Operating time (weighted mean difference -68.3 minutes) and intraoperative blood loss were both significantly reduced with the pylorus-preserving procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, the overall impact of a pylorus-preserving procedure on gastrointestinal function remains unclear. Of the trials included in the meta-analysis in which posttreatment gastric emptying was assessed, three reported significant benefits in favor of conventional surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/40,43,44\">",
"     40,43,44",
"    </a>",
"    ], one found a non-statistically significant benefit in favor of the pylorus-preserving procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/39\">",
"     39",
"    </a>",
"    ], and one found similar rates in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/42\">",
"     42",
"    </a>",
"    ]. Data from uncontrolled studies are also conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the available data suggest that, for suitable cases, perioperative morbidity and mortality and long-term survival are not adversely affected by the use of pylorus-preserving techniques. The impact of a pylorus-preserving approach on gastrointestinal function remains an open question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359877545\">",
"    <span class=\"h4\">",
"     Subtotal stomach-preserving pancreaticoduodenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtotal stomach-preserving pancreaticoduodenectomy aims to preserve as much stomach as possible while minimizing problems related to delayed gastric emptying that are associated with preserving the pyloric ring in the face of a loss of vagal innervation (",
"    <a class=\"graphic graphic_figure graphicRef60689 \" href=\"UTD.htm?5/43/5810\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/39,50\">",
"     39,50",
"    </a>",
"    ]. In this procedure, the duodenum, pylorus, and 1 to 2 cm of stomach are resected with the pancreatic specimen and the jejunal anastomosis fashioned to the distal antrum (",
"    <a class=\"graphic graphic_figure graphicRef77363 \" href=\"UTD.htm?39/32/40448\">",
"     figure 3",
"    </a>",
"    ). One study compared the incidence of delayed gastric emptying after this operation with standard or pylorus-preserving pancreatoduodenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/50\">",
"     50",
"    </a>",
"    ].&nbsp;Although the rate was marginally less compared with a pylorus-preserving operation, there was no difference from conventional pancreaticoduodenectomy. The incidence of ulceration may be higher than with conventional pancreaticoduodenectomy (due to retained antrum producing large amounts of gastrin), but no improvements in median survival or disease-free survival have been demonstrated with this procedure. Some surgeons feel that by not performing antrectomy, the yield of lymph nodes in the resected specimen is reduced, thus altering the stage of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435189204\">",
"    <span class=\"h3\">",
"     Minimally invasive pancreaticoduodenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreaticoduodenectomy is a relative late-comer in the minimally invasive surgery revolution, primarily because of the technical complexity of the procedure. The development of specialized instruments and technology, and, more specifically, robotic techniques, was needed before a minimally invasive Whipple procedure was even technically feasible. However, even with the technology available, minimally invasive pancreaticoduodenectomy is a complex operation that is suited only for selected patients. Robot-assisted pancreaticoduodenectomy is plagued by long operative times and high conversion rates to open surgery. More importantly, and in contrast to other robotic applications, robot-assisted pancreaticoduodenectomy has not been associated with lower rates of perioperative morbidity (eg, pancreatic fistula) or mortality rates. As such, further interest and resource allocation in this field remains highly controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=see_link\">",
"     \"Robot-assisted laparoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436301805\">",
"    <span class=\"h3\">",
"     More extensive surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436302189\">",
"    <span class=\"h4\">",
"     Ultraradical surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraradical surgery with portal vein resection, total pancreatectomy, and retroperitoneal lymphadenectomy has been performed, primarily in Japan, in an attempt to improve the outcomes from resection. Proponents argue that the more extensive resection allows removal of multifocal disease and additional potentially involved peripancreatic nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/52\">",
"     52",
"    </a>",
"    ]. It also eliminates the need for pancreaticoenteric anastomosis, thereby removing the risk of a postoperative leak or pancreatic fistula. However, several reports failed to demonstrate improved survival and, as with total pancreatectomy, patients who underwent this procedure developed diabetes, which was often difficult to control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/11,53\">",
"     11,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436301287\">",
"    <span class=\"h4\">",
"     Total pancreatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total pancreatectomy was first advocated to remove more tissue potentially involved with the malignancy and to avoid a pancreaticojejunal anastomosis, the source of considerable morbidity and mortality. However, single institution studies suggested higher operative morbidity and mortality compared with pancreaticoduodenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Over time, perioperative (30-day) mortality has progressively declined; however, as with pancreaticoduodenectomy, morbidity remains high [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/57\">",
"     57",
"    </a>",
"    ]. A review of the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) database (2005 to 2009) found a mortality rate of 5.4 percent among 166 patients who underwent total pancreatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/18\">",
"     18",
"    </a>",
"    ]. Perioperative mortality for pancreaticoduodenectomy (n=4317) and distal pancreatectomy (n=2364) were 2.9 and 1.7 percent, respectively. The incidence of complications was similar between the procedures at 31.9, 34.7, and 27.8 for total pancreatectomy, pancreaticoduodenectomy, and distal pancreatectomy, respectively.",
"   </p>",
"   <p>",
"    Furthermore, the metabolic consequences of total pancreatectomy, permanent exocrine insufficiency, and diabetes (which is brittle and difficult to manage) led to concerns as to a potentially detrimental impact on quality of life and long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/55,56,58,59\">",
"     55,56,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, total pancreatectomy is sometimes required in order to achieve a microscopically negative resection margin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Contemporary data on total pancreatectomy are lacking, and single institution series are limited by small numbers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/57,62,63\">",
"     57,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term outcomes are not necessarily worse following total as compared with partial pancreatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/57,64\">",
"     57,64",
"    </a>",
"    ]. This was illustrated in a retrospective cohort study of 4021 patients who had a pancreatectomy with curative intent for adenocarcinoma and were reported to the NCI SEER database between 1998 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/64\">",
"     64",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 376 patients who had a total pancreatectomy, perioperative mortality rates at one month (8.6 versus 6.3 percent) and three months (13.8 versus 10.8 percent) were not significantly higher than in patients who underwent partial pancreatectomy. There were no significant differences when the analysis was conducted separately according to primary tumor site (head,",
"      <span class=\"nowrap\">",
"       body/tail,",
"      </span>",
"      unspecified location).",
"     </li>",
"     <li>",
"      Kaplan-Meier survival estimates for all three tumor locations demonstrated similar long-term survival after total as compared with partial pancreatectomy (at three years, 20 versus 15 percent for head, 22 versus 24 percent for",
"      <span class=\"nowrap\">",
"       body/tail,",
"      </span>",
"      and 20 versus 25 percent for unspecified location, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the use of total pancreatectomy where oncologically appropriate (ie, under conditions where it would yield a tumor-free resection margin while a conventional Whipple procedure would not). This typically occurs when a tumor of the pancreatic head extends into the body or tail of the pancreas. Total pancreatectomy also plays a role in the treatment of some main-duct intraductal papillary mucinous neoplasms (IPMNs), which may involve the entire length of the pancreatic duct, either continuously or in a multifocal fashion. When both types of pancreatic resection would provide a tumor-free margin, total pancreatectomy provides no additional benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436301294\">",
"    <span class=\"h4\">",
"     Regional pancreatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional pancreatectomy involves resection and reconstruction of the superior mesenteric vein-portal vein confluence and extensive en bloc regional lymph node dissection. However, as with total pancreatectomy, the morbidity of a regional pancreatectomy is higher than that associated with conventional pancreatectomy, and there is no apparent improvement in either local control or survival when a regional pancreatectomy is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436301337\">",
"    <span class=\"h4\">",
"     Extended lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some groups (mainly in Japan) routinely complement the Whipple operation with an extensive lymph node dissection (extended lymphadenectomy), since periampullary malignancies frequently metastasize to lymph nodes that are beyond the confines of the conventional pancreaticoduodenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, there is no consistent evidence to support the use of extended lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective trial comparing conventional pancreaticoduodenectomy versus a more extended lymphadenectomy was conducted in 81 patients with a potentially curable adenocarcinoma of the pancreatic head [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/71\">",
"       71",
"      </a>",
"      ]. While overall survival was identical for both treatment groups, subgroup analysis demonstrated better survival in patients with positive nodes undergoing extensive lymphadenectomy. Survival curves were superimposable upon those of node-negative patients.",
"     </li>",
"     <li>",
"      Two subsequent larger randomized controlled trials of conventional versus radical (extended) pancreaticoduodenectomy concluded that survival rates were not different than those obtained with a conventional Whipple procedure but that quality of life, particularly in the early postoperative period, was worse in those undergoing extended lymphadenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/53,72\">",
"       53,72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, extended lymphadenectomy appears to convey no survival benefit, and it may be associated with a compromised quality of life, particularly in the early postoperative period. Pancreaticoduodenectomy with standard lymphadenectomy is the operation of choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436301373\">",
"    <span class=\"h4\">",
"     Vascular resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portal vein resections were initially performed as a component of regional pancreatectomy, which did not improve survival. (See",
"    <a class=\"local\" href=\"#H436302189\">",
"     'Ultraradical surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    More recently, some centers are performing resection and reconstruction of a short segment of the portal vein or superior mesenteric vein (SMV) for isolated limited tumor involvement of the SMV, portal vein, or",
"    <span class=\"nowrap\">",
"     SMV/portal",
"    </span>",
"    vein confluence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/73\">",
"     73",
"    </a>",
"    ]. Vascular resection and reconstruction at the time of pancreaticoduodenectomy is controversial because of the added complexity of the operative procedure, and the poor quality of the published data that examine whether vascular resection represents a poor prognostic factor for survival duration (mainly due to the lack of information as to completeness of resection).",
"   </p>",
"   <p>",
"    Because of these issues and the inability to consistently determine the presence or absence of tumor adherence or invasion preoperatively, practice guidelines have failed to make a clear recommendation on the use of SMV or portal vein resection at the time of pancreaticoduodenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data suggest that patients with tumors involving the portal vein appear to be no more likely to have positive lymph nodes or poor prognostic histologic parameters (eg, aneuploidy) than those without portal vein involvement, suggesting that vein invasion is a function of tumor location rather than an indicator of aggressive tumor biology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Whether perioperative mortality rates are different is unclear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single center reports that largely reflect highly selected patients treated at high-volume institutions report similar morbidity and perioperative mortality rates and comparable survival durations of patients who undergo venous resection and reconstruction versus those who do not as long as a macroscopically complete (R0 or R1) resection has been accomplished [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/78-80\">",
"       78-80",
"      </a>",
"      ]. A systematic review of 12 such reports concluded that portal",
"      <span class=\"nowrap\">",
"       vein/superior",
"      </span>",
"      mesenteric vein resection combined with pancreatectomy is a safe and feasible procedure that increases the number of patients who undergo curative resection and, therefore, provides important survival benefits to selected groups of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, in contrast to these data from single center analyses, analysis of data on 3582 patients undergoing pancreatectomy for pancreatic cancer and derived from the American College of Surgeons National Surgical Quality Improvement Program database suggests significantly higher rates of postoperative morbidity (39.9 versus 33.3) and mortality (5.7 versus 2.9 percent) in patients who undergo pancreaticoduodenectomy with, as compared to without, vascular resection [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/82\">",
"       82",
"      </a>",
"      ]. This database includes patients treated at institutions with different levels of expertise, and it is likely that in many, if not most cases, the vascular resection was unplanned. These two factors could contribute to the higher perioperative morbidity and mortality rates. &nbsp;",
"     </li>",
"     <li>",
"      Thus, although this is a controversial area, pancreaticoduodenectomy with vein resection and reconstruction should be considered a standard approach for pancreatic adenocarcinomas focally involving the portal vein or SMV, provided that adequate inflow and outflow veins are present, the tumor does not involve the superior mesenteric artery (SMA) or hepatic artery, and an",
"      <span class=\"nowrap\">",
"       R0/R1",
"      </span>",
"      resection can be accomplished [",
"      <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arterial resection and reconstruction (mostly of the superior mesenteric and hepatic arteries) is performed infrequently, and therefore there are fewer data supporting its use. The morbidity and mortality of the operation increases markedly when these are performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TUMORS IN THE BODY OR TAIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because adenocarcinomas involving the body or tail of the pancreas usually do not cause obstruction of the intrapancreatic portion of the common bile duct, early diagnosis is rare; the majority have locally advanced or metastatic disease at the time of presentation. In the rare patients who appear to have potentially resectable disease by computed tomography scan, laparoscopic exploration should precede attempted resection, since a significant proportion will have occult peritoneal metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H1618421#H1618421\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Staging laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection of cancers located in the body or tail of the pancreas consists of a distal subtotal pancreatectomy, usually combined with splenectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2569?source=see_link\">",
"     \"Distal pancreatectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Outcomes of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scant data available regarding the outcome of surgical resection for tumors of the body and tail of the pancreas suggest a short survival, high perioperative mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/83\">",
"     83",
"    </a>",
"    ], and poor prognosis compared with those with cancers involving the head of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], although this is not a universal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/86\">",
"     86",
"    </a>",
"    ]. In one study, for example, only 13 of 105 patients (12 percent) with cancer of the body or tail of the pancreas had resectable tumors, and median survival was only 13 months after surgery, with only five patients remaining alive at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, even in the setting of completely resected, node-negative pancreatic cancer, the majority of patients die of their disease. Tumor stage is the most important prognostic factor. Estimated survival in a series of 21,512 patients undergoing pancreatectomy for pancreatic adenocarcinoma reported to the National Cancer Database between 1992 and 1998 and stratified according to stage at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    ) are illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef71233 \" href=\"UTD.htm?0/59/957\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although five-year survival rates are dismal for all disease stages (2 to 31 percent in this database series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/87\">",
"     87",
"    </a>",
"    ]), survival probabilities change over time. This was illustrated in a retrospective analysis of 1822 patients undergoing curative-intent surgery for pancreatic cancer at Johns Hopkins between 1970 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/88\">",
"     88",
"    </a>",
"    ]. The two-year conditional survival at three years (ie, the probability of surviving to postoperative year five given that the patient had already survived three years) was 66 percent, versus a five-year actuarial survival calculated from the time of surgery of 18 percent. Patients with high lymph node ratios (the number of metastatic divided by the total number of resected nodes) or positive margins saw the greatest increases in two-year conditional survival as more time elapsed. &nbsp;",
"   </p>",
"   <p>",
"    In addition to stage, other factors that influence prognosis after resection are the status of the surgical margins, possibly the width of the surgical margin, tumor size, tumor differentiation and the presence or absence of lymphatic invasion within the tumor, and both preoperative and postoperative serum CA 19-9 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/14,30-32,36,79,89-94\">",
"     14,30-32,36,79,89-94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As has been seen in colon and gastric cancer, the number of negative nodes examined also impacts prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. At least some data support the view that pathologic examination of at least 15 nodes in the pancreatectomy specimen is necessary to accurately stage a node-negative adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/96\">",
"     96",
"    </a>",
"    ]. However, in contrast to other sites in the gastrointestinal tract, the number of involved or examined lymph nodes is not included in the nodal (N) stage designation for the",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    staging system (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A postresection nomogram has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/97\">",
"     97",
"    </a>",
"    ] and validated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/34/8746/abstract/95\">",
"     95",
"    </a>",
"    ] to predict the probability that a patient will die of pancreatic cancer within three years of surgery. In addition to the tumor (T) and node (N) status, this nomogram incorporates clinical (age, sex, presence of back pain or weight loss, tumor location), pathologic (histologic differentiation, tumor size, margin status, number of positive nodes) and surgical (type of resection) variables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/21/11602?source=see_link\">",
"       \"Patient information: Pancreatic cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/55/31603?source=see_link\">",
"       \"Patient information: Pancreatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the only potentially curative treatment for pancreatic adenocarcinoma. Unfortunately, because of the late presentation of the disease, only 15 to 20 percent of patients are candidates for pancreatectomy.",
"   </p>",
"   <p>",
"    Absolute contraindications to resection include (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Preoperative staging'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metastases in the liver, peritoneum, omentum, or any extraabdominal site",
"     </li>",
"     <li>",
"      Encasement (more than one-half of the vessel circumference) or",
"      <span class=\"nowrap\">",
"       occlusion/thrombus",
"      </span>",
"      of the superior mesenteric vein (SMV) or the SMV-portal vein confluence",
"     </li>",
"     <li>",
"      Direct involvement of the superior mesenteric artery (SMA), inferior vena cava, aorta, celiac axis, or hepatic artery, as defined by the absence of a fat plane between the low density tumor and these structures on CT scan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tumors in the head/uncinate process",
"    </span>",
"    &nbsp;&mdash;&nbsp;For potentially resectable pancreatic cancers within the head or uncinate process, the standard operation is pancreaticoduodenectomy (Whipple procedure), which consists of removal of the pancreatic head, duodenum, first 15 cm of the jejunum, common bile duct, gallbladder, and a partial gastrectomy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Conventional pancreaticoduodenectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cancers of the pancreatic head and uncinate process can be treated by either a conventional or a pylorus-preserving Whipple operation.&nbsp;No compelling evidence is available to suggest that either of these procedures is superior to the other and the preferences of the surgeon and patient should prevail. Although some studies suggest modestly higher rates of delayed gastric emptying with a pylorus-preserving approach, the impact on gastrointestinal function remains an open question. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Pylorus-preserving pancreaticoduodenectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no added benefit to be gained by regional pancreatectomy or extended lymphadenectomy, and we recommend that these procedures not be performed (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H436302189\">",
"     'Ultraradical surgery'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H436301337\">",
"     'Extended lymphadenectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although this is a controversial area, vein resection and reconstruction is a standard approach for pancreatic adenocarcinomas focally involving the portal vein or SMV, providing that adequate inflow and outflow veins are present, the tumor does not involve the SMA or hepatic artery, and a macroscopically complete",
"    <span class=\"nowrap\">",
"     (R0/R1)",
"    </span>",
"    resection can be accomplished. (See",
"    <a class=\"local\" href=\"#H436301373\">",
"     'Vascular resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients presenting with obstructive jaundice, uncertainty as to the benefit of preoperative drainage has led to differing approaches. We suggest biliary decompression for selected patients in whom surgery will be delayed for longer than two weeks (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ) and we recommend it in the presence of cholangitis (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). Others routinely decompress all jaundiced patients with an endoscopically placed plastic stent prior to surgery. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Role of biliary drainage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tumors of the tail/body",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of cancers located in the body or tail of the pancreas consists of a distal subtotal pancreatectomy, usually combined with splenectomy. We suggest laparoscopic exploration prior to attempted resection, since a significant proportion will have occult peritoneal metastases (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Tumors in the body or tail'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H1618421#H1618421\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Staging laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/3\">",
"      Smith RC, Pooley M, George CR, Faithful GR. Preoperative percutaneous transhepatic internal drainage in obstructive jaundice: a randomized, controlled trial examining renal function. Surgery 1985; 97:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/4\">",
"      Pitt HA, Gomes AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985; 201:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/5\">",
"      Lai EC, Mok FP, Fan ST, et al. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994; 81:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/6\">",
"      McPherson GA, Benjamin IS, Hodgson HJ, et al. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg 1984; 71:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/7\">",
"      Hatfield AR, Tobias R, Terblanche J, et al. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 1982; 2:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/8\">",
"      Eshuis WJ, van der Gaag NA, Rauws EA, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg 2010; 252:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/9\">",
"      van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/10\">",
"      Mumtaz K, Hamid S, Jafri W. Endoscopic retrograde cholangiopancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgery. Cochrane Database Syst Rev 2007; :CD006001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/11\">",
"      Strasberg SM, Drebin JA, Soper NJ. Evolution and current status of the Whipple procedure: an update for gastroenterologists. Gastroenterology 1997; 113:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/12\">",
"      Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993; 217:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/13\">",
"      Balcom JH 4th, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/14\">",
"      Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/15\">",
"      Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/16\">",
"      Pellegrini CA, Heck CF, Raper S, Way LW. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg 1989; 124:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/17\">",
"      Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987; 206:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/18\">",
"      Kneuertz PJ, Pitt HA, Bilimoria KY, et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg 2012; 16:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/19\">",
"      Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/20\">",
"      Birkmeyer JD, Warshaw AL, Finlayson SR, et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999; 126:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/21\">",
"      Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008; 207:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/22\">",
"      Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/23\">",
"      Gooiker GA, van Gijn W, Wouters MW, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011; 98:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/24\">",
"      Cullen JJ, Sarr MG, Ilstrup DM. Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. Am J Surg 1994; 168:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/25\">",
"      Yeh TS, Jan YY, Jeng LB, et al. Pancreaticojejunal anastomotic leak after pancreaticoduodenectomy--multivariate analysis of perioperative risk factors. J Surg Res 1997; 67:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/26\">",
"      Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/27\">",
"      Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997; 226:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/28\">",
"      Shukla PJ, Barreto SG, Kulkarni A, et al. Vascular anomalies encountered during pancreatoduodenectomy: do they influence outcomes? Ann Surg Oncol 2010; 17:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/29\">",
"      Gaujoux S, Sauvanet A, Vullierme MP, et al. Ischemic complications after pancreaticoduodenectomy: incidence, prevention, and management. Ann Surg 2009; 249:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/30\">",
"      Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/31\">",
"      Benassai G, Mastrorilli M, Quarto G, et al. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital 2000; 52:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/32\">",
"      Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/33\">",
"      Bakkevold KE, Arnesj&oslash; B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/34\">",
"      Tsao JI, Rossi RL, Lowell JA. Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation. Arch Surg 1994; 129:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/35\">",
"      Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/36\">",
"      Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/37\">",
"      Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/38\">",
"      Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol 2012; 19:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/39\">",
"      Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005; 92:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/40\">",
"      Lin PW, Shan YS, Lin YJ, Hung CJ. Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure. Hepatogastroenterology 2005; 52:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/41\">",
"      Wenger FA, Jacobi CA, Haubold K, et al. [Gastrointestinal quality of life after duodenopancreatectomy in pancreatic carcinoma. Preliminary results of a prospective randomized study: pancreatoduodenectomy or pylorus-preserving pancreatoduodenectomy]. Chirurg 1999; 70:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/42\">",
"      Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004; 240:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/43\">",
"      Bloechle C, Broering DC, Latuske C, et al. Prospective randomized study to evaluate quality of life after partial pancreatoduodenectomy according to Whipple versus pylorus preserving pancreatoduodenectomy according to Longmire-Traverso for periampullary carcinoma. Dtsch Gesellschaft Chir 1999; Suppl-1:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/44\">",
"      Paquet KJ. Vergleich der partiellen Duodenopankreatektomie (Whipple operation) mit der pylorouserhaltenden Zephaloduodenopankreatektomie: eine prospektive kontrollierte, randomisierte Langzeitstudie. Chir Gastroenterol 1998; 14:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/45\">",
"      Diener MK, Heukaufer C, Schwarzer G, et al. Pancreaticoduodenectomy (classic Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2008; :CD006053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/46\">",
"      Williamson RC, Bliouras N, Cooper MJ, Davies ER. Gastric emptying and enterogastric reflux after conservative and conventional pancreatoduodenectomy. Surgery 1993; 114:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/47\">",
"      Klinkenbijl JH, van der Schelling GP, Hop WC, et al. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 1992; 216:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/48\">",
"      McLeod RS, Taylor BR, O'Connor BI, et al. Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. Am J Surg 1995; 169:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/49\">",
"      Warshaw AL, Torchiana DL. Delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy. Surg Gynecol Obstet 1985; 160:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/50\">",
"      Fujii T, Kanda M, Kodera Y, et al. Preservation of the pyloric ring has little value in surgery for pancreatic head cancer: a comparative study comparing three surgical procedures. Ann Surg Oncol 2012; 19:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/51\">",
"      Zeh HJ, Zureikat AH, Secrest A, et al. Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions. Ann Surg Oncol 2012; 19:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/52\">",
"      Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery 1973; 73:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/53\">",
"      Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/54\">",
"      Grace PA, Pitt HA, Tompkins RK, et al. Decreased morbidity and mortality after pancreatoduodenectomy. Am J Surg 1986; 151:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/55\">",
"      Brooks JR, Brooks DC, Levine JD. Total pancreatectomy for ductal cell carcinoma of the pancreas. An update. Ann Surg 1989; 209:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/56\">",
"      Karpoff HM, Klimstra DS, Brennan MF, Conlon KC. Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 2001; 136:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/57\">",
"      Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg 2009; 250:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/58\">",
"      Dresler CM, Fortner JG, McDermott K, Bajorunas DR. Metabolic consequences of (regional) total pancreatectomy. Ann Surg 1991; 214:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/59\">",
"      Andr&eacute;n-Sandberg A, Ihse I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg 1983; 198:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/60\">",
"      Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/61\">",
"      Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004; 139:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/62\">",
"      Schmidt CM, Glant J, Winter JM, et al. Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 2007; 142:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/63\">",
"      M&uuml;ller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg 2007; 246:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/64\">",
"      Nathan H, Wolfgang CL, Edil BH, et al. Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective. J Surg Oncol 2009; 99:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/65\">",
"      Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/66\">",
"      Sindelar WF. Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 1989; 124:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/67\">",
"      Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg 1984; 199:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/68\">",
"      Ishikawa O, Ohhigashi H, Sasaki Y, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988; 208:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/69\">",
"      Tsuchiya R, Tsunoda T, Yamaguchi T. Operation of choice for resectable carcinoma of the head of the pancreas. Int J Pancreatol 1990; 6:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/70\">",
"      Stojadinovic A, Brooks A, Hoos A, et al. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003; 196:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/71\">",
"      Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/72\">",
"      Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/73\">",
"      Evans DB, Farnell MB, Lillemoe KD, et al. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1736.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/75\">",
"      Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/76\">",
"      Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996; 223:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/77\">",
"      Murakami Y, Uemura K, Sudo T, et al. Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. J Surg Oncol 2013; 107:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/78\">",
"      Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/79\">",
"      Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/80\">",
"      Martin RC 2nd, Scoggins CR, Egnatashvili V, et al. Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes. Arch Surg 2009; 144:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/81\">",
"      Ramacciato G, Mercantini P, Petrucciani N, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 2009; 16:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/82\">",
"      Castleberry AW, White RR, De La Fuente SG, et al. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol 2012; 19:4068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/83\">",
"      Wade TP, Virgo KS, Johnson FE. Distal pancreatectomy for cancer: results in U.S. Department of Veterans Affairs hospitals, 1987-1991. Pancreas 1995; 11:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/84\">",
"      Johnson CD, Schwall G, Flechtenmacher J, Trede M. Resection for adenocarcinoma of the body and tail of the pancreas. Br J Surg 1993; 80:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/85\">",
"      Dalton RR, Sarr MG, van Heerden JA, Colby TV. Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery 1992; 111:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/86\">",
"      Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996; 223:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/87\">",
"      Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007; 110:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/88\">",
"      Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2012; 118:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/89\">",
"      Meyer W, Jurowich C, Reichel M, et al. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today 2000; 30:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/90\">",
"      Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/91\">",
"      Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/92\">",
"      Helm J, Centeno BA, Coppola D, et al. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer 2009; 115:4080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/93\">",
"      Kinsella TJ, Seo Y, Willis J, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 2008; 31:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/94\">",
"      Franko J, Hugec V, Lopes TL, Goldman CD. Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer &lt;1 or 2 cm. Ann Surg Oncol 2013; 20:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/95\">",
"      Ferrone CR, Kattan MW, Tomlinson JS, et al. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 2005; 23:7529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/96\">",
"      Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 2007; 142:767.79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/34/8746/abstract/97\">",
"      Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004; 240:293.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2482 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8746=[""].join("\n");
var outline_f8_34_8746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Staging laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TUMORS IN THE HEAD OF THE PANCREAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445902203\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Role of biliary drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H445902151\">",
"      - Vascular evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H436301891\">",
"      Pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Conventional pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Perioperative morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H436301993\">",
"      - Modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pylorus-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H359877545\">",
"      Subtotal stomach-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H435189204\">",
"      - Minimally invasive pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H436301805\">",
"      - More extensive surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H436302189\">",
"      Ultraradical surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H436301287\">",
"      Total pancreatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H436301294\">",
"      Regional pancreatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H436301337\">",
"      Extended lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H436301373\">",
"      Vascular resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TUMORS IN THE BODY OR TAIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Outcomes of surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS AND PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tumors in the head/uncinate process",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tumors of the tail/body",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2482|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17303\" title=\"figure 1\">",
"      Conventional pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/43/5810\" title=\"figure 2\">",
"      Pylorus-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/32/40448\" title=\"figure 3\">",
"      Subtotal stomach preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2482|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 1\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/59/957\" title=\"table 2\">",
"      NCDB surg surv panc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2569?source=related_link\">",
"      Distal pancreatectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/55/31603?source=related_link\">",
"      Patient information: Pancreatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/21/11602?source=related_link\">",
"      Patient information: Pancreatic cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=related_link\">",
"      Robot-assisted laparoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_34_8747="Indications for IDUS";
var content_f8_34_8747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for intraductal ultrasound",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Biliary tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Suspected but undetected choledocholithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Distinguish benign from malignant bile duct strictures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Local tumor staging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Distinguish benign from malignant pancreatic duct strictures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Local tumor staging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Characterize cystic tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Localize islet cell tumors not identified by endoscopic ultrasound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Assess for multifocal islet cell tumors in MEN-I",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8747=[""].join("\n");
var outline_f8_34_8747=null;
var title_f8_34_8748="Asbestosis histologic grades";
var content_f8_34_8748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic grades of asbestosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Grade",
"of severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        No fibrosis associated with bronchioles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 or I",
"       </td>",
"       <td>",
"        Early fibrosis involving walls of at least one",
"respiratory bronchiole, with or without extension into septa of",
"adjacent alveoli; fibrosis confined to alveolated walls of respiratory",
"bronchioles and ducts and not present in more distant alveoli.",
"Alveolitis and inflammation similar to that caused by cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 or II",
"       </td>",
"       <td>",
"        More severe fibrosis involving acinus: alveolar ducts",
"and/or two or more layers of adjacent alveoli. Normal lung remains in a",
"zone between adjacent bronchioles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 or III",
"       </td>",
"       <td>",
"        Fibrosis advanced and coalescent, involves entire",
"acinus; all lung between at least two adjacent bronchioles is affected.",
"Some alveoli are completely obliterated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4 or IV",
"       </td>",
"       <td>",
"        Honeycomb remodeling and large (up to 1 cm) dilated",
"spaces grossly visible in parenchyma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Grade",
"of extent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A or 1",
"       </td>",
"       <td>",
"        Only occasional bronchioles are involved. Most appear",
"normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B or 2",
"       </td>",
"       <td>",
"        <span style=\"font-weight: bold;\">",
"         \"",
"        </span>",
"        More",
"than occasional\" but less than half of bronchioles are involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C or 3",
"       </td>",
"       <td>",
"        More than half of bronchioles are involved",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Developed in 1980 by a committee of the College of American Pathologists.",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8748=[""].join("\n");
var outline_f8_34_8748=null;
var title_f8_34_8749="Periop psychotropics";
var content_f8_34_8749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perioperative management of psychotropic agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name or class of drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical considerations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with brief NPO state",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with prolonged NPO state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics",
"       </td>",
"       <td>",
"        Some agents are associated with QT prolongation, and occasionally cause hypotension or arrythmias. No recent data available.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery in patients with high risk of developing psychoses.",
"       </td>",
"       <td>",
"        <p>",
"         Continue therapy up to and including day of surgery. Parenteral formulations are available for haloperidol, chlorpromazine, aripriprazole, olanzapine, and ziprasidone.&nbsp;",
"        </p>",
"        <p>",
"         If prolonged NPO state is anticipated, depot formulations(eg, haloperidol decanoate) could be considered, to begin well before surgery in consultation with psychopharmacologist.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Abrupt withdrawal can result in agitation, HTN, delirium, and seizures.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery. Parenteral diazepam, lorazepam, and chlordiazepoxide are available for prolonged NPO state.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buspirone",
"       </td>",
"       <td>",
"        No known adverse effects.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery. No parenteral substitution available but parenteral diazepam, lorazepam, or chlordiazepoxide can be used for prolonged NPO state.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"       <td>",
"        Continuation may prolong the effect of muscle relaxants and, due to impaired renal concentrating ability, can cause hypovolemia and hypernatremia.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery with close monitoring of electrolytes and volume status.",
"       </td>",
"       <td>",
"        Resume with oral intake. No parenteral substitution available. When needed, may use parenteral valproate or a second-generation antipsychotic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoamine oxidase inhibitors",
"       </td>",
"       <td>",
"        If continued and direct acting sympathomimetic agents like ephedrine are used during anesthesia, can result in severe HTN. If agents like meperidine or dextromethorphan are used, can result in \"serotonin syndrome.\"",
"       </td>",
"       <td>",
"        For emergency procedures a MAO-safe anesthetic technique should be used. For other surgeries, anesthesiologist and psychiatrist should collaborate and decide either to use MAO-safe anesthetic technique or discontinue the medication. If discontinued should be stopped for&nbsp;two weeks prior to surgery.",
"       </td>",
"       <td>",
"        Resume with oral intake. No parenteral substitution available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin reuptake inhibitors",
"       </td>",
"       <td>",
"        Increased risk of bleeding.",
"       </td>",
"       <td>",
"        Discontinue therapy&nbsp;three weeks prior to surgery in patients undergoing high-risk procedures (such as certain CNS procedures).",
"       </td>",
"       <td>",
"        Resume with oral intake. No parenteral substitution available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"       <td>",
"        Continuation may increase the potential for arrythmias. Abrupt withdrawal can lead to insomnia, nausea, headache, increased salivation, and increased sweating.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery for patients on high doses. Patients on low doses and in whom perioperative arrythmia is likely should discontinue for&nbsp;seven days prior to surgery.",
"       </td>",
"       <td>",
"        Resume with oral intake. No parenteral substitution available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"       <td>",
"        No known adverse effects.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery. Resume with oral intake. A parenteral formulation (valproate sodium) is available.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8749=[""].join("\n");
var outline_f8_34_8749=null;
var title_f8_34_8750="Normal permanent tooth eruption";
var content_f8_34_8750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Age of normal permanent tooth eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mandibular eruption is shown in red.",
"    <br>",
"     Maxillary eruption is shown in blue.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright WB Saunders 2000.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_34_8750=[""].join("\n");
var outline_f8_34_8750=null;
var title_f8_34_8751="Contents: Endocrine tumors";
var content_f8_34_8751=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Endocrine tumors",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Endocrine tumors",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adrenal tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22282\">",
"           Epidemiology and clinical manifestations of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31225\">",
"           Establishing the cause of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/25/21913\">",
"           Establishing the diagnosis of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/0/3081\">",
"           Medical therapy of hypercortisolism (Cushings syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1016\">",
"           Overview of the treatment of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17834\">",
"           Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/8/18569\">",
"           The adrenal incidentaloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40762\">",
"           Treatment of adrenocortical carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Carcinoid tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/11/12472\">",
"           Carcinoid heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metastatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple endocrine neoplasia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43240\">",
"           Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38871\">",
"           Multiple endocrine neoplasia type 1: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatic endocrine tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18330\">",
"           Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/35/22071\">",
"           Diagnostic dilemmas in hypoglycemia: Illustrative cases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31640\">",
"           Glucagonoma and the glucagonoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/30/12777\">",
"           Insulinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/34/3623\">",
"           Somatostatinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/59/16311\">",
"           The VIPoma syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parathyroid tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/26/5545\">",
"           Diagnosis and differential diagnosis of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8954\">",
"           Management of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13688\">",
"           Parathyroid carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40387\">",
"           Parathyroid cysts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30361\">",
"           Pathogenesis and etiology of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18377\">",
"           Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pituitary tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30776\">",
"           Causes and clinical manifestations of acromegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29992\">",
"           Causes, presentation, and evaluation of sellar masses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22489\">",
"           Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43076\">",
"           Diagnosis of acromegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41413\">",
"           Diagnosis of hypopituitarism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/34/41510\">",
"           Management of lactotroph adenoma (prolactinoma) during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/20/327\">",
"           Thyrotropin (TSH)-secreting pituitary adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7322\">",
"           Treatment of acromegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/41/8857\">",
"           Treatment of gonadotroph and other clinically nonfunctioning adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/52/31561\">",
"           Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23721\">",
"           Anaplastic thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/47/23288\">",
"           Chemotherapy and immunotherapy for medullary thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28345\">",
"           Chemotherapy for differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/16/14599\">",
"           Clinicopathologic staging of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4165\">",
"           Exogenous hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/17/39191\">",
"           External beam radiotherapy in the treatment of thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9560\">",
"           Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/23/38263\">",
"           Medullary thyroid cancer: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/15/8440\">",
"           Overview of papillary thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/17/44313\">",
"           Overview of the management of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/49/1818\">",
"           Radiation-induced thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34010\">",
"           Radioiodine treatment of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/39/37496\">",
"           Serum thyroglobulin in the management of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13799\">",
"           Struma ovarii",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/6/41064\">",
"           Surgical treatment of differentiated thyroid cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-0313C379EE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_34_8751=[""].join("\n");
var outline_f8_34_8751=null;
